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Abstract 
 
The aim of this research was to develop a new work model for hospital pharmacists 
based on risk assessment of patients using an electronic prescribing and administration 
system (EPMA).  
Systematic review was performed to identify risk factors associated with clinical 
pharmacy intervention. Those factors which can be measured by the EPMA in a UK 
teaching hospital were subsequently identified. Data was extracted from the EPMA 
relating to risks in intervention recipients on medical and surgical wards and those 
patients present concurrently.  
Univariable and multivariable analysis was performed and a risk score calculated. 
Receiver operating curves (ROCs) determined predictability of the score. 
Risk factors for pharmacist intervention were: age, female gender, patient compliance, 
unavailable stock, prescription of warfarin, number of allergies, comorbidities, regular 
prescriptions, anti-epileptics, thrombolytics/anticoagulants, central nervous system 
agents, and chemotherapy / immunosuppressants. The area under the ROC for the risk 
score was 0.61.  
Multiple factors were significantly and independently associated, with an increased 
intervention rate. However, it was not possible to generate a useful model for directing 
clinical pharmacy services. Inverse relationships were demonstrated between some risk 
factors usually associated with problems with medicines use. 
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Background 
 
In the United Kingdom (UK), the general public’s perception of the role of the pharmacist 
is most frequently manifested through their interaction with their local community 
pharmacist found in the high street. A general concept of the “chemist”, who supplies 
medicines against prescriptions from general practitioners and who at times, may advise 
on the treatment of minor ailments, may be the extent of the layman’s understanding of 
a pharmacist’s role. However, pharmacists are extensively trained healthcare 
professionals who perform many different highly skilled tasks not only in a community 
environment, but in research, industry, educational and hospital settings. To practice as a 
pharmacist, candidates must obtain a four-year masters degree in pharmacy (MPharm) 
and in addition, spend 6 to 12 months working in a patient facing setting working towards 
performance standards set out by the regulatory body, the General Pharmaceutical 
Council (GPhC). In addition, successful completion of a pre-registration examination is 
required before candidates may be entered onto the GPhC register as a pharmacist. This 
tight regulation and ongoing requirement for continuing professional development (CPD) 
post registration is intended to ensure that all pharmacists deliver a high quality service 
to safeguard the public.  
Whatever the chosen practice setting for a pharmacist, the core aim, either directly or 
indirectly, is to ensure that patients receive the right medicine, to the right patient, at the 
right dose, by the right route at the right time (a traditional concept termed The Five 
“Rights” of Medicines Administration1,2 ). Whether it be through research to develop 
effective medication education for pharmacists or student pharmacists or through the 
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widely recognised process of prescription checking, pharmacists have medication efficacy 
and patient safety at the very heart of their practice. 
In the hospital setting, the core pharmacist role is involved with confirming the 
appropriateness of medicines prescribed for in- and outpatients. In the UK, hospital 
pharmacists visit inpatient wards and confirm that any patient medication is appropriate, 
ensuring that all relevant monitoring occurs and amendments to prescriptions have been 
made in response to any clinical changes in the patient. This form of pharmacy is most 
often referred to as “clinical pharmacy” and those pharmacists practicing in this way as 
"clinical pharmacists”. 
Hospital pharmacists are unique amongst other healthcare workers in that they are rarely 
referred patients for review. Physiotherapists, speech and language and occupational 
therapists are frequently referred patients by either medical or nursing staff. In effect, 
patients are triaged prior to referral with respect to services provided by the professions 
allied to medicine (AHPs).  For most clinical pharmacists practising in the UK’s National 
Health Service (NHS) however, local policy requires that they review all inpatient charts 
daily on the wards, which they are allocated. However, in the UK there is no national 
guidance which dictates how frequently pharmacists must review inpatient medication 
charts. In addition, with a shortage of doctors and nurses in the NHS, the role of the 
clinical pharmacist has been expanding. Many pharmacists are now non-medical 
prescribers and some are being trained as advanced clinical practitioners (ACPs) capable 
of clinical assessment of patients and diagnosis.  Consequently, in recent years, owing to 
increasing bed numbers and rising expectations in terms of practice with no 
corresponding increase in resources, hospital pharmacists have sought to find ways of 
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becoming more efficient in their way of working while still retaining the quality of service 
they have been bound to deliver by their professional responsibilities. 
The aim of the present research is to develop a new work model for the review of 
inpatients by hospital clinical pharmacists based on risk assessment of patients generated 
by an electronic prescribing system. The intention is to identify evidence-based risk 
factors for review of inpatient medication and use these risk factors to develop a form of 
clinical pharmacist triage, directing  pharmaceutical expertise to those who are most in 
need.  
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CHAPTER 1 
INTRODUCTION 
 
5 
 
1. Introduction 
1.1. History of Clinical Pharmacy 
 
1.1.1. Background 
 
During the past three decades there has been growing evidence that the safe, effective 
and efficient management of medicines improves outcomes for patients by delivering 
high quality patient centred care3–5. In most hospitals in the United Kingdom (UK), 
Pharmacy Services are responsible for delivering medicines management through a 
variety of initiatives involving the procurement, supply and use of medicines.  
Since the 1970s Pharmacists have been responsible for the delivery of most hospital 
pharmaceutical services. During the 1960s much of the role of the hospital pharmacist 
was involved in extemporaneous preparation and supply of pharmaceutical products. A 
pharmacist could rarely be seen conversing with patient and the majority of hospital 
pharmacies were located in hospital basements well away from key services and the 
multidisciplinary team.  
Figure 1.1 shows some of the activities and environment in the Pharmacy Department at 
Queen Elizabeth Hospital in Birmingham, UK, in the 1960s. The pictures show an 
emphasis on compounding, aseptic preparation and wide-scale manufacture of sterile 
fluids.  
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Figure 1.1 Queen Elizabeth Hospital Birmingham (UK) in the 1960s 
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However in the 1970s and 1980s the role of the hospital pharmacist in the UK expanded 
to meet the increasing requirement for quality and productivity in the hospital setting. 
The expansion of large scale manufacturing of medicines by pharmaceutical companies 
quashed the necessity for the relatively small-scale production by local hospital 
pharmacies. Hospital pharmacists began to expand their role.  
Hospital pharmacists are no longer simply the providers of a medicines supply function 
but are responsible for many aspects of pharmaceutical care requiring detailed 
knowledge of medicines, medicines action and use.   The development of pharmacists’ 
clinical expertise over the past three decades, supported by the introduction of new 
postgraduate qualifications, has improved the quality of these services. Examples include 
ward based pharmacy, therapeutic drug monitoring (TDM), pharmacist prescribing, 
support to pre-admission clinics, medicines reconciliation, antimicrobial stewardship, 
management of electronic prescribing systems, governance of medicines and advanced 
clinical practitioner roles (ACPs). Almost all of these initiatives require a degree of clinical 
expertise acquired currently in a post graduate role and most are termed under the 
umbrella of “Clinical Pharmacy” as opposed to the more traditional function of “supply” 
which remains a core function of most Pharmacy Departments. 
In 2008 the Department of Health issued a White Paper6, which recognised the 
significance of clinical pharmacist expertise in improving patient services, this was further 
reinforced in 20107 when their role in refining treatment through medicines optimisation 
was supported. Despite government support, the benefits of clinical pharmacy have been 
notoriously difficult to demonstrate and high quality research difficult to find. Research is 
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complex mainly owing to the fact that almost all of the functions performed by clinical 
pharmacists overlap with responsibilities of other healthcare professionals and in most 
cases, the pharmacists role is preventative in nature which makes the measurement of 
outcomes difficult.  There has however, been some work which has demonstrated the 
worth of clinical pharmacy through a reduction in adverse drug events (ADEs), reduction 
in the length of hospital stay, reduction in readmission rates and lower overall treatment 
costs3–5. 
 
1.1.2. What is Clinical Pharmacy? 
 
Clinical Pharmacy is defined as a health science discipline in which pharmacists provide 
patient care that optimises medication therapy and promotes health, wellness and 
disease prevention8.  In practice, pharmacists are by definition “clinicians” and as such 
Clinical Pharmacy includes all services performed by pharmacists practising in hospitals, 
community pharmacies, nursing homes and any other setting where medicines are 
prescribed and administered. 
Clinical pharmacy services are a combination of medicines management (which includes 
how medicines are procured and supplied) and pharmaceutical care. Pharmaceutical Care 
defined by Hepler and Strand9 as “the responsible provision of drug therapy for the 
purpose of achieving outcomes which improve the patient’s quality of life”, put the 
patient at the heart of care through the development and implementation of 
pharmaceutical care involving both the patient and the multidisciplinary team. It is this 
patient centred approach, which makes clinical pharmacy differ from the discipline of 
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“pharmacy” which simply embraces the knowledge of synthesis, chemistry and 
preparation of drugs.  Clinical pharmacy is directed to the needs of patients with regards 
to medicines use, methods of administration, adverse drug effects, patterns of use and 
patient outcomes. 
 
1.1.3. Ward- Based Clinical Pharmacy Services 
 
In the United Kingdom (UK) during the 1960s and 70s, advances in the numbers and 
range of medicines available and an increasing awareness of adverse drug events led to 
the use of ward-based prescriptions in the hospital setting10. This in turn led to 
pharmacists expanding their more traditional roles of dispensing and manufacturing by 
leaving the pharmacy department to practice ward based pharmacy.  
Through direct contact with both the patient and the multidisciplinary team in the ward 
environment, clinical pharmacists have been able to demonstrate their knowledge and 
skills concerning medicines and prove their worth in the hospital setting.  Most ward- 
based pharmacy services generally include a clinical pharmacy review for every patient on 
a ward and aim to do this daily. The review generally consists of confirming the 
appropriateness of all the medicines prescribed for the patient starting with medicines 
reconciliation. Medicines reconciliation on admission includes confirming, 
comprehensively, the patient’s medicines prior to admission and reconciling them with 
those prescribed as an inpatient. Acting in an advisory role, pharmacists will then 
communicate with prescribers and nursing staff regarding any inaccuracies and make 
recommendations for the administration and supply of drugs, future drug treatment and 
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monitoring.  Often a pharmaceutical care plan is developed for those patients with 
complex drug needs or monitoring to ensure appropriate follow up and communication 
with other pharmacy staff. Any intervention into a patient’s treatment is recorded by the 
pharmacist as a clinical pharmacy intervention. 
Ward based pharmacy provided the first evidence of pharmacists’ clinical expertise, in 
the hospital setting. In 1986 the Nuffield Report11 detailed the significance of clinical 
pharmacy. Today, it is the ward based pharmacy service which is the most common form 
of clinical pharmacy services.  
Although hospitals in the UK have different operational systems in place for delivery of 
ward based clinical pharmacy services, almost all of them now deliver (or aspire to 
deliver) the following: 
 Medicines Reconciliation as per National Institute of Clinical Excellence (NICE) 
guidance12 which states that pharmacists should be involved with medicines 
reconciliation as soon as possible after admission 
 Clinical pharmacist review, validation and sign off of medications 
 An advisory role to prescribers and nursing staff 
 Recording of pharmacist interventions 
 Counselling of patients on new drugs or those with Committee on Safety of 
Medicines (CSM) or National Patient Safety Agency (NPSA) warnings 
 Supply of the correct product, initiated by a member of the pharmacy team 
These however, are considered core services and over time, clinical pharmacists have 
expanded their role owing to a demand for their expertise.   
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An increase in patient numbers coupled with an aging population, the increasing public 
demand for improved access to medicines, demand for improvements in quality and 
efficacy without a corresponding increase in pharmacy resources, have all put an 
increasing strain on clinical pharmacists. The pharmacist role, like many other healthcare 
professional roles, has developed in response to these pressures. Pharmacist prescribing 
has enabled pharmacists to work autonomously to “fine tune” patients’ drug regimens, 
prescribe adjunctive treatments and to prescribe against agreed protocols. Counselling of 
patients at the bedside is routine. Despite these additional responsibilities, clinical 
pharmacists in most National Health Service (NHS) Trusts in the UK perform a daily 
pharmaceutical review on more patients than ever before, yet at the same time must 
retain and ensure the safety and quality of their review. It is not unusual for pharmacists 
to be responsible for the pharmaceutical care of more than a hundred patients daily as 
ward sizes increase in an attempt to improve efficiency. 
 
1.1.4. Advances in Technology 
The number of admissions to secondary care has increased year on year over the last 
three decades, in the 5 years preceding 2013 alone, admissions to hospitals in England 
increased by 13 percent to on average 41,500 patients per day (data from the Health and 
Social Care Information Centre (HSCIC)). Consequently, coupled with rising patient 
expectations, and the increasing complexity of drug treatments and administration 
regimens, demands on clinical pharmacists have increased. However, despite this, 
pharmacists have managed to retain patient safety at the heart of their work even when 
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faced with additional necessity for documentation and expanded roles. It is possible that 
many of the operational changes, which have enabled these improvements, have been 
due to the advances in technology.  
In the early 1990s ward based pharmacy was performed solely by reviewing paper 
prescription charts at the patient’s bedside and reviewing the laboratory results at the 
nurse’s station for any patients deemed to be at high risk of an ADE dependent on their 
test results.  
The use of paper documentation was inefficient as it was a time consuming process. 
Sometimes clinical notes would be difficult to locate or be in use by another member of 
the multidisciplinary team. If a patient was having a procedure or in theatre, then neither 
the patient’s prescription chart or notes, would be available to the pharmacist.  
Figure 1.2 Pharmacist review of a paper prescription chart in the ward environment in the 
1990s 
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In the early 1990s, despite there being concerns regarding communication across the 
primary/secondary care interface, medicines reconciliation was not carried out as the 
norm. At this time, even FP10 prescriptions issued by general practitioners were not 
computer generated and did not include a tear off slip summarising medications (Figure 
1.3) now used widely by clinical pharmacists to inform them of the patient’s drug history 
when performing medicines reconciliation.   
Figure 1.3 Repeat Prescription slip from FP10 
 
As a result, communication of medicines related issues at the primary/secondary care 
interface was poor13,14. Between 1995 and 200015, prescribing in the community became 
solely electronic but despite widespread concerns, there was no corresponding move to 
electronic prescribing in the hospital setting. 
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The quality of pharmaceutical review in the early 1990s was also poor in comparison to 
the reviews undertaken in most NHS Trusts today.  Prescription charts, written by hand, 
were often illegible or ambiguous and since their design varied between settings, it was 
(and remains the case where they are still in use) difficult to educate prescribers in their 
use.  Incidents frequently occurred owing to a breakdown of communication between 
healthcare professionals in the acute care setting and poor documentation was 
frequently a cause of drug errors16.  
Despite these limitations, paper charts are still used in many settings where electronic 
alternatives are not available. To combat issues of errors arising owing to poor 
documentation and movement of prescribers (particularly locums) between settings, a 
decade ago, the NHS in Wales (advised by the All Wales Medicines Strategy Group) 
adopted an all Wales inpatient prescription chart (Figure 1.4) and like most prescription 
charts it was developed in collaboration with clinical pharmacists with the aim to reduce 
medication errors.  
The EQUIP study17, which was sponsored by the General Medical Council (GMC) to 
investigate the cause of prescribing errors amongst hospital doctors found that the 
causes of errors were multifactorial although much more could be done during 
undergraduate training to improve prescribing activity. The study did not investigate the 
effect of using a standardised prescription chart but it did advocate their standardisation. 
Movement of hospital doctors and now, non-medical prescribers is increasing between 
hospitals, which supports the case for greater commonality. 
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Despite the experience in Wales, elsewhere in the UK, owing to the increasing complexity 
of drug administration and changes to legislation and standards for patient assessment, 
the necessity for comprehensive documentation has resulted in drug charts which are 
technically challenging and far from intuitive for those using them.  Over the past decade 
many acute Trusts in England have turned to electronic prescribing and administration 
systems (electronic prescribing and medicines administration (EPMA)) in an attempt to 
improve patient safety and efficiency. The Francis Report  in 201218 called on the NHS to 
make better use of technology and in May 2013, the Health Secretary announced a £260 
million technology fund set up to support his call for a paperless NHS by 2018. It was 
thought likely that most of the fund (called the “Integrated Digital Care Fund”) would be 
spent on investment in electronic prescribing in acute Trusts. 
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Figure 1.4 All Wales Prescription Chart 
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1.2. Clinical Pharmacy at University Hospitals NHS Foundation Trust 
(UHBFT) 
 
1.2.1. Electronic Prescribing at UHBFT 
Most acute trusts in the UK already employ at least some form of electronic prescribing 
documentation, mostly in a single speciality. However some Trusts use electronic 
prescribing and administration systems across the entire in - and outpatient population. 
The majority will also have access to other electronic databases enabling timely review of 
laboratory data at the patient’s bedside enabling a more detailed and comprehensive 
clinical overview of the patient by clinical pharmacists.  In some Trusts in the UK, EPMA 
systems include laboratory data, observations, assessments and much more in one single 
electronic system. Many of these more complex systems include prompts and alerts 
when prescribing and admitting patients providing decision support for users. Such 
systems are frequently termed clinical decision support systems (CDS or CDSS). 
University Hospitals Birmingham NHS Foundation Trust (UHBFT) employs an EMPA 
system, which was built and developed in house which now has numerous CDS elements, 
inputted over the past 15 years by pharmacists and prescribers. The system, known as 
the Prescribing and Information Communication System (PICS), has transformed the way 
in which clinical pharmacy is delivered in the Trust. Prior to using the PICS, clinical 
pharmacists covering inpatient wards would be responsible for an average of 50 patients 
each day. Now, with access to reliable, comprehensive laboratory results, observations, 
assessments and admission details in the PICS, pharmacists may review 70-100 patients 
daily. 
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Figure 1.5 Review of a Patient’s Medication Chart by a Pharmacist at the Patient’s 
Bedside 
 
Using the PICS, the clinical pharmacy review is more visible and quantifiable than reviews 
using a paper chart.  An individual pharmacists’ performance can be measured by key 
performance indicators (KPIs) audited from direct outputs from the PICS such as; number 
of pharmacist sign offs, number of interventions, number of falls drug assessments and 
number of drug histories completed. Audit data to support educational initiatives 
concerned with most aspects of prescribing and administration of medicines is available 
to clinical pharmacists on request since every “click” in the system is auditable.  
The PICS allows clinical pharmacists to carry out all of the functions they performed on a 
paper chart with improved access to additional patient information with the ability to 
educate prescribers “en mass” through a series of drug templates, prompts, warnings and 
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alerts built into the system by pharmacists and clinicians. However, in simple terms, the 
PICS has the benefits of legibility, accessibility and errors caused by erroneous or absent 
information on a handwritten chart. Figure 1.6a and 1.6b compare examples of a 
handwritten and electronic inpatient prescription charts respectively at UHBFT.  
Figure 1.6a Handwritten inpatient chart in use in some UHBFT wards pre 2005 
Figure 1.6b PICS inpatient chart in use in all UHBFT wards post 2005 
  
21 
 
However, despite these potential benefits it is important to recognise that there are also 
potential pitfalls to electronic prescribing19–22. Training of staff to use the system takes 
time and the implementation of such systems requires a great deal of planning to prevent 
adverse events during the switch from paper to an electronic system. Pre-set 
prescriptions may result in poor education of junior doctors when moving between 
clinical settings since they are no-longer required to learn doses and treatment regimens. 
It is also important that a system is not overloaded with warnings and alerts since “alert 
fatigue” can cause prescribers to dismiss alerts without considering their significance. It is 
imperative that these factors are taken into consideration when designing and 
programming an EPMA system. 
 
1.2.2. The Clinical Pharmacist Review at UHBFT. 
UHBFT consists of 30 inpatient wards each consisting of 36 beds and 7 specialist units, 
which are served by the clinical pharmacy service. Like most acute trusts, inpatient wards 
at UHBFT are allocated a pharmacist on a daily basis. The allocation is generally 
determined by the knowledge and experience of the clinical pharmacist with respect to 
the ward speciality and forms a daily rota.  
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Figure 1.7 Example of the Clinical Pharmacy Rota at UHBFT 
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More experienced pharmacists are usually allocated specialities and wards where 
patients with more complex medical issues are more likely to be sited, such as Critical 
Care Units and wards caring for transplant patients. Less experienced pharmacists are 
usually allocated elderly care and trauma specialities where drug regimens in the main, 
are less complex.  
Unlike AHPs who are referred patients for review, pharmacists are responsible for 
reviewing every patient on their allocated ward on admission and in theory, again on a 
daily basis until discharge. Clinical pharmacy services use this method for allocation of 
workload in almost all trusts in the UK. 
At UHBFT, pharmacists are required to comply with the local clinical pharmacy standards 
for review of each patient on their allocated ward/s. The standards require that for each 
patient the following is completed: 
1. Medicines Reconciliation undertaken and recorded on the PICS 
2. Validation and sign off on PICS of all medicines prescribed  
3. Interventions into the patient’s drug regimen documented on the PICS 
4. Drugs assessed for risk of falls and recorded on the PICS for those patients at risk 
of falls 
5. Patient counselled and recorded on the PICS for newly prescribed medicines or 
those with an NPSA or CSM warning referring to counselling points against them 
Each pharmacist has around 2 hours allocated to review a 36 bed ward in order that a 
clinical pharmacy service is provided to all inpatient areas (with the exception of 
ambulatory care).  
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Medicines reconciliation alone takes an average 22 minutes to perform23 so that where a 
ward has more than 5 new patients a day, pharmacists find it an almost impossible task 
to complete the quality of care they should be delivering as part of the local clinical 
pharmacy standards.  
On review, a pharmacist may deem a daily pharmacy visit to be unnecessary for patients 
who are unlikely to need pharmaceutical intervention in order they may prioritise their 
workload.  Currently prioritisation predominantly involves targeting new patients and 
assessing their requirements for further pharmacy intervention.  New patients can be 
identified from a list view on the PICS since they do not have a green cross next to their 
name denoting that a drug history has been documented as part of the medicines 
reconciliation process (Figure 1.8). The pharmacist will then perform an ad hoc risk 
assessment which includes checking clinical, biochemical, and pharmaceutical details in 
the PICS to determine whether or not the patient is receiving the appropriate choice of 
medicine, in the right dose, frequency and at the right time, if they are at risk of 
experiencing an adverse drug event (ADE) and crucially if the patient requires an 
intervention into their treatment.   
However, since most of the information used by a pharmacist to risk assess a patient is 
held within the PICS, it may be more efficient if the information was used to develop a 
risk model in the PICS to highlight those patients at most need of pharmacist review.  For 
example patients with certain complex medical issues or with certain demographics may 
predispose them as “high risk” for an ADE. If patients at high risk could be highlighted in 
the PICS, the information could be utilised to direct the pharmacy service to patients who 
are most likely to have a requirement for a pharmacist’s intervention.  
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Figure 1.8 Pharmacy Patient List View on PICS 
Patients who have not yet had Medicines Reconciliation performed by Pharmacy will not 
have a Pharmacy “green cross” next to their name. 
 
 
 
 
 
26 
 
 
1.3. Risk Assessment and Pharmaceutical Risk Models. 
 
1.3.1. Background to Risk Assessment. 
The Oxford Dictionary defines risk assessment as “a systematic process of evaluating the 
potential risks that may be involved in a projected activity or undertaking.” Risk 
assessment is the assessed potential for adverse consequences resulting from a hazard. A 
risk assessment process should distinguish between hazards (the potential to cause 
harm) and risk (the likelihood of that harm being realised during a specified amount of 
risk exposure).  
Probably the most common example of formal risk assessment is a Health and Safety risk 
assessment which is carried out in the workplace and involves assessing the risk of harm 
to employees when undertaking their daily duties. However, it was the aviation industry 
who first introduced risk assessment more than 20 years ago24 as a means of ensuring the 
safety of the general public and who today, employ multiple risk assessment processes at 
the core of complex Safety Management Systems. As patient and government 
expectations rise in terms of safety and quality in healthcare, there has been a move to 
replicate the experiences of the aviation industry.  
 
 
 
27 
 
1.3.2. Pharmaceutical Risk Assessment of Patients 
Most clinical pharmacists who prioritise the pharmaceutical care of their patients will be 
unaware that they are effectively using their knowledge and skills to risk assess patients 
in order to determine which patient receives the benefit of a full and complete clinical 
pharmacist review. However, some clinical pharmacists are familiar with the concept and 
have developed local models to allow systematic risk assessment of patients. In some 
cases risk assessment has been used to identify those patients in the community and in 
the hospital setting who are at risk of experiencing a medication related issue25 (Figure 
1.9). In other cases, risk assessment has been used to identify low risk 
departments/wards from which the clinical pharmacy service can be withdrawn should 
the need arise (e.g. in the event of a pandemic) (Fig. 1.10). 
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Figure 1.9 Examples of Pharmaceutical Risk Assessment of Patients in the Community and 
in Hospital 
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In the case of review of patients by AHPs, the referral process to AHPs serves as a risk 
assessment. A medical practitioner or nurse will review the patient holistically and make 
referral to an appropriate AHP if required. An intervention made by the AHP may 
subsequently mitigate the risk. The prescription of a medicine is by far the commonest 
intervention in healthcare and as such over 99% of the inpatient population will be 
prescribed a medicine. To prevent all patients with a prescription from being referred to 
a pharmacist, referral by another healthcare professional would require knowledge of the 
medicines prescribed and the quality of referral likely to be dependent on the 
pharmaceutical knowledge of the referrer. An alternative may be to provide a detailed 
checklist for completion by the referrer but this may be time consuming and eventually 
lead to failure of the referral system. However, an automated risk assessment model in 
PICS, developed using the expertise of pharmacists and based on evidence would enable 
high risk patients to be highlighted (or referred) to clinical pharmacists and potentially 
pharmacy technicians, enabling the pharmacy team to direct services to those patients in 
greatest need. 
The pharmacy department at UHBFT has already used models for risk assessment of 
wards to determine whether the department should provide a clinical pharmacy service 
to the areas assessed, particularly at times when pharmacist resource was stretched e.g. 
winter pressures. The audit tool has been used across the West Midlands and in the 
North West of England (Figure 1.10). 
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Figure 1.10 Pharmaceutical Risk Assessment of Departments / Wards. 
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The tool assesses patients in the clinical areas against a number of risk factors thought to 
contribute to the need for a clinical pharmacist review (such as age, number of medicines 
the patient is taking, renal and liver function), and combines this with a score determined 
by the respective speciality and collates the results to produce an overall risk score for 
the ward concerned. The higher the risk score, the greater the need for a clinical 
pharmacy service in that area. The hazards included in the tool have been defined by 
clinical pharmacists as those recognised as potential risk factors when performing clinical 
pharmacy duties; and although the potential risks are similar to those used in the tool 
represented in Figure 1.9, there is little evidence to support the choice of hazards in any 
of the tools developed and it is not clear if the list of hazards are comprehensive.  
In 2011 UHBFT used the tool in Figure 1.10 to assess the need for a clinical pharmacy 
service across the Trust. Data was gathered using a paper-based method with manual 
extraction of the necessary data from PICS. The results were collated and compared 
against the current clinical pharmacy service. However, it came as little surprise to find 
that those areas which were not covered by a clinical pharmacy service had an extremely 
low risk score and those with a high risk score such as critical care and renal wards, 
already had a high pharmacist to patient ratio. Pharmacy managers had already used 
their pharmaceutical knowledge to direct services to those areas in greatest need 
without the use of the tool. Subsequently there was no change to the clinical pharmacy 
service and despite an increase in the number of beds across the trust, there was no 
corresponding increase in pharmacist numbers. 
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It was clear that a new way of working was required for clinical pharmacists but a number 
of questions would need to be answered in order that an evidence base could be 
established for clinical pharmacy services and the assurance of patient safety. 
1. What are the evidence based risks associated with patients experiencing an 
adverse drug event in hospital? 
2. Can patients be risk assessed individually for their requirement for a clinical 
pharmacy review in the same way that whole wards have been risk assessed 
previously? 
3. Can this risk assessment be achieved in real time using an electronic prescribing 
system (PICS) at UHBFT? 
4. Can a triage/referral system be developed in PICS to direct clinical pharmacy 
services to those patients at risk of experiencing a problem with their medicines 
and send more experienced pharmacists to those patients in greatest need? 
 
 
 
1.4. Research Question 
Is it possible to develop an electronically generated “risk score” based on an individual’s 
pharmaceutical and clinical risk, which is capable of directing a hospital clinical pharmacy 
service to those inpatients most in need of pharmaceutical intervention? 
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1.5. Aims 
The research topic aims to: 
 Develop a risk assessment tool as a safe and effective method of delivering a 
clinical pharmacy inpatient service in which the need for a clinical review by a 
member of the pharmacy team, is clearly defined, based on pharmaceutical and 
clinical risk as determined through an electronic prescribing system. 
 
 
1.6. Objectives 
Research objectives will be to: 
 Determine which parameters are associated with the risk of patients experiencing 
an adverse drug event using a systematic review of the literature.  
 Determine whether the risk parameters identified can be quantified through 
University Hospitals Birmingham’s (UHBFT) electronic prescribing system 
(Prescribing and Information Communication System (PICS)). 
 Quantify risk factors using analysis of clinical pharmacy interventions as a possible 
predictor of a preventable drug related problem. 
 Design a risk management model based on a numerical risk score for hospital 
inpatients to determine which patients are most in need of intervention by a 
member of the pharmacy team in order to reduce risk. 
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CHAPTER 2 
RISK FACTORS ASSOCIATED WITH  
THE REQUIREMENT FOR PHARMACEUTICAL INTERVENTION IN THE 
HOSPITAL SETTING:  
A SYSTEMATIC REVIEW OF THE LITERATURE 
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2. Risk Factors Associated with the Requirement for 
Pharmaceutical Intervention in the Hospital Setting:  
A Systematic Review of the Literature. 
 
2.1. Introduction 
 
2.1.1. Background. 
 
There are many studies which aim to determine the risk factors which lead to patient 
admission to the hospital setting and indeed these studies are valuable in meeting the 
QIPP agenda26  in the United Kingdom (UK) by preventing admissions into secondary care. 
QIPP is a national policy driver in the UK, which seeks to reduce costs in the UK National 
Health Service (NHS) through improving Quality, Innovation, Productivity and Preventing 
(QIPP) readmission to hospital. 
It has been shown that more than 6% of all hospital admissions are due to adverse drug 
events (ADEs)27 with the result that there have been an increasing number of community 
based methodologies trialled internationally to identify and target patients displaying risk 
factors for intervention.28–33 Most of these studies have used incident report review, 
prescription chart review, direct observation or trigger tools to identify at-risk patients. 
The trigger tool method in which patients are screened for perceived risk factors for 
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ADEs, has been shown to be the most effective and labour–efficient method for 
identifying vulnerable patients34. At the same time, the availability of electronic 
prescribing systems (EP) and clinical decision support (CDS) has resulted in the 
development of a number of “trigger tools” for adverse drug events driven by rule based 
alerts programmed into a CDS system35–37. 
However, research into drug related problems post hospital admission is not so 
accessible and the use of a number of different terminologies and definitions such as 
ADEs, Adverse Drug Reactions (ADRs), Drug Errors, Drug Related Problems (DRPs) and 
Medication Related Problems (MRPs) make it difficult to make comparisons between 
studies available. As a result there are fewer studies in secondary care, which seek to 
determine the causative factors of adverse outcomes from the use of drugs. 
A number of corporate approaches to assess risks associated with drug usage exist. 
Retrospective assessment of incident reports in the hospital setting in the UK is 
widespread with the majority of acute trusts identifying local trends in drug-related 
incidents. Reporting ADRs to the Medicines and Healthcare Regulatory Agency (MHRA) 
and drug related incidents to the National Patient Safety Agency (NPSA) (replaced by the 
NHS Commissioning Board Special Health Authority and now, NHS England) has been the 
norm for many years with the result that there has been an increasing awareness of high 
risk prescribing areas amongst pharmacists and prescribers. The NPSA have issued 
alerts38 in this area including those pertaining to high risk drugs, drug omissions, patients 
who are nil by mouth and the administration of medicines using syringe drivers. Similarly, 
the Institute for Safe Medicines Practices (ISMP) in the United States39 and the Australian 
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Commission on Safety and Quality in Health Care (ACSQHC)40 have used a similar system 
of alerts raising awareness of the risk of ADEs in organisations internationally.  
This increasing awareness of risk in the hospital setting has led researchers in the UK to 
pilot a national trigger tool, The Medication Safety Thermometer41, which seeks to 
identify patients at risk of harm from omission of high risk drugs using data pooled from 
reports to the NPSA. This may prove to be a valuable tool in reducing patient harm but 
does not address all of the risks that a pharmacist should target.  
In most UK hospitals, clinical pharmacists aim to review all in-patient prescription charts 
with the intention of identifying any medicines related problems and performing any 
necessary intervention into the patient’s care by making recommendations for changes in 
drug therapy or further monitoring of the patient. By performing such pharmacist 
interventions, pharmacists have become familiar with certain types of medicines or 
patient factors, which more often predispose the patient to intervention and may 
endeavour to ensure that all patients with such factors receive an in-depth review of 
their medicines chart. Essentially as part of their daily review, pharmacists already 
perform a risk assessment of sorts when reviewing patients’ drug charts. As a result, 
patients with impaired renal or liver function, those taking anti-epileptics or medication 
for Parkinson’s disease or displaying polypharmacy, may already be in receipt of 
increased pharmacist monitoring albeit ad hoc and qualitative. Assessment of the impact 
of pharmaceutical intervention is also usually qualitative with the result that the value of 
clinical pharmacy services is not well documented, communicated or perceived by 
hospital managers in the UK. 
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Patients are unlikely to be documented as “high risk” for medicines related problems and 
/ or in need of targeted intervention by the pharmacist with the possible exception of 
cases where a pharmaceutical care plan has been employed. However, producing a 
pharmaceutical care plan is extremely labour intensive and is therefore often only 
completed for the most complex cases in the acute setting. National initiatives such as 
reduction of dosage omissions, targeting high risk drugs, supporting patient adherence 
and expanded roles are increasingly taking up the time of the clinical pharmacist. In a risk 
driven, resource limited environment, targeting clinical pharmacy services to ensure safe, 
timely, high quality services centered on patient safety should be paramount. 
 
2.1.2. Aims 
 
The purpose of this systematic review is to determine the evidence base for measurable 
risk factors that pre-dispose to the requirement for an intervention by a pharmacist or to 
the development of a drug related problem (DRP). The review seeks to list those risk 
factors for pharmaceutical intervention or DRPs with the intention that they may be used 
in further research to build an evidence-based trigger tool, targeting individuals at risk of 
DRPs in the hospital setting. In particular, the aim is to target high-risk patients on 
general medical and surgical wards rather than patients in specialist settings where the 
presence of specialist equipment and personnel may already mitigate the risks associated 
with the use of medicines.  
 
The aims of this systematic review are to search the international literature to: 
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a) Determine factors associated with the requirement for pharmaceutical 
intervention and prevention of potential subsequent DRPs; 
b) Determine measurable risk factors for DRPs; 
c) Document the frequency and critically review papers reporting such risk factors. 
 
 
2.1.3. Objective 
 
The objective is to document all primary research identifying measurable risk factors for 
pharmaceutical intervention or drug related issues which may be retrieved prospectively 
from a patient’s clinical records during their inpatient stay in hospital whether these be 
demographic, clinical or otherwise.  
The intention is that the results may be used for further research to identify patients at 
risk of experiencing problems with their medicines and requiring intervention with a view 
to targeting pharmaceutical input in the hospital setting. To search for potential risk 
factors for interventions only would depend upon an assumption that pharmacists are 
comprehensively targeting all issues related to adverse outcomes associated with the use 
of medicines. 
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2.2. Methods 
 
Identification of measurable risk factors associated with adult hospital inpatients on 
non-specialist wards, which affect the number (or type) of pharmaceutical 
interventions or drug related problems. 
A literature review was conducted systematically using the principles and checklist set 
out in the PRISMA statement42 in order to source all primary research identifying 
measurable risk factors for drug related problems or pharmaceutical interventions. The 
term “drug related problem” (DRP) in this review included all definitions of adverse drug 
events (ADEs), adverse drug reactions (ADRs), drug related errors, medication related 
problems (MRP) or drug related problems (DRP) in the literature. No date or language 
restrictions were applied during the review. However, the search was closed in July 2013 
and identified no papers prior to 1966. 
Paper Inclusion Criteria:  Measurable risk factors, patients over 16 years, inpatients in 
secondary or tertiary care centres, all definitions of  ADEs, ADRs, MRPs, DRPs and clinical 
pharmacy interventions, inpatients in medical and surgical wards, all primary research 
and systematic reviews. 
Paper Exclusion Criteria: Qualitative risk factors (e.g. patient’s previous knowledge of 
medicines), studies reporting outcomes indirectly associated with pharmacist 
interventions or adverse events associated with medicines e.g. medicines adherence, 
studies of patients 16 years or less, outpatients, ambulatory care and community based 
studies, studies solely in patients in specialist care settings e.g. intensive care, summary 
articles (with the exception of systematic reviews) and discussion articles. 
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Initially on-line searches were conducted of databases 1-10 included in Table 2.1. 
Searches were undertaken in the chronological order of inclusion in the table. 
The PICOS method43 was used to formulate the review question and identify free text 
search terms through a combination of mind-mapping by the primary author and a focus 
group consisting of 10 members of the UK West Midlands Clinical Pharmacy Group: 
 Population - adult hospital inpatients  
 Intervention – unknown risk factors  
 Comparison – no risk factors  
 Outcomes – a problem associated with medicines use or the requirement for 
pharmaceutical intervention 
 Study design – Primary research and systematic reviews 
Free text search terms included: Risk, Risk Assessment, Clinical Risk, Susceptibility, Drug, 
Medicine, Medicines Reconciliation, Drug History, Clinical Check, Age, Elderly, Adult, 
Compliance Aids, Medicines Adherence, Comorbidity/ies, Long term conditions, 
Therapeutic Drug Monitoring, Renal Function, Liver function, prescription, Early warning 
score, Dose/Dosage, Pharmacy Review, Biochemistry, Urea and Electrolytes, Tests, 
Microbiology, Intervention, Adverse Drug Event, Adverse Drug Reaction, Drug Error, 
Medication Error and Pharmacy Service. 
 
MeSH descriptors were identified from free text terms inputted into the databases listed 
in Table 2.1 and included: Risk, Risk Factor, Hospital Risk, Risk Assessment, Lifestyle Risk 
Reduction, Risk Reduction, clinical prediction rule, clinical prediction, health risk, health 
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risk appraisal, Pharmaceutical Preparations, medicine, Drug Administration Schedule, 
Drug administration routes, Drug Combinations, Drug Hypersensitivity, Drug Interactions, 
Drug Synergism, Drug Therapy Drug toxicity, Medical history taking, Drug prescriptions, 
Decision Support techniques, clinical pharmacy, Medical informatics, Pharmacists, 
Pharmacy service Hospital, Pharmacy Service, Hospital, Clinical Pharmacy Information 
Systems, Drug Utilization Review, Pharmaceutical services, intervention studies, 
Pharmacy Service, Hospital, medication errors. 
 
Following the database search a manual search was conducted of Journals 11-21 in Table 
2.1 using on-line access. 
Initial searches found no papers linking risk factors with the requirement for a 
pharmaceutical intervention. Further on-line searching was conducted for grey-literature 
using the free text search terms listed above, and in particular for Internet publications 
linked to pharmaceutical interventions, using Google and Firefox as a browser. 
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Table 2.1 Databases and Journals Searched 
Name of 
Database 
Location Description Pros Cons 
1. Medline www.ncbi.nlm.nih.
gov/PubMed 
Bibliographic records (with 
and without abstracts) of 
biomedical literature from 
1966 onwards. 
Extensive electronic database 
with literature from 1966. 
Clinical Pharmacy not in 
practice prior to 1966 
North American 
emphasis? Less 
International studies and 
non-English language. 
2.EMBASE www.embase.com Biomedical literature from 
1974 onwards 
Greater European emphasis Greater European 
emphasis. ?international 
studies. Has a high 
pharmacological content. 
3.Cochrane 
Data Base of 
Systematic 
Reviews 
http://www.cochr
ane.co.uk/en/inde
x.html 
Database of systematic 
reviews, includes reviews of 
work in progress 
Cochrane reviews base their 
findings on research that 
meets certain quality criteria 
and authors of reviews apply 
methods which reduce the 
impact of bias 
Includes only systematic 
reviews and trials which 
meet strict criteria, will 
exclude grey literature 
and papers with a weaker 
evidence base which may 
be a problem if there are 
few papers available on 
the subject 
4.CINAHL www.cinahl.com Records of literature on all 
aspects of nursing and allied 
health disciplines 
May cover qualitative studies Unlikely to include clinical 
pharmacy as not a true 
AHP 
5. 
Dissertation 
Abstracts 
http://www.umi.c
om/en-
US/catalogs/datab
ases/detail/pqdt.s
html 
Dissertation Abstracts, 
Dissertation Abstracts 
International (DAI) or the 
ProQuest Dissertations and 
Theses (PQDT) database is a 
bibliography of American 
(and international) 
dissertations published by 
University Microfilms 
International (UMI) / 
ProQuest, Ann Arbor, since 
1938.  
It covers doctoral dissertations 
accepted at an accredited 
American institution since 
1861. Selected Masters theses 
have been included since 1962; 
since 1988, the database 
includes citations for 
dissertations from 50 British 
universities that are available 
at The British Document Supply 
Centre. 
UMI has changed it’s 
name and owner several 
times and the 
bibliographical data 
therefore appears under 
different labels. It also 
covers few dissertations 
outside US and UK. 
6.Science 
Citation Index 
http://thomsonre
uters.com/en/pro
ducts-
services/scholarly-
scientific-
research/scholarly
-search-and-
discovery/web-of-
science-core-
collection.html  
 Relevant studies found through 
electronic or manual searches 
can be used to identify further 
relevant citations on the same 
topic through citation search 
on Science Citation Index 
Requires thorough 
searches before using the 
citation Index 
7.Conference 
Papers Index 
http://ca2.csa.co
m/factsheets/cpi-
set-c.php 
Records of conference 
presentations 
Will cover some unpublished 
work presented at conferences 
Unpublished work may be 
of poorer quality than 
published peer reviewed 
work 
8.uk Clinical 
Research 
Network: 
Portfolio 
Database 
http://public.ukcr
n.org.uk 
Details of research in 
progress 
Gives details of work underway 
which may not yet be 
published 
only covers research in the 
UK. Since work may be 
unpublished, no indication 
of the quality of the 
research. Does not include 
any projects listed before 
2007 
9.National 
Research 
Register 
Archive 
http://www.nihr.a
c.uk/Pages/NRRAr
chive.aspx 
Details of research 
documented prior to CRN in 
2007 
Covers work not included in 
CRN portfolio 
Only covers research in 
the UK. Requires follow up 
to indicate if any papers 
were published and the 
quality of this work 
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10.SIGLE 
(System for 
Information 
on Grey 
Literature) 
http://www.open
grey.eu 
Bibliographic database 
covering European non-
conventional literature in 
the field of pure and applied 
natural sciences and other 
areas 
Quick method for searching 
grey literature 
Database for grey 
literature can never be 
comprehensive (like other 
databases). Does not 
cover non-European grey 
literature 
11.Clinical 
Pharmacist 
http://www.phar
mpress.com/prod
uct/13527967/clin
ical-pharmacist 
Leading British clinical 
pharmacy journal. Founded 
in 2009  
May show work not yet 
published to database and grey 
literature of relevance 
Quality of work may be 
variable. Only covers 
British research post 2008 
12.Hospital 
Pharmacist 
http://www.phar
mj.com/backissue
s/hp.html 
Leading British clinical 
pharmacy journal. Founded 
in 2000  
May show grey literature of 
relevance 
Quality of work may be 
variable. Only covers work 
2000-2008 
13.British 
Journal of 
Clinical 
Pharmacy 
http://www.clinic
alpharmacy.org.uk
/home 
British Journal founded in 
2009 
May show grey literature of 
relevance 
Quality of work may be 
variable. Only covers 
British research 
14.British 
Journal of 
Clinical 
Pharmacolog
y 
http://onlinelibrar
y.wiley.com/journ
al/10.1111/(ISSN)
1365-2125 
Journal from the British 
Pharmacological Society. 
One of the world's leading 
clinical pharmacology 
journals. 
Publishes papers, original 
papers, short communications, 
correspondence, and reports 
on all aspects of drug action in 
man. Peer reviewed. 
Quality of work may be 
variable. Mainly British 
research. 
15.European 
Journal of 
Hospital 
Pharmacy 
http://ejhp.bmj.co
m/ 
The premier communication 
platform for European 
hospital pharmacists, EJHP 
Science and Practice is a 
major source for continuing 
education as well as updates 
on advances in the practice 
and standard of 
pharmaceutical care for 
patients 
Peer-reviewed papers, 
features, conference reports 
and more on topics covering all 
aspects of hospital pharmacy 
from both a scientific and 
practice perspective 
International work not 
included 
16.American 
Journal of 
Hospital 
Pharmacy 
currently without 
website accessed 
at: 
https://www.rese
archgate.net 
 Monthly Journal from the 
American society of Hospital 
Pharmacists.1958-1994 only 
Includes American innovation Details work only until 
1994. Excludes 
international work 
17.American 
Journal of 
Health -
System 
Pharmacy 
http://www.ajhp.
org/content/by/ye
ar 
Current journal from the 
American Society of Hospital 
Pharmacists from 1994-date 
Includes American innovation Excludes international 
work 
18.Australian 
Journal of 
Hospital 
Pharmacy 
Currently without 
website accessed 
at:http://search.in
formit.com.au/bro
wseJournalTitle;re
s=IELHEA;issn=031
0-6810 
The Australian Journal of 
Hospital Pharmacy was the 
official journal of The 
Society of Hospital 
Pharmacists of Australia 
(SHPA) from 1996 to 2001, 
succeeded by the Journal of 
Pharmacy Practice and 
Research 
Includes Australian work Only includes work until 
1996 
19.Journal of 
Pharmacy 
Practice and 
Research 
http://search.infor
mit.com.au/brows
eJournalTitle;res=I
ELHEA;issn=1445-
937X 
Australian Pharmacy 
Practice Journal from 2002 
to date 
Includes Australian work Excludes international 
work 
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20. 
International 
Journal of 
Clinical 
Pharmacy 
(Known as 
Pharmacy 
World and 
Science Prior 
to 2011) 
http://www.spring
er.com/medicine/i
nternal/journal/11
096 
International Journal which 
includes Australian work of 
clinical pharmacy and 
related practice orientated 
subjects 
Includes Australasian work ? Biased towards work 
reported in English 
language 
21. 
International 
Journal of 
Pharmacy 
Practice 
http://onlinelibrar
y.wiley.com/journ
al/10.1111/(ISSN)
2042-7174 
Produced by the Royal 
Pharmaceutical Society, 
Medline-indexed, peer 
reviewed, international 
journal. 
 One of the leading journals 
publishing health services 
research in the context of 
pharmacy, pharmaceutical 
care, medicines and medicines 
management. Regular sections 
in the journal include, 
editorials, literature reviews, 
original research, personal 
opinion and short 
communications. 
? Biased towards work 
reported in English 
language 
 
 
After screening the abstracts, all potentially relevant full text publications were evaluated 
through intensive reading. Citations included in the retrieved articles were reviewed and 
if relevant, were sourced, evaluated and citations checked. 
All sourced articles were tabulated to allow validation of a final list of citations and a final 
list of included papers drawn up. The validation of this final list was carried out by a 
pharmacy research graduate. Using the tabulated list of sourced articles and the agreed 
inclusion/exclusion criteria, the research graduate independently evaluated the articles 
against their respective abstracts.  Where the abstract did not provide sufficient 
information for the article to be evaluated against the inclusion/exclusion criteria, the full 
text was provided to the research graduate.  
Finally, the research graduate and primary author met to discuss any remaining articles 
where an agreement had not been reached during the independent evaluation until final 
concurrence was achieved.  
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In order to quantify the results of the review, a thematic analysis was undertaken. 
Through intensive reading, risks were identified as such as those listed as independent 
risk factors in the research conclusions and subsequently tabulated to allow for common 
themes (risks) to be identified.  
Statistical identification of the risk factor as an independent risk factor was not required 
for identification in the review results table although where statistical methods excluded 
or included a risk factor as an independent risk factor, this was noted in the conclusions. 
Positive and “negative” associations of risk factors were also noted in the results table. A 
“negative” association was not a risk factor with a protective association but noted as 
such where the research had shown there to be no association between the risk factor 
and DRPs or the requirement for a pharmacist intervention. 
Positive and negative associations with risk factors were documented in Table 2.2 as 
reported in the text and totaled in order to identify the most commonly reported risk 
factors. 
All risk factors identified in the literature by more than 1 primary research paper were 
listed and all others noted as “other”. 
Those studies which demonstrated an association between certain drugs or drug classes 
and risk of problems associated with medicines were further tabulated in Table 2.3 to 
identify which drugs are most commonly associated with DRPs (all definitions included). 
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2.3. Results 
 
Figure 2.1 indicates the publication outputs at each stage of the review process. 
Using search terms “risk” and “adverse drug events”, 44,731 articles were identified 
initially from online searches. This was reduced to 7,720 through the use of “AND” as the 
Boolean operator to link to a 3rd relevant search term.  
All resulting titles were viewed and 120 abstracts identified for possible inclusion in the 
review from searching online search engines. 
A further 29 full text papers were identified from manual searching Journals 11-21 in 
Table 2.1. In total 149 full texts were sourced. 
A preliminary screen of the sourced texts and cross referencing of citation by the primary 
author resulted in a list of 82 papers which were tabulated and sent for independent 
evaluation by a pharmacy research graduate. 
Intensive reading by the primary author of the resulting 82 papers eliminated a further 46 
in accordance with the study inclusion/exclusion criteria.   
The same 46 were independently eliminated by the research graduate, while 2 papers of 
the 82 were included back into the final results after discussion and agreement with the 
primary author. 
The resulting 38 papers were tabulated in Table 2.2. 
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 Figure 2.1 Systematic Review Process 
 
Free text search “risk” and “adverse drug events” 
Employment of “AND” as Boolean operator with multiple search terms 
Review of abstracts 
Manual identification of papers 
Clinical 
Pharmacist 
2 
J Pharm Pract 
& Research 
9 
Int J Pharm 
Practice 
4 
Aus J Hosp 
Pharmacy 
2 
Am J Health-
Sys Pharm 
0 
Am J Hosp 
Pharmacy 
0 
Hospital 
Pharmacist 
0 
Int J Clin 
Pharmacy 
2 
Br J Clin 
Pharmacy 
0 
Br J Clin 
Pharmacol 
8 
Eur J Hosp 
Pharmacy 
2 
149 full papers 
sourced 
82 papers 
tabulated  
Preliminary Screen -73 
36 papers 
identified  
Intensive reading -46 
Validation +2 papers 
38 Final Papers  
Cross-referencing +6 
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Table 2.2 Overview of Studies of Patient Risk Factors for Drug-related Problems 
Reference 
Study Setting 
 
Study Design 
SCS = Single Centre Study 
MCS = Multicentre Study 
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Limitations to Study 
Alderman, C.P. and 
Farmer, C. (2001) 44 
Australian 
teaching hospital 
SCS 
Prospective study of prevalence of pharmacy interventions with manual collection of 
data. 
67 interventions 

  

 
  
SCS only. Sample size very small. 
No denominator (no. of interventions  may be affected by 
prescription rate) 
Al-Hajje, A.H., Atoui, F., 
Awada, S., et al. (2012) 45 
Beruit university 
hospital 
SCS 
Prospective study involving clinical pharmacy students trained to identify DRPs on a 
medical ward round and analysis of resulting interventions 
90 DRPs in 572 
patients 


  

 
  
No denominator (increase in percentage of DRPs related to a 
particular drug may be due to an increased number of prescriptions 
for that drug) 
Bates, D.W., Miller, E.B., 
Cullen, D.J., et al. (1999) 
46 
US. Medical and 
surgical inpatients 
2 Tertiary care hospitals – 
2 methods used:  
1. Cohort study 
2. Nested matched case control study 
Cohort Study 2109 
Case Control 247 of 
4108 total 
admissions 

 

 
  
Only 2 tertiary centres which may hinder generalizability to other 
care settings. Cohort analysis looked only at information available 
electronically. 
Blix, H.S., Viktil, K.K., 
Reikvam, \A Asmund, et 
al. (2004)47 
5 general 
hospitals - 
Norway. 
MCS -Medical inpatients excluding A&E departments 
Prospective manual recording of assumed clinical and pharmacological risk factors. 
Impact of various risk factors on occurrence of different categories of DRPs using 
multivariate analysis 
827 patients     
  
Bowman, L., Carlstedt, 
B.C., Hancock, E.F., et al. 
(1996)48 
US general 
hospital 
SCS medical inpatients. 
Prospective drug chart review. Univariante logistic regression to identify covariate 
predictors of ADR from laboratory, demographic and total drug exposure. Stepwise 
multivariate logistic regression to identify those univariate indicators that best predict 
ADR occurrence 
1024 patients 



 
  
SCS only. 
Bowman, L., Carlstedt, 
B.C. and Black, C.D. 
(1994)49 
US general 
hospital 
SCS medical inpatients. 
Prospective observational study using manual chart review by pharmacists 
304 ADRs in a total 
of 1024 patients 


  

 
  
The study is quite old and SCS only so that drugs used in the study 
may differ somewhat from those used 20 years on. 
Calderón-Ospina, C. and 
Bustamante-Rojas, C. 
(2010)50 
US university 
hospital 
SCS 
Prospective study including manual assessment of adult inpatients. All reports of ADRs 
subsequently evaluated by 3 independent researchers 
102 patients 

     
  
Small sample size may have led to overestimation of percentage of 
cases 
Camargo, A.L., Ferreira, 
M.B.C. and Heineck, I. 
(2006)51 
Brazilian 
university hospital 
SCS 
Cohort study using logistic regression analysis to identify risk factors. Factors 
demonstrating significant association with an ADR were included in the multivariate 
logistic regression model. 
360 ADRs    
  
19.7% of the ADRs were prior to admission, this review is primarily 
focused on ADRs in the inpatient setting 
Carbonin, P., Pahor, M., 
Bernabei, R., et al. 
(1991)
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Italy – general 
hospital- medical 
and geriatric 
wards 
MCS 
Prospective study using clinician identification of ADR, logistic regression to determine 
risk factors and multivariate logistic regression to identify independent risk factors 
788 ADRs from 
9,148 admissions 

    



ADRs may have been under reported as relying on physician 
reporting. 
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Limitations to Study 
Classen, D.C., Pestotnik, 
S.L., Evans, R.S., et al. 
(2005)53 
US tertiary care 
centre 
SCS 
Prospective study of all patients admitted over an 18 month period 
648 patients with 
ADEs in a total of 
36,653 admitted 
patients 


  

 
  
Authors acknowledge that age may not be an independent risk 
factor. Further studies required to investigate this. Number of ADEs 
identified appears low and potentially, minor ADEs may have been 
undetected by this method 
Claydon-Platt, K., 
Manias, E. and Dunning, 
T. (2012)54 
Australian 
teaching hospital 
SCS conducted over 2 years 
Retrospective cohort study of medication related problems in inpatients with diabetes. 
Risk factors associated with medication-related problems were identified using random 
effect logistic regression 
571 patients in a 
total of 5205 
admitted patients  
    
 

Data used was collected for other purposes so links to other risk 
factors may have been omitted. Risk factors in diabetes may not be 
valid in other cohorts. 
Davies, E.C., Green, C.F., 
Taylor, S., et al. (2009)55 
UK university 
hospital 
SCS over a six month period 
Prospective cohort study of ADRs. Risk factors for ADRs were identified using 
multivariable analysis. 
545 patients from 
3695 patient 
episodes 
  

 
 

SCS, likely to be variation between different hospitals because of the 
differences in the local population characteristics and specialities 
within the hospitals 
Dequito, A.B., Mol, 
P.G.M., van Doormaal, 
J.E., et al. (2011)56 
Holand –general 
hospitals 
2 Dutch hospitals using CPOE - 5 month data collection .Prospective cohort study. 
Univariante analysis followed by multivariante analysis analysis was performed using a 
logistic regression to establish independent risk factors for preventable ADEs and non-
preventable ADRs 
349 patients from 
603 admissions 
   
 

Only gastroenterology, rheumatology, geriatrics and internal medical 
patients included. Results may not be transferable to other 
specialities and hospitals. 
Fattinger, K., Roos, M., 
Vergères, P., et al. 
(2000)57 
Switzerland 
teaching hospital 
2 teaching hospitals. 
Prospective cohort study using a purpose built database. Clinical events were reported 
in a separate database by separate personnel to avoid bias. Regression analysis used to 
identify risk factors. 
2102 patients of 
4331 admissions 
  

 
  
ADRs included “accepted” side-effects e.g. Nausea and vomiting 
from chemotherapy 
Fields, W., Tedeschi, C., 
Foltz, J., et al. (2008)58 
United States – 
community 
hosiptal 
2 community non-teaching hospitals Prospective study using a multi-method approach - 
voluntary self-reports, e-prescribing, laboratory triggers and pharmacist intervention 
surveillance. 
1052 medication 
safety events- of 
these 318 were 
classified as errors 
 
  

 
  
Analysed data from medication errors only and did not address other 
ADEs 
Gurwitz, J.H. and Avorn, 
J. (1991)59 
United States 
Literature review  examining the association of age with ADRs 
Medline search for articles between 1966 and 1990.   
  

 
  
Review over 20 years old but principles likely to still apply 
Hoonhout, L.H., de 
Bruijne, M.C., Wagner, 
C., et al. (2010)60 
Netherlands 
MCS 
Analysis of medication-related adverse events (MRAEs) identified by retrospective chart 
review of patients admitted to 21 hospitals in 2004 
140 patients of 7889 
admissions 


  

 
  
Difficult to make comparisons to other studies due to differing 
definition of MRAEs however, conclusions look similar to other 
studies 
Hurwitz, N. (1969)61 
Irish university 
hospital 
SCS 
Prospective study using a rank correlation to determine relationship between age, sex, 
length of stay in hospital, no. of drugs, history of previous drug reactions, allergic 
disease, jaundice, diabetes and renal disease. 
 
118 ADRs from 
1,160 patients 

  

 
  
SCS from 1969. Are the same factors relevant with the differing drug 
groups available in the inpatient setting today? 
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Hurwitz, N. and Wade, 
O.L. (1969)62 
Irish general 
hospital 
SCS 
Prospective study of patients admitted to surgical and medical wards by means of case 
note review and patient interview 
118 patients of 
1,160 patients 
receiving drugs 


  

 
  
SCS from 1969. Are the same factors relevant with the differing drug 
groups available in the inpatient setting today? 
Johnston, P.E., France, 
D.J., Byrne, D.W., et al. 
(2006)63 
US University 
Hospital 
SCS 
Prospective analysis of AE reports. A three stage logistic regression model used to 
evaluate key indicators of the most vulnerable patient populations 
59,531 admissions, 
including 782 AEs 
which included 83 
ADRs and 699 errors 
  

 
 

The number of ADRs in this study was small (only 83) while the study 
mainly collected data on medication errors. 
Kanjanarat, P., 
Winterstein, A.G., Johns, 
T.E., et al. (2003)64 
United States 
Literature Review 
Key word search of Medline and International Pharmaceutical Abstracts and by manual 
search. 
Ten studies between 
1994 and 2001 


  

 
  
Only 10 studies reviewed. Does not include more recent work and 
therefore does not cover newer therapies. 
Kelly, W.N. (2001a)65 
Study from Clin-
Alert, an 
abstracting 
service in the US. 
Retrospective study of case reports of fatal ADEs published between 1976 and 1995. 
447 cases involving a 
fatal ADE. 


  

 
  
No denominator. An increase of fatal ADEs may have been 
attributable to the number of prescriptions in the respective class. 
Kelly, W.N. (2001b)66 
Study from Clin-
Alert, an 
abstracting 
service in the US. 
Retrospective study of case reports of drug-induced permanent disabilities published 
between 1978 and 1997. 
227 cases involving a 
drug-induced 
permanent disability 


  

 
  
No denominator. An increase in disabilities may have been 
attributable to the no. of prescriptions in the respective class. Study 
includes children which this systematic review excludes 
Krähenbühl-Melcher, A., 
Schlienger, R., Lampert, 
M., et al. (2007)67 
Switzerland 
Literature Review 
Electronic Search using Medline and Embase for articles published between 1990 and 
2005. Subsequent manual search of resulting articles for original research. 
11 studies reporting 
risk factors for ADRs. 


 
 
 Comprehensive review but excludes drugs to market post 2005. 
Marcellino, K. and Kelly, 
W.N. (2001)68 
Study from Clin-
Alert, an 
abstracting 
service in the US. 
Retrospective study of case reports of drug-induced threats to life published between 
1977 and 1997. 
846 drug-induced 
life threats. 


  

 
  
No denominator. An increase in life threats may have been 
attributable to the number of prescriptions in the respective class or 
that the associated condition treated was a risk to life. 
O’Connor, M.N., 
Gallagher, P., Byrne, S., 
et al. (2012)69 
Irish University 
Hospital 
SCS. Study to examine the GerontoNet ADR risk score in elderly patients. Prospective 
study, ADRs identified through patient and physician consultation and case note 
analysis. Multivariante logistic regression examined  influence of individual variables on 
ADRs 
135 ADRs from 513 
acutely ill patients 
 

 
  
Sample size quite small and single centre only 
Onder, G., Petrovic, M., 
Tangiisuran, B., et al. 
(2010)70 
Italy 
MCS - 4 European university hospitals .Data from an Italian research group used to 
identify variables associated with ADRs using stepwise logistic regression and used to 
compute the ADR risk score. The risk score was then validated in a sample of older 
adults. 
383 ADRs in 5936 
patients 

      
 
Risk score may not be relevant in the under 65 age group and the 
risk score excludes any other risk factors. 
Pearson, T.F., Pittman, 
D.G., Longley, J.M., et al. 
(1994)71 
US community 
hospital 
SCS. Retrospective analysis of ADRs through internal voluntary reporting system. Patient 
characteristics compared for patients experiencing preventable and non-preventable 
ADRs 
203 

  

 
 

Reliance on voluntary reporting of ADRs. Actual number of ADRs may 
have been much higher resulting in a small sample size. 
Although the ADRs were all independently reviewed, all the 
reviewers were pharmacists which may have introduced bias. Single 
centre only 
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Runciman, W.B. (2003)72 Australia Literature review of systematic reviews and national data collections 53, 388 ADRs 

  

 
  
Review does include community data but the studies are separated 
out in the review to detail specifics in secondary care 
Samuel, S.A., Rajendran, 
S.D., Ebenezzar, S., et al. 
(2002)73 
2 general 
hospitals in India 
2 sites. Prospective study post introduction of an ADR monitoring programme. Manual 
reporting of ADRs and patient interview. 
152 ADRs 

  

 
  
Includes some data from the outpatient setting. No denominator i.e. 
number of ADRs recorded with probable causative agent but no 
record of number of prescriptions for respective agent. 
Schimmel, E.M. (2003)74 
US university 
hospital 
Reprint of Annals of Internal Medicine, 1964, volume 60, pages 100-110. Prospective 
study. Recording by house officers of all noxious events in patients admitted under them 
119 ADEs    

 
  
Excludes ADEs which did not have a harmful outcome e.g. if the 
house officer altered treatment before an adverse incident occurred. 
Does not report a rate of ADEs for each drug i.e. no denominator. 
Relevance now with new drug groups available? Also single centre. 
Smith J.W., Seidl, L.G. 
and Cluff, L.E. (1966)75 
US university 
hospital 
SCS. Prospective study with manual chart review 
151 drug reactions 
in 900 patients 
   

 


Only rate of reactions reported, multivariante logistic regression 
required to determine if independent risk factors. 1965 study and 
drug groups used today have altered somewhat. 
Steel, K. (2004)76 United States 
Reprint of the New England Journal of Medicine, 1981, volume 304, pages 638-42. 
Prospective study of medical pts. - manual review of case notes vs. a standardised 27 
item instrument to identify iatrogenic issues. Hospital interventions categorised and 
included no. and type of drugs 
290 pts experiencing 
iatrogenic illness. 
208 caused by drugs 


  

 
  
Study from 1979. Drugs prescribed today may result in greater or 
less risk. No denominator included to determine rate of ADRs. 
Unclear if the study covered ADEs such as hypoglycaemia with 
insulin? Is this covered by the definition of iatrogenic illness? 
Tegeder, I., Levy, M., 
Muth-Selbach, U., et al. 
(1999)77 
University 
Hospital, 
Germany. 
SCS. Retrospective case note analysis to assess if changes in lab data due to ADR and if 
physician recognised this 
294 patients 
 
  

 
 

Small sample size. Changes in lab data may be a consequence of the 
ADR and not a pre-disposing risk factor for developing an ADR. 
Van den Bemt, P., 
Egberts, A.C.G., 
Lenderink, A.W., et al. 
(2000)78 
.Dutch  general 
hospital. 
Study in 2 Dutch general hospitals 
149 ADEs in 538 
patients 
   

 
 

Study from 1996 so groups of drugs prescribed may now be a little 
outdated. 
Van Kraaij, D.J., 
Haagsma, C.J., Go, I.H., et 
al. (1994)79 
Dutch general 
hospital. 
SCS- Patients 65 years and over Naranjo’s algorithm used to estimate the probability of 
adverse event being attributable to a drug. Multiple regression analysis used to measure 
interrelationships between variables 
120 ADRs in 105 
patients 


  

 
  
Study only includes patients 65 years and over. Only single centre 
and medical patients only included 
Viktil, K.K., Blix, H.S., 
Moger, T.A., et al. 
(2007)80 
Norwegian 
general hospitals 
MCS - 5 sites. Prospective cohort study using manual case note/chart review by the 
MDT. 
Univariante analysis and a multivariante logistic regression to assess influence of gender, 
age and clinical risk factors on no.s of drugs prescribed. 
827 patients 

   

 
  
Drug discontinuations during hospital stay not recorded 
Wiffen, P., Gill, M., 
Edwards, J., et al. 
(2002)81  
Systematic review of the literature .Comprehensive search of MEDLINE (1966-1999), 
EMBASE (1980 -1999) and International Pharmaceutical Abstracts (1970-1999) 
 
    


Excludes studies post 2000. Most studies cited refer to elderly pts 
only which excludes drugs and characteristics common in the young. 
    
28 18 14 9 9 7 5 4 3 3 10 Positive Associations 
    
0 0 7 0 2 1 0 1 0 0 0 Negative Associations 
 
54 
 
Ten risk factors were identified in more than 1 primary research paper (see below in 
descending order of prevalence): 
Prescription of certain drugs or classes of drugs, polypharmacy, elderly patients (defined 
as over 60-75 years or older), female gender, poor renal function, the presence of 
multiple co-morbidities, length of patient stay, history of drug allergy or sensitivity, 
patient compliance issues and poor liver function. 
Table 2.3 lists the 28 studies that reported that the prescription of certain drugs or 
classes of drugs were a risk factor in the development of drug related problems. The ten 
most common classes of drugs reported to be associated with DRPs in the hospital setting 
are, in descending order of prevalence: 
Intravenous antimicrobials, thrombolytics/anticoagulants, cardiovascular agents, CNS 
agents, corticosteroids, diuretics, chemotherapy, insulin/hypoglycaemics, opiates and 
antiepileptics.
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Table 2.3 High Risk Drugs for Drug-related Problems 
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Alderman, C.P. and Farmer, C. (2001)44             
Al-Hajje, A.H., Atoui, F., Awada, S., et al. (2012)45             
Blix, H.S., Viktil, K.K., Reikvam, \AAsmund, et al. 
(2004)47 
          
theophylline, allopurinol, potassium, 
and levothyroxine 
Bowman, L., Carlstedt, B.C. and Black, C.D. (1994)49             
Calderón-Ospina, C. and Bustamante-Rojas, C. (2010)50  

Betablockers 
         
Camargo, A.L., Ferreira, M.B.C. and Heineck, I. (2006)51             
Classen, D.C., Pestotnik, S.L., Evans, R.S., et al. (2005)53             
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             
2.4. Discussion 
 
2.4.1. High Risk Drugs 
 
The ten risk factors most frequently associated with drug related problems are not 
unsurprising and yet are poorly documented as such in the literature. The identity of the 
drugs themselves and the associated class effects are the most commonly reported risk 
factor for DRPs and yet it is not possible to quantify the risk associated with the use of an 
individual drug or drug class. For example, intravenous antibiotics are the most 
frequently reported drug class increasing the risk of DRPs, while thrombolytics and 
anticoagulants constitute the second most prevalent group. However, none of the 
publications identified by the systematic review quantify those risks. Further research 
would be beneficial to identify a risk score for each drug class to facilitate comparisons 
and measures for prevention.  Similarly there is no information that compares risks 
associated with drugs within each class.  
The four most commonly named groups were antimicrobials, anticoagulants and 
thrombolytics, cardiovascular drugs and drugs acting on the central nervous system 
(CNS). Definitions of these classes of drugs were not included in almost all of the papers 
reviewed. While definition of antimicrobials, anticoagulants and thrombolytics are quite 
well defined in reference sources such as the British National Formulary (BNF), 
cardiovascular and CNS drugs are more difficult to define with some drugs belonging to 
more than one category. Without clear definitions of drug categories, interpretation of 
the findings and further research could be problematic. In the case of antimicrobials, 
none of the researchers considered the possibility that the presence of infection may 
58 
 
have been the causative factor leading to a DRP.  Further, without a specific definition of 
antimicrobials it is not clear whether a distinction should be made between the risks 
associated with the use of intravenous antimicrobials, compared to oral and topical 
forms. 
It is important to identify that any conclusions taken from this review are interpreted in 
general medical and surgical settings only. In order to obtain meaningful data, 
researchers have investigated groups of patients taking widely available and frequently 
prescribed medicines in hospital. None of the review papers reported the frequency of 
prescribing for a particular drug class i.e. there was no reported denominator. It is 
possible that the large number of DRPs associated with diuretics for example is 
associated with their widespread use. Some of the newer drugs to the market which the 
researcher would expect to be associated with a large number of DRPs compared to the 
number of prescriptions such as monoclonal antibodies, anti-retrovirals and anti-rejection 
drugs, are not included in any of the review papers and the results do not mirror alerts 
for high risk drugs issued nationally and internationally38–40.  
The present review did not impose a date restriction on papers despite concerns that this 
might have a direct impact on the range of drugs identified as high risk. However, only 
the inclusion of diuretics as a high-risk category seemed unexpected. On review of the 
date of the articles citing diuretics as a high risk drug category, four of the eight 
publications were published post 2005; should all papers prior to 2005 in the review been 
excluded, diuretics would remain as a top ten high risk drug.  
One approach to increasing awareness of the risks associated with individual medicines 
could be that in the future, all drugs are risk assessed before they come to the market as 
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part of the clinical trial process. Products could be assigned a risk score prior to issue of 
market authorisation using a process similar to that undertaken for intravenous 
medication under UK NPSA Alert 20. In light of post marketing studies and national 
incident reporting systems, modifications of risk scores could accompany national patient 
safety alerts. 
2.4.2. Polypharmacy 
 
It is widely accepted and undisputed in the literature, that polypharmacy has a direct 
effect on the number of drug related problems. Polypharmacy has also been shown to be 
an independent risk factor for the development of DRPs47,48,51,52,55–57,69,70,78,80. Various 
definitions of polypharmacy exist ranging from prescription of 2 to 6 or more medicines82. 
However, it is more likely that there is a continuous relationship80, possibly exponential81 
between the number of drugs taken and the risk of developing a drug related problem. 
2.4.3. Age 
 
Older age (definitions vary from over 60 years50,61,63,67 to over 75 years69) was reported as 
a risk factor for drug related problems in 14 studies, however a further 6 
studies47,48,51,52,57,79 reported  that age is not an independent risk factor for DRPs. The 6 
studies which demonstrated that age is unlikely to be an independent risk factor used 
multi-variant analysis and logistic regression to show that the association of older age 
with DRPs is more likely to be associated with the increased incidence of multiple co-
morbidities, multiple medications, poor renal function and compliance issues in elderly 
persons rather than a direct association with their age per se. This was supported by a 
literature review59 over 20 years ago which recognised that most studies examining age 
and ADRs (including all definitions) failed to control for multiple drugs and multiple co-
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morbidities. As the elderly population increases and research in this area continues, it is 
likely that the risks associated with the use of drugs in old age will become clearer. 
However, it seems logical that as life expectancy increases, exceeding the age of 65 years 
is unlikely to influence the likelihood of suffering an adverse drug reaction whereas the 
prevailing general state of health will.  
One study54 reported that the age group 18 -50 years was a risk factor for ADEs, but it is 
likely that this was due to the fact that the study group comprised only diabetic  patients. 
2.4.4. Renal Function 
 
Poor renal function was the 4th most frequently reported risk factor, listed in nine 
papers46–48,58,67,69–71,75. However, as long ago as 1966, Smith75 recognised that this risk 
factor is only likely to increase the rate of ADRs when using certain groups of drugs that 
are eliminated renally. However, any patient with poor renal function may have the 
potential to be prescribed one of these drugs and, as such, may already be deemed at risk 
of a DRP prior to prescription. The recommended dosage or frequency adjustments in 
renal failure are well documented for affected agents so that this risk may be minimised 
if appropriately identified. This was supported by Fields and co-workers58 who recognised 
the importance of early estimation of creatinine clearance (CrCl) through computerised 
order entry to identify renal function as a risk factor for preventable adverse drug events. 
 
2.4.5. Gender 
 
Female gender is the 5th most frequently reported risk factor for experiencing drug 
related problems with nine papers reporting an association48,49,54–57,61,67,81. However, it is 
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possible that the link between DRPs and female gender may be weak since one paper 
demonstrated that gender was not an independent risk factor for ADRs51 while another 
reported that adverse drug events occurred more often in men than in women63. 
However, numbers in the latter study63 were small and most adverse events were due to 
drug errors, which are unlikely to be affected by the gender of the patient. Further 
detailed research is required to define the precise relationship. 
 
2.4.6. Co-morbidities 
 
Seven papers included multiple co-morbidities as a risk factor for DRPs 21,26,28,30,44,55,24. 
However, Camargo51 used multivariate logistic regression and identified that multiple 
diagnoses were unlikely to be an independent risk factor for ADRs. It is possible that the 
increased number of medicines taken by patients with multiple co-morbidities could have 
a bearing on the number of DRPs experienced by patients. Conversely, it is also possible 
that a patient’s susceptibility to ADRs is increased by their poor overall health, that their 
metabolism of drugs may be affected by their condition or additional unknown factors.  It 
would be advisable for more research to be carried out in this area. 
 
2.4.7. Length of Stay 
 
Length of hospital stay was reported as a risk factor49,51–53,56 for DRPs. This seems a logical 
connection in that any adverse event (drug related or otherwise) is more likely to occur 
the longer the patient is observed, which in the case of hospital inpatients would be 
dependent on their length of stay. However, it was reported in a single paper51 that there 
is an association between the follow-up period (period of time as an inpatient after an 
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ADR). In this case it is possible that the occurrence of an ADR caused the increase in 
length of stay through treatment failure, drug toxicity or other factors. None of the 
review papers reported that patients were more likely statistically to experience a DRP 
the longer the patient stayed in hospital i.e. the intra-patient risk at any point in time 
does not increase with the length of inpatient stay. However, it is also likely that patients 
who have longer hospital stays suffer from complex conditions or are more unwell, 
making them more susceptible to drug related problems throughout their stay: under 
such circumstances length of stay would be unlikely to be an independent risk factor. 
 
2.4.8. History of Allergy and Compliance Issues 
 
Other risk factors for DRPs included in the literature were previous history of allergy or 
ADR and compliance issues listed as risk factors in four47,61,70,71 and three47,52,81 papers 
respectively. Patients who may have a genetic predisposition to ADRs or who display 
atopic characteristics may be more likely to experience ADRs. Smith75 noted that 
although there was not an overall increase of ADRs in this group, there was an increase in 
allergic reactions. 
Compliance issues included assumed non-compliance, low cognition, and other factors 
affecting patients taking their medicines such as alcohol abuse and swallowing 
difficulties. Such barriers to compliance intuitively would predispose patients to DRPs. 
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2.4.9. Liver Function 
 
The association of deteriorating liver function with DRPs is less well documented. Only 3 
papers47,70,75 list deteriorating liver function as a risk factor. In an analogous situation to 
those with renal impairment, poor liver function is likely to only be associated with an 
increased risk of DRPs when certain drugs are used i.e. those whose elimination or 
distribution is hepatic or affected by the reduction in protein metabolism which 
accompanies deterioration of liver function. Again this relationship was recognised by 
Smith75 who noted in his study that although the overall rate of ADRs was not increased 
by decreasing liver function, the rate for certain groups of drugs was slightly increased.  
Drug management in hepatic failure generally differs to therapy in renal failure. Often the 
risks of hepatotoxicity drive the decision to treat with a drug or not, in contrast to dosage 
or frequency adjustments required to avoid immediate toxicity or treatment failure 
encountered in renal failure. Prescribers often only have one of two options when 
considering a drug for use in liver failure: “to use or not to use?” - essentially a 50 percent 
chance of making the correct decision and avoiding toxicity which may (or may not) result 
in an adverse drug event. The likelihood of ADEs in patients with renal failure as opposed 
to liver failure seem much greater owing to errors in prescribing. These issues are 
compounded in renal failure owing to drug accumulation or treatment failure as CrCl 
reduces. 
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2.4.10. Other Risk Factors 
 
Other risk factors which were uniquely identified (and were therefore not tabulated as 
top 10 risk factors in this review) included admission to a medical ward55, elderly care 
ward, rheumatology ward or gastroenterology ward56, source of admission (e.g. from 
home, general practitioner, clinic etc.)63, insurance class (U.S)63, infection75, changes in 
patient’s biochemical/haematological parameters77, new drug initiation in hospital78, 
single marital status27, use of drugs with a narrow therapeutic index67 and therapeutic 
drug monitoring (TDM) requirement in the absence of a pharmacokinetics service71. Since 
these associations were only reported in single studies, there may have been 
explanations for the reported risk factors. It seems likely that drugs with a narrow 
therapeutic index or requiring TDM are indeed generic risk factors in all specialities and 
that starting a new drug in any setting poses a risk owing to drug error or poor 
compliance. However, it is less obvious that factors such as single marital status are 
independent risk factors for drug related problems. Perhaps married patients may be 
older and their lifestyle more predictable providing a supportive environment for 
improved compliance.  
 
2.4.11. Limitations to the Review 
 
The search methodology relied on appropriate links being created from databases to key-
words in the literature. When the full texts were evaluated, 44 citations were identified 
from cross-referencing. It was found that 30 of these papers were available through 
databases listed in Table 2.1 indicating that the online database search had not captured 
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all relevant papers. However, these databases were rechecked using various other 
combinations of the search terms listed in an attempt to confirm that no other papers 
remained. In particular, cross-referencing identified a number of older articles which have 
been included in this review but whose significance may be debatable owing to 
differences in drug treatments available historically. 
Most notably, no outputs listing risk factors requiring intervention by a pharmacist were 
detected using these methods. It is possible that research into pharmacist interventions 
would assume a direct correlation between pharmacist intervention and an adverse drug 
event. Researchers may deem it more appropriate to assess risk factors leading to the 
latter since the presence of an adverse event suggests that either there has been no 
preventative intervention or an intervention has been unsuccessful in prevention of the 
adverse event. Whichever is the case, without a proven correlation between 
pharmaceutical intervention and the outcome of an adverse event, research 
methodology may be better directed at risk factors leading to adverse events caused by 
medicine use.  
Similarly, research into pharmacist interventions is more likely to be carried out by 
pharmacists themselves who already target patients perceived to be at risk, this may 
result in bias. Intervention research is more likely to be targeted at those areas 
pharmacists may be missing i.e. actual reported DRPs rather than pharmacist 
interventions i.e. the near miss. Pharmacists may wish to determine whether DRPs are 
preventable, non-preventable or partially preventable through pharmaceutical 
intervention before targeting clinical pharmacy services to patients with risk factors for 
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DRPs. Certainly, research in this area is lacking and has resulted in difficulties in 
quantifying the worth of clinical pharmacy services. 
There were further limitations to the review in that the search method employed relied 
on the use of a number of electronic databases (Table 2.1) all of which used English as the 
primary language. Similarly, all of the journals searched were publications in the English 
language. As a consequence, although the databases included citations from 
international journals, it is likely that there is a bias towards publications in the English 
language and that other work, in particular from the Far East may have been overlooked. 
The review which was completed in 2013, imposed no date restriction on papers included 
however, the oldest paper identified was from 1966, papers prior to this date are less 
likely to be comprehensively included in the electronic databases searched. It is 
recognised that this may have a bearing on those drugs included as high risk. Further, up-
to-date research is required in this area since inclusion of current, accepted high risk 
drugs are conspicuous in their absence from recent literature e.g. monoclonal antibodies, 
anti-retrovirals and biosimilars. There is currently little difference in those drug groups 
associated with DRPs and those included in the literature prior to 2005. It is also possible 
that the lack of inclusion of a denominator in papers reporting classes of high-risk drugs 
caused some of the newer drug classes to be absent from the more recent research 
papers. 
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2.5. Conclusions 
 
Review of the literature found 38 papers, which detailed 10 measurable risk factors 
linked with drug related problems in hospital inpatients. Each were identified in the 
literature by more than one primary research article. There were no papers which 
detailed the risks associated with the likelihood of experiencing a pharmaceutical 
intervention. More research is required in this area as although it is likely that 
interventions are carried out where there is a risk of a problem associated with the use of 
medicines, this cannot be assumed. It is possible that there are additional factors, which 
cause pharmacists to intervene which have not been previously identified. 
All of the risk factors for DRPs are potentially identifiable from an individual patient’s 
records on admission to hospital and it is hoped that these risk factors may be used to 
identify patients at risk with a view to targeting pharmaceutical input in order to 
minimise the risk of a DRP. Risk factors include older age, polypharmacy, presence of 
multiple comorbidities, poor renal function, poor liver function, compliance issues, 
female gender, length of hospital stay, previous history of allergy or ADR and class of drug 
prescribed. 
Prescriptions which are associated with a high risk for DRPs include antimicrobials 
(intravenous antibiotics), anticoagulants and thrombolytics, cardiovascular drugs and 
drugs acting on the central nervous system (CNS). More research is required to ensure 
that newer drug classes are included in research into risks associated with DRPs and 
whether the risks associated with the use of high-risk drugs are preventable. 
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CHAPTER 3 
IDENTIFICATION OF COMMON CATEGORIES  
OF PHARMACIST INTERVENTIONS 
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3. Identification of Common Categories of Pharmacist 
Interventions. 
 
3.1. Introduction 
 
3.1.1. Background 
A pharmacy intervention can be defined as:  
‘An intervention which results in the correction of a prescribing/transcribing error or the 
provision of pharmaceutical advice which optimises the patient’s care’83.  
A pharmacist intervention is not a clinical pharmacy review of a patient’s medication but 
an intervention into their treatment as a consequence of such a review. Not all inpatients 
in hospital in the UK will be the recipient of a pharmacy intervention but most will receive 
a pharmacy review of all their medications.  
Chapter 2 concluded that there were no studies within the limitations of the systematic 
review, which identified risk factors leading to pharmacist interventions. It is possible that 
this is due to poor association between pharmacist interventions and adverse drug 
events (ADEs) with the result that research into risk factors leading to outcomes for 
patients is more likely to be directed at adverse events in order to achieve reliable 
research outcomes. Historically, this poor association may be for a number of reasons but 
it seems logical that when conducting research regarding risks associated with ADEs or 
other drug related problems to review data where events actually occurred rather than 
pharmacist interventions, which in essence, constitute a “near miss”. 
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However, although evidence of a direct correlation between pharmacist interventions 
and medicines related incidents is poor, there is increasing evidence that pharmacist 
interventions in certain settings, do or can, lead to a reduction in ADEs3,84–87. As a 
practicing pharmacist in a tertiary care setting, the researcher is also aware that it is 
common place for pharmacists to record the circumstances which lead to an intervention 
and the precise detail of the respective intervention. In comparison ADEs are often poorly 
recorded and at worse, undocumented88,89. This wealth information regarding pharmacist 
interventions gives a unique opportunity for analysis of the circumstances peri-
intervention and potentially (assuming we accept the hypothesis of a “near miss”), the 
circumstances prior to an ADE. 
Pharmacist interventions are usually recorded on intervention forms which prompt the 
intervening pharmacist to record specific details of the intervention and outcome. 
Documentation forms may be paper based (e.g. Figure 3.1), paper based with later 
transfer to electronic database or more recently directly into an electronic database (e.g. 
Figure 3.2). 
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Figure 3.1 Example of Hard Copy Intervention Documentation Tool 90 
 
 
Figure 3.2 Example of an Electronic Intervention Documentation Tool 91 
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The main purpose of documentation of pharmacist interventions is twofold. The first 
from an operational perspective, is that they provide evidence of service or individual 
performance and the second is to provide analytical data for research into the 
interventions and the ADEs which, in theory, they prevent. Consequently pharmacists 
have developed numerous different tools to record interventions, which enable 
retrospective data analysis. However, there is no national or international guidance on 
what should be documented and the categories of information documented vary. 
Pharmacists use their own pharmaceutical knowledge and expertise to determine the 
local procedure for documentation and usually adapt a regional or a prestigious centre’s 
approach and categorisation to suit local initiatives. 
What shouldn’t be ignored is that almost always, one of the purposes of documentation 
of pharmacist interventions is to enable analysis of the documentation to find “patterns” 
in the intervention data either after local informal review (which is most often the case) 
or after formal research. These “patterns” potentially identify where most frequently 
interventions are occurring with a view to putting preventative measures in place. For 
example, a simple analysis of intervention data might show that prescribers consistently 
prescribed the incorrect dose of drug x, on finding this “pattern” in the data, the 
pharmacy team may issue guidance on dosage for the drug. 
In essence, pharmacists have developed intervention documentation forms to analyse 
not only what happens when they perform an intervention for operational purposes but 
where and why they are performing interventions. Assuming that interventions are a 
“near miss” for an ADE the categorisation of “where” and “why” of Pharmacist 
intervention documentation may constitute perceived risk factors for ADEs.   
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3.1.2. Aims 
The purpose of this systematic review is to identify which categories are most commonly 
used when documenting pharmacy interventions in secondary or tertiary care. These 
categories may also be risk factors for ADEs. 
All categories of interventions will be included, not just those which are thought to 
identify risk factors for intervention or ADE. This is because there may be risk factors 
which have not been previously identified in the literature or recognised by researchers 
but have been used as categories for analysis for other purposes (e.g. financial and 
economic evaluation).  
The intention is that the results together with those risk factors identified in Chapter 2, 
may be used for further research to identify patients at risk of problems associated with 
the use of medicines and requiring intervention with a view to targeting pharmaceutical 
input in hospital. 
 
3.1.3 Objective 
The primary objective is to identify and document all measurable categories of 
pharmacist interventions in secondary or tertiary hospital settings which may be 
retrieved prospectively from a patient’s clinical records during their inpatient stay in 
hospital whether these be demographic, clinical or otherwise.  
Objectives include: 
a) Identify all measurable categories by searching the literature and tabulating the 
results; 
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b) Determine which of these risk factors may be retrieved from clinical 
documentation through intensive reading. 
 
3.2. Methods 
 
Identification of quantitative and measurable categories used when documenting or 
analysing pharmacist interventions in the adult inpatient setting in secondary care. 
A systematic review was conducted to source primary research identifying measurable 
categories for pharmacist interventions. All definitions of pharmacist interventions were 
included.  No language restrictions were imposed however publications prior to the year 
2000 were excluded. 
The author used mind mapping to identify the following free text search terms: pharmacy 
intervention, pharmacist intervention, pharmaceutical intervention, categories, 
categorization, analysis, documentation, review, recording. 
 
Paper Inclusion Criteria:  Measurable intervention categories, patients over 16 years, 
inpatients in secondary or tertiary care centres, all definitions of pharmacy interventions,  
inpatients in medical and surgical wards, all primary research and systematic reviews. 
 
Paper Exclusion Criteria: Qualitative categories, studies of patients 16 years or less, 
outpatients, ambulatory care and community based studies, studies solely in specialist 
care settings dealing with narrow group of patients e.g. intensive care and diabetes 
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patients, summary articles (with the exception of systematic reviews) and discussion 
articles. Table 3.1 details the databases searched. 
 
Table 3.1 Databases Searched to Identify Common Categories of Pharmacist Interventions 
Name of 
Database 
Location Description 
1. Medline www.ncbi.nlm.nih.gov/PubM
ed 
Bibliographic records (with and 
without abstracts) of biomedical 
literature from 1966 onwards. 
2.EMBASE www.embase.com  Biomedical literature from 1974 
onwards 
3.Cochrane 
Data Base of 
Systematic 
Reviews 
http://www.cochrane.co.uk/
en/index.html 
Database of systematic reviews, 
includes reviews of work in progress 
 
3.3. Results 
 
An initial search (Figure 3.3) of the online databases using the free text search terms 
listed identified the following number of articles, the title of which was reviewed by the 
researcher: 
PubMed- Initial, 146 articles 
Embase – Initial, 236 articles 
Cochrane Database – Initial 14 reviews 
The web was also searched using a domestic search engine, to identify any grey 
literature. One study was identified by this method. 
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Forty two articles were identified from the title alone and this was reduced to 31 after 
review of the abstract. A further 6 articles were removed owing to publication prior to 
the year 2000 and consequently a total of 25 full text articles were sourced for intensive 
reading. Of the remaining articles, 6 were discarded at intensive reading since they did 
not document the classification system used in the study or were discussion articles 
concerning the principles of and necessity for comprehensive and retrievable 
documentation of clinical interventions by pharmacists. 
The final 19 articles are listed in Table 3.2. As part of the intensive reading process, the 
categories of interventions used both at the documentation stage of the intervention and 
during analysis which took place as part of the study was recorded in Table 3.3. 
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Figure 3.3   Review Process 
 
 
 
 
 
 
 
 
 
 
Free text search  
Identification of titles 
Duplicates 
Removed 
Intensive reading -6 
42 
Abstract Review 
31 
Date Restriction 
25 full text articles 
sourced 
19 final articles 
tabulated 
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Table 3.2 Studies Using Categorisation of Interventions. 
Author, Year Country Study Type Study Aim Intervention definition 
Method of 
Recording 
Classification Source 
Alderman et 
al., 200144 
Australia Prospective analysis of intervention 
considered to have the potential to 
cause considerable harm over a 30 day 
period 
To study the “near miss” scenarios detected in the 
course of clinical pharmacy practice, providing the 
opportunity to implement systemic solutions 
“Any action by a clinical pharmacist which 
directly results in a change in patient 
management or therapy” 
Paper-based Demographics, not 
referenced. 
DRP categories from 
Strand et al.92 
Allameh et 
al., 201393 
Iran Retrospective, descriptive study of 
2,227 interventions from 3,152 records. 
To assess the impact of clinical pharmacy services by 
categorising into, types, severity, resolution and 
accuracy 
No definition Paper-based Severity score based on 
Knudsen et al.94 Other 
categories not referenced 
Allenet et al., 
200695 
France Prospective study including design and 
validation of intervention form 
To validate an instrument for documentation of 
clinical pharmacy interventions in French speaking 
hospitals 
“A change in drug therapy initiated by the 
pharmacist” 
Paper- based DRP categories adapted 
from Strand et al.92 
Amara et al., 
201091 
United 
States 
Retrospective analysis of web-based 
documentation tool for intervention 
recording 
To assess the first 6 years of documented 
interventions after introduction of a Web-based 
documentation tool 
No definition Web-based Quantifi® clinical 
intervention monitoring 
tool 
Bedouch et 
al., 201296 
France Prospective cohort study in 7 wards of a 
French teaching hospital using 
computerised physician order entry 
(CPOE) 
To analyse pharmacist interventions in a setting 
using CPOE and  ward-based pharmacy 
“Any action initiated by a pharmacist 
directly resulting in a change of the 
patient’s management or therapy” 
CPOE DRPs and interventions 
categorised according to a 
validated tool used by the 
French Society of Clinical 
Pharmacy- Allenet et al 
200695. However, 
categories have been 
amended  since 2006 
Boardman H 
and 
Fitzpatrick R. , 
200197 
United 
Kingdom 
Prospective observational study in 4 
acute trusts 
To determine what activities  pharmacists actually 
undertook on a  clinical pharmacy ward visit and to 
compare this to the usual method of measuring 
clinical pharmacist performance, self-reported 
pharmacist interventions 
“those activities where the pharmacist 
was involved in a query about the 
patient’s treatment whether that be a 
change or an alteration in drug therapy or 
advice for doctors or nurses to monitor a 
patient for possible problems” 
Paper-based 
and 
observational 
Categories derived from 
observation pre-study and 
analysis post result 
collection 
Divall et al., 
201098 
United 
States 
Development of a Pharmacy School 
wide intervention form by Pharmacy 
practice Faculty consensus and upload 
to a secure Website 
To implement and evaluate a school wide, web-
based clinical intervention form to document types 
and impact of pharmacy students’ clinical activities 
during advanced pharmacy practice experiences 
No definition Web-based No source stated as 
developed “in house” 
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Author, Year Country Study Type Study Aim Intervention definition 
Method of 
Recording 
Classification Source 
Dornan T et 
al.,  200917 
United 
Kingdom 
EQUIP Study - Mixed method study 
including literature review and 
comprehensive quantitative and 
qualitative studies on prevalence and 
causes of prescribing errors 
To explore the causes of prescribing errors made by 
FY1 doctors concentrating on the interplay between 
the doctor’s educational backgrounds and factors in 
the practice environment 
No definition Paper-based No source stated, 
developed to gather 
information required for 
study 
Donyai et al., 
200899 
United 
Kingdom 
Prospective, comparative study in a 
tertiary care centre 
To determine the effects of electronic prescribing on 
quality of prescribing as indicated by prescribing 
errors and pharmacists’ clinical interventions 
“any proactive or reactive (in response to 
a question from another healthcare 
professional) activity undertaken to 
suggest changes to drug therapy or 
monitoring that involved contacting 
healthcare staff” 
Paper-based Prescribing error type and 
stage was classified 
according to Dean et al. 
2002100 as was stage of 
intervention. Severity of 
prescribing error classified 
according to Dean et al. 
1999101 
Dooley et al., 
2004102 
Australia Prospective study examining resource 
implications of pharmacist’s 
interventions assessed by an 
independent clinical panel 
To determine the cost savings of pharmacist initiated 
changes to hospitalised patients drug therapy or 
management in 8 acute teaching hospitals 
“any action which directly resulted in a 
change to patient management or 
therapy” 
Paper-based No source referenced 
Fernandez-
Llamazares et 
al., 
2012103 
Spain Prospective descriptive study in a 
teaching hospital 
To validate the inter-rater reliability of the method 
used to record interventions at the research hospital 
with a view to ensure consistency in recording 
No definition Paper- based 
then 
transferred 
into 
Microsoft 
Access 
Based on Overhage and 
Lukes, 1999104 and the 
Third Consensus 
Conference of Granada. 
Khalili et al., 
2011105 
Iran Prospective interventional study in an 
Iranian teaching hospital 
To determine the frequency and type of medication 
errors and the pharmacists role in detection and 
prevention 
No definition Paper based Medication errors 
classified according to 
Pharmaceutical Care 
Network Europe 
Foundation. 
Kucukarslan 
et al., 20033 
United 
States 
Prospective, single-blind, standard care 
controlled study  
To evaluate the impact of having a pharmacist 
participate in a physician’s ward round and to 
document the interventions made when doing so 
No definition Paper based Intervention type classified 
according to Leape et al., 
199984 
Lada and 
Delgado., 
2007106 
United 
States 
Prospective study evaluating 
documented pharmacy interventions 
To analyse pharmacist interventions and 
resuscitation experiences involving pharmacists to 
assess the potential cost avoidance associated with 
pharmacist interventions 
No definition Paper based 
and entered 
into database 
weekly 
No source referenced for 
intervention type. Severity 
score as per Lee et al., 
2002107 
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Author, Year Country Study Type Study Aim Intervention definition 
Method of 
Recording 
Classification Source 
MacKinnon, 
2003108 
United 
States 
Prospective descriptive study of 
pharmacy interventions 
To analyse pharmacist interventions using an 
internet based documentation system 
No definition Web-based Elements of intervention 
recording form developed 
over a 10 year period 
testing paper collection 
forms. Mackinnon, 2002109 
Millar et al., 
2007110 
New 
Zealand 
A questionnaire based cross-sectional 
survey of all pharmacy managers in 
publically and privately funded 
hospitals  
To investigate the perceived value and the recording, 
storage and use of pharmacists’ clinical data in New 
Zealand hospitals 
“any action taken by a pharmacist that 
aims to change patient management or 
therapy” 
NA- Survey 
requesting 
details of 
recording 
methodology 
nationwide 
NA- Survey requesting 
details of recording 
methodology nationwide 
Nurgat et al., 
2011111 
Saudi 
Arabia 
Retrospective comparative study of a 
web-based tool versus multi-user PC 
software 
To develop a database for documenting pharmacist 
interventions through a web based application and 
to determine if the new tool had benefits in terms of 
documentation compliance and ease of calculating 
cost savings 
No definition Web-based Developed in house from a 
previous paper-based 
system 
Olson et al., 
2005112 
Canada Retrospective pilot study to analyse 
documented clinical interventions 
To identify benefits of pharmacists by determining 
their impact on patient care and to identify potential 
problems with data collection and cost estimation to 
improve future documentation of services 
No definition Paper-based Interventions classified 
according to Leape et al., 
199984. DRPs which led to 
these interventions 
classified according to 
Overhage and Lukes, 
1999104. 
 
Stevenson et 
al., 2011113 
United 
States 
Descriptive prospective study of 
development of a web-based 
documentation tool 
To evaluate the effectiveness and impact of a web-
based tool for documentation of clinical 
interventions by pharmacy PharmD students. 
No definition Web-based Quantifi® clinical 
intervention monitoring 
tool 
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No. of sub categories 
Alderman 
et al., 
200144 
                    6 
DRP – 7: 
No indication, Unfulfilled indication, Suboptimal dose, 
High dose 
Drug interaction, Adverse drug reaction, Inappropriate 
drug selection 
Allameh et 
al., 201393 
                   1 
Accuracy 
4 
Severity – 3: 
Minor potential inconvenience to pt 
Potentially influence treatment of pt but correctable 
Potentially influence treatment of pt, intensive treatment 
is required 
DRP – 7 (“improper medication use” further subdivided 
into 11 categories): 
Dose adjustment, Improper medication use, Monitoring 
Recommendations 
Interaction, ADR, Peri-operative, Order clarification/ pt 
education 
Intervention/Action type – 5: 
Counselling, Recommendations to the Pt 
Recommendations to the Prescriber, Recommendations 
to the Nurse 
ADR Reporting  
Allenet et 
al., 200695 
                    4 
DRP -10: 
Non-conformity with guidelines or contraindication, 
untreated indication 
Subtherapeutic dosage, Supratherapeutic dosage, Drug 
without indication 
Drug Interaction, Adverse Drug Reaction, Improper 
administration 
Failure to receive drug, Drug monitoring 
Intervention/Action – 7: 
Addition of a new drug, Drug discontinuation, Drug 
switch 
Change of administration route, Drug monitoring 
Administration mode optimisation, Dose adjustment 
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No. of sub categories 
Amara et 
al., 201091 
                    9 
No DRP category. However, the intervention type/Action 
is definitive of the DRP e.g. “unapproved abbreviation 
clarified”. The intervention type being subdivided into a 
“drop down” menu from which the intervention type 
may be selected. The paper does not specify how many 
subcategories are in this drop down. 
Bedouch et 
al., 201296 
                   
1 
Mode of 
communication 
6 
DRP- 10:  
as per Allenet et al.; 2006 
Action - 4: 
Drug Choice, Dose adjustment, Drug monitoring, 
Optimisation of administration 
Mode of Communication: 
Computer, Oral, Ward round 
Boardman 
H and 
Fitzpatrick 
R. , 200197 
                   
2 
Desired 
outcome and 
Info. gathered 
7 
DRPs – 13: 
Omission/legality, Dose, Duration, Administration, 
Adverse Effect, Interaction 
Choice of Drug, Formulary, Pharmacokinetics, Other, 
Supply issue 
Request for information, Addition of cautionary labelling 
Divall et 
al., 201098 
                    7 
Intervention Type/Action- only top 5 listed in paper: 
Dose Adjustment, Education of (patient) or (prescriber) 
New drug for untreated indication, Subtherapeutic 
regimen 
Drug information 
Acceptance – 6: 
Recommendation accepted as is, accepted with 
modifications, DI or education provided, intervention 
completed/Rejected, Unable to follow up  or unresolved, 
Left blank/not documented 
Severity (clinical significance) -5: 
No significance, Somewhat significant, Significant 
Very significant, Left blank/not documented 
Dornan T 
et al.,  
200917 
                   
3 
Dose, 
Frequency 
and Actual or 
potential harm 
13 
Severity of DRP – 4 
Major (Potentially Lethal), Serious (Potential for harm) 
Significant (clinical affect but unlikely to cause harm) 
Minor (no clinical affect, no harm) 
Grade of Prescriber – 8 
Foundation year 1, Foundation year 2, Specialist trainee 
Staff Grade, Consultant, Pharmacist, Nurse, Other 
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No. of sub categories 
Donyai et 
al., 200899 
 
                    4 
Unclear from paper if other information was gathered 
Dooley et 
al., 2004102 
                   
2 
Details of 
therapy before 
and after 
intervention 
and therapy at 
discharge 
9 
Purpose of intervention  - 9 
Decrease of potential side effects, Increase of efficacy 
Reduced mortality and morbidity, Symptom control, Cost 
savings 
Decreased actual adverse drug effects, Assist compliance 
Formulary reasons, Other 
Intervention type/ Action - 6 
An alteration to patient monitoring, Initiation of therapy 
Discontinuation of therapy, Change of a drug, Change of 
dosage, Other 
Severity - 4 
Life Threatening, Major, Moderate, Minor 
 
Fernandez-
Llamazares 
et al., 
2012103 
                   
2 
Cause of DRP 
& Type of 
prescription 
10 
DRP (termed negative outcome associated with the use 
of a medicine (NOM) in this study – 7 
No NOM. No medicine related problem identified 
Potential or real NOM, related to untreated health 
problem 
Potential or real NOM, related to the effect of 
unnecessary medication 
Potential or real NOM, related to qualitative lack of 
effectiveness 
Potential or real NOM, related to the quantitative lack of 
effectiveness 
Potential or real NOM, related to the qualitative lack of 
safety 
Potential or real NOM, related to the quantitative lack of 
safety 
 
Khalili et 
al., 2011105 
                    5 
DRP – 4 
Drug Choice Problem (subdivided into 6 further 
categories) 
Dosing Problem (subdivided into 4 further categories) 
Drug Use Problem (subdivided into 2 further categories) 
Interactions (subdivided into 2 categories) 
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No. of sub categories 
Kucukarslan 
et al., 
20033 
                   
2 
Race and 
No. of co-
morbidities 
9 
Intervention Type – 9 (Leape et al.) 
Clarification of drug order, Provision of drug information 
Recommendation of alternative therapy, Identification of 
drug interaction 
Identification of systems error, Identification of drug 
allergy 
Approval of a non-formulary use of a drug, Provision of 
special order drug 
Identification of an ADE 
Lada and 
Delgado., 
2007106 
                   1. 
Time of day 
4 
Intervention Type - 15 
Provision of drug information, Recommendations for 
dosage adjustment 
Formulary interchange, Initiation of medications, 
Alternative drug therapy 
Discontinuation of drug therapy 
Changes in medication therapy due to allergy notification 
Drug therapy duplication prevention, Changes in the 
route of administration 
Questions from Nursing Staff, Order clarification, Drug 
compatibility issues 
Patient information, Toxicology, Drug interaction 
identification 
MacKinnon
, 2003108 
                    7 
DRP Classification –  8 
Order clarification, Drug product selection, Wrong drug, 
Dosage 
Adverse drug reaction, Contraindication, Inappropriate 
compliance 
Referral needed 
Severity – 3 
Significant, Moderate, Mild 
Acceptance/ Outcome – 2 
Expected outcome,  
Results 
 
Millar et 
al., 2007110 
 
88% 
 
63% 
 
63% 
 
88% 
 
Acceptance 
54% 
Outcome 
20% 
   
88% 
 
88% 
 
75%  
 
50%  
 
96% 
 
75% 
 
10% 
 
25% 
 
20%  
3 
Effect on cost 
saving 33%, 
Info sources 
used 10% and 
Other info 10% 
17 
Intervention type – 2 
Sub-classified 88% 
Free-typed 88% 
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No. of sub categories 
Nurgat et 
al., 2011111 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
   
 
 
 
 
    
1 
Other drugs 
prescribed 
10 
DRP – 9 
No indication, No drug order for medical condition, 
Formulary duplication, Inappropriate drug selection, 
Inappropriate dosage regimen (subdivided into dose, 
frequency, duration, route and rate), Prescribed drug not 
administered, Potential/Actual (ADR/Allergy/Toxicity) 
Potential/ Actual Drug interaction (subdivided into drug-
drug, drug-food, drug-disease, drug-lab test), 
Miscellaneous (subdivided into lab, pt counselling, 
answer question, other) 
Type of Intervention - 4 
Pharmacokinetics, Pharmacotherapeutics, Drug 
information, Miscellaneous 
Severity - 3 
Potentially severe/high, Important/moderate, Minor/low 
Acceptance - 4 
Accepted, Modified then accepted, Denied, Unknown 
Expected outcome - 4 
Cost saving (subdivided into unnecessary drug, change to 
dosage regimen, change to less expensive drug, indirect 
cost saving), Enhanced therapeutic effect, ADR/Toxicity 
prevented/resolved 
Olson et 
al., 2005112 
 
 
 
 
 
 
  
 
 
     
 
 
 
 
 
 
 
    
2 
Date of 
admission and 
Estimated cost 
9 
Intervention type – (adapted from Leape et al.) 
Order clarification or correction, Provision of drug 
information, Formulary management, Assessment of 
adverse drug event, Assessment of drug interaction, 
Consideration of special order or investigational drug 
Recommendation of alternative medication, Other 
DRP – (adapted from Overhage and Lukes) 
Sub-therapeutic dose, Untreated disease state, Potential 
overdose, Failure to receive drug, Non-formulary agent, 
No indication for use of prescribed drug, Distributional 
error, Inappropriate drug choice, Adverse drug event, 
Drug interaction, Inappropriate frequency, Inappropriate 
duration, Inappropriate monitoring parameters, 
Inappropriate combination, Inappropriate admission time 
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No. of sub categories 
Stevenson 
et al., 
2011113 
                    9 
Intervention type subdivided into a “drop down” menu 
from which the intervention type may be selected. The 
paper does not specify how many subcategories are in 
this drop down. 
Total: 17 14 13 12 12 9 8 7 5 4 4 4 3 3 3 3 3 2 2 
11 studies 
20 “0ther” 
categories 
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The four most common categories of intervention were intervention action/type, drug 
related problem (DRP), severity of near miss and drug Involved. All of the studies 
categorised interventions with respect to the DRP, intervention action or both. In all 
studies, DRP and/ or intervention action categories had at least 4 subcategories.  
Severity of the “near miss” was subcategorised into at least 3 categories. 
In order to make comparisons between the subcategories used for DRP and intervention 
action categories, the subcategories were tabulated in Tables 3.4 and 3.5 in order of 
frequency used. 
It was noted that DRP subcategories included the following, which were in fact, 
intervention actions taken by the pharmacist as a consequence of a DRP and therefore 
were not included in Table 3.4: 
Clarification of order; Addition of cautionary labelling; Referral needed; Patient 
counselling/education; Answer to a question provided. 
It was noted that intervention action/type subcategories included the following which 
were actually descriptions of the subcategories of DRPs which led to the intervention 
action and therefore were not included in Table 3.5: 
Sub-therapeutic regimen; Identification of drug interaction; Identification of systems 
error; Identification of drug allergy; Identification of an ADE; Drug therapy duplication 
prevention; Drug compatibility issues; Toxicology; Drug interaction identification; 
Pharmacokinetics; Pharmacotherapeutics; Assessment of adverse drug event; 
Assessment of drug interaction. 
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Alderman et al., 
200144 ✓ ✓ ✓  ✓     ✓ ✓           
Allameh et al., 201393 ✓ ✓  ✓   ✓  ✓            ✓ 
Allenet et al., 200695 ✓ ✓   ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓          
Bedouch et al., 
201296 ✓ ✓   ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓          
Boardman H and 
Fitzpatrick R. , 200197 ✓ ✓ ✓ ✓   ✓ ✓     
 
✓ 
  
 
✓ 
 
 
✓ 
 
✓ 
 
✓ 
 
Fernandez-
Llamazares et al., 
2012103 
   ✓ ✓ ✓                
Khalili et al., 2011105   ✓ ✓   ✓               
MacKinnon, 2003108  ✓ ✓ ✓           ✓       
Nurgat et al., 2011111 ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓   ✓          
Olson et al., 2005112 ✓ ✓ ✓  ✓ ✓  ✓ ✓ ✓ ✓ ✓ ✓ ✓   ✓     
Total: 8 8 6 6 6 5 5 5 5 4 4 4 2 1 1 1 1 1 1 1 1 
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Table 3.5 Comparison of Categories of Intervention Action/Type 
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Allameh et al., 
201393 
     ✓     ✓    ✓ ✓ 
Allenet et al., 200695 ✓  ✓ ✓   ✓  ✓ ✓    ✓   
Divall et al., 201098  ✓ ✓ ✓ ✓ ✓           
Dooley et al., 
2004102 ✓  ✓ ✓   ✓   ✓       
Kucukarslan et al., 
2003
3
 ✓ ✓   ✓   ✓    ✓ ✓    
Lada and Delgado., 
2007106 ✓ ✓ ✓ ✓ ✓ 
 
✓ 
 
✓ ✓ ✓  ✓ ✓     
Nurgat et al., 
2011111 
 ✓               
Olson et al., 2005112 ✓ ✓   ✓   ✓     ✓    
Total: 5 5 4 4 4 3 3 3 2 2 2 2 2 1 1 1 
90 
 
3.4. Discussion 
 
In general the results indicated that there is no universal consensus regarding the 
categorisation and recording of pharmacy interventions. This may be partly due to the 
fact that none of the 19 papers identified in the search were designed to identify an 
appropriate categorisation system for the documentation and analysis for interventions. 
Categories were mainly determined in response to the objective of the research; for 
example, Dooley et al., 2004102 had the objective of determining the cost savings of 
pharmacist initiated changes to drug therapy and therefore the categories included in the 
study were those allowing calculation of the associated costs and potential cost savings 
as a result of intervention i.e. time taken for the intervention, whether or not the 
intervention was actually accepted, details of therapy before and after the intervention 
and therapy at discharge.  
A number of studies had a similar objective of validating a documentation 
tool95,91,98,103,111,112,113. However, “validation” and therefore the categories used are 
dependent on the detailed objective of the study or the purpose for which 
documentation is stored and analysed. Validation to determine if the new tool has 
benefits in terms of documentation compliance and ease of calculating cost savings 
(Nurgat et al.111) requires different categories for analysis than validation to determine 
the inter-rater reliability of the method used to ensure consistency in recording 
(Fernandez-Llamazares et al.103). 
Some studies referenced categorisation of severity of DRP/intervention, DRP and 
intervention action/type to previous categorisation systems.  
Severity of the DRP was referenced in 3 studies93,99,106 using previous systems used by 
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Knudsen94, Dean101 and Lee107. However, all of the studies adapted the scoring system 
before use. Similarly where DRP categories and intervention categories were 
referenced44,95,96,99,103,105,3,108,112, the categorisation systems where adapted before use in 
all but one study96, demonstrating the lack of consistency and agreement regarding 
intervention categorisation and documentation. 
Where defined, the studies agreed regarding the definition of a pharmacist intervention, 
with all definitions being based on “Any action initiated by a pharmacist directly resulting 
in a change of the patient’s management or therapy”. Twelve of the nineteen studies did 
not however explicitly define pharmacist intervention, which the author interprets as a 
likely reflection of widespread acceptance of the definition. 
One of the studies conducted by Millar et al.110, was of particular interest since it 
investigated categories used to record pharmacy interventions via a questionnaire to all 
hospital pharmacy managers. It is likely that this study gives a more detailed and 
comprehensive description of intervention categories used in hospital practice since 
investigational studies using interventions may not always list the detail of categories, 
which are not relevant to the study. For example, Millar’s study110 identified that the date 
and pharmacists’ identification was recorded in 96% and 88% of hospitals respectively 
and it is probable that due to Millar’s study design (where managers were specifically 
asked if these categories were included), the percentages are an accurate reflection of 
documentation rate. However, despite this high percentage, very few investigational 
studies recorded the documentation of date or pharmacist’s identification. Only 2 other 
papers111,112 listed date and 4 listed, pharmacists’ identification97,98,108,111 as a category for 
intervention documentation. In general, papers describing investigations using 
interventions listed the categories used for analysis rather than those which were actually 
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documented when recording the intervention such as who performed the intervention 
and when. Date, pharmacists’ identification and patient identification are recorded as 
standard in UK hospital pharmacy to allow for follow up and accountability of the 
pharmacist. Millar’s study110  also indicates categories which pharmacy managers have 
determined may be of practical use to a clinical pharmacy service. For example, a third of 
hospitals documented intervention-associated cost savings; 88% documented where 
these interventions were being made while only 63% documented the severity/risk of the 
potential DRP. This is surprising as severity/risk was one of the most frequently recorded 
categories in the other papers identified.  
The results of the present investigation indicated some consensus in categorisation of 
pharmacists’ interventions. Categories which were documented in more than 50% of 
papers included drug name (12 papers), DRP (14 papers), Severity/ Risk (13 papers), 
Intervention Action/Type (17 papers), and whether or not the intervention was 
accepted/outcome (12 papers). 
The recording of drug name which would allow further categorisation to drug class 
(recorded as an alternative to drug name in a single paper95) is fundamental to the 
analysis of pharmacy interventions for a variety of reasons such as identifying the 
potential risks associated with drugs/ drug classes, identifying the need for education and 
training around specific drugs, identifying specific specialities requiring increased 
pharmaceutical input/monitoring and quantifying cost savings associated with 
interventions. Where the drug name has not been documented as a separate category it 
may have been recorded as a free text entry. It is likely that the recording of drug 
name/class is included in much nearer to 100% of intervention documentation systems as 
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it is very difficult to document a meaningful intervention without mentioning the name of 
the drug involved.  
Thirteen of the 19 papers categorised the intervention according to the potential 
severity/risk of the drug related problem. Most severity/risk categories were 
subcategorised into their “potential to cause harm” or their “clinical significance”. 
However, it is likely that pharmacists recording interventions would interpret and 
therefore categorise “clinical significance” according to the potential for the DRP to cause 
harm to the patient so that the two categories are probably equivalent. In five of the 
papers91,98,108,111,113, detailed explanation of each subcategory was poor with the use of 
“minor”, “moderate” or “severe” giving little guidance as to their definition. As such, 
these may be open to inter-pharmacist interpretation for many reasons, which may 
include experience, clinical knowledge and specific circumstances of the intervention e.g. 
clinical details of the respective patient and others. Where there is a clear definition for 
each subcategory, it is less likely that there will be variance in pharmacist interpretation. 
Dornan et al.17 used a simple 4-point scale combining the description of clinical 
significance and the potential to cause harm and validated the intervention scores using a 
panel of 2 independent pharmacists and 2 clinicians. 
All of the studies attempted to subcategorise either “DRP” or “intervention type/action” 
or both.  Most hospital pharmacies are aware that analysis of the cause of interventions 
(the DRP) and the resulting actions (intervention type/action) may allow patterns to be 
identified in order that preventative measures may be implemented e.g. education and 
training of prescribers and pharmacists or both. However, it is surprising to note that 
consensus regarding the sub-categorisation of DRPs was poor (Table 3.4.) with only 5 sub-
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categories used in more than 50% of studies which subcategorised DRPs (interaction, 
ADR, wrong drug, wrong dose and no indication).  Furthermore, there were 5 
subcategories which were inappropriately used to document DRPs since they were 
actions taken as a consequence of a DRP namely, clarification of order; addition of 
cautionary labelling; referral needed; patient counselling/education and answer to a 
question provided. This appears to demonstrate confusion between sub-categories used 
for DRPs and those used for intervention action/type. This was particularly evident in 
studies assessing sub-categories used for intervention action/type (Table 3.5). Thirteen 
subcategories were used which were DRPs rather than intervention action/type and, of 
the remainder, only 2 sub-categories (change of drug and drug information) were 
common to more than 50% of studies. 
 
3.5. Conclusions 
 
Currently there is little agreement in the literature regarding categorisation for analysis or 
standardisation of documentation of pharmacy interventions. It is possible that the 
routine documentation of hospital pharmacy interventions does have a degree of 
standardisation indicated by Millar et al.110 but further research is required to identify 
which categories would be beneficial to record in order to allow analysis to improve 
patient safety and improve pharmacy services.  
Most intervention categories recorded as part of research studies are directly related to 
the objective of the study and are determined at the time of the study design, which 
limits the design to prospective analysis in some cases. If standardisation of 
documentation could occur such that it were possible to achieve most common study 
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objectives using an agreed proforma, this would allow retrospective analysis of 
interventions without time consuming coding and thus the inclusion of larger sample 
sizes. 
In particular, there is little consensus and some confusion regarding the sub-
categorisation of the drug related problem precipitating the intervention and the 
resulting intervention action with subsets of each category often included in the alternate 
set. Standardisation of these sub-categories would provide a platform to identify 
patterns, which may allow prevention of the DRP. 
Prevention of DRPs is of particular interest, since analysis of pharmacist interventions as 
“near miss” incidents would allow the identification of patient risk factors. Categories 
used by the studies identified in this search which may be used to identify individual 
patients prior to the intervention occurring using most electronic prescribing systems 
include: gender, stage of stay, age, allergies, consultant ID, drug class/name, no. of drugs, 
disease state, administration problems (identified using missed doses on drug chart), 
monitoring issues and use of a non-formulary drug. Most other DRPs can only be 
identified by detailed analysis of the medication chart by a clinical pharmacist. 
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CHAPTER 4 
DEVELOPMENT OF  
A DATASET REQUEST 
97 
 
4. Development of a Dataset Request. 
4.1 Introduction 
4.1.1. Background 
4.1.1.1. Information Identified from Chapters 2 and 3. 
 
Chapters 2 and 3 identified possible risk factors for pharmacy intervention into patient 
treatment from the literature using a systematic review of measurable risks associated 
with DRPs and review of categories of pharmacist interventions respectively. 
The systematic review in Chapter 2 identified a number of measurable risks for DRPs (all 
definitions included) which are well known yet poorly documented as such.  However, 
the link between these risks and an intervention by a pharmacist is unproven. Although 
identifying and rectifying any issues related to the use of medicines, is a fundamental part 
of a pharmacist’s role, in practice, there is no evidence to confirm that pharmacists 
comprehensively identify all DRPs. It is also possible that pharmacists identify a number 
of issues with drugs and prevent some DRPs which are subsequently never identified by 
the literature or similarly they intervene in situations which are not identified as DRPs by 
the literature. Without further research it cannot be assumed that risks associated with 
DRPs are identical to those factors which cause a pharmacist to intervene into a patient’s 
treatment. 
In contrast, the systematic review of common categories of pharmacist interventions 
identified factors which clinical pharmacists record for later review which may (or may 
not) be well known as risk factors for DRPs but have direct links to pharmacist 
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interventions.  Some of the categories/factors recorded by pharmacists are the same 
factors identified by the systematic review of Chapter 2 but also a number of additional 
factors were identified.  These additional factors may or may not be risk factors for 
pharmacist intervention and the possible associated DRPs which these interventions aim 
to prevent.  However, pharmacists record this data for the purposes of research, audit, 
analysis or review and have (in most cases) used their experience and pharmaceutical 
knowledge to determine the detail of interventions which it may be necessary to record. 
Senior hospital pharmacists in the UK regularly perform informal analysis of their 
intervention data to identify any local patterns in interventions performed. As a result, 
risk reduction measures may be put in place. For example, where interventions are 
repeatedly associated with a particular drug, education of prescribers provides a form of 
risk reduction.  In the United States, clinical pharmacists have already recognised that 
categories of pharmacist interventions may also be risk factors for patients experiencing 
DRPs. The American Society of Health-System Pharmacists use an intervention form 
which identifies some categories as risk factors but it is unclear what the evidence base 
for this is.114 
However, it may be that where pharmacists record an intervention category for another 
purpose, that category too may also constitute as a risk factor. For example, pharmacists 
may record details of the consultant ID in order to refer serious interventions to the 
consultant team concerned, however, the prescribing consultant (team) may also be a 
risk factor. This could be for a number of reasons: as an independent risk factor, e.g. 
should the team be prone to making prescribing errors, or a dependent risk factor, e.g. 
should the team be prescribing high risk drugs or prescribing in more complex cases etc.. 
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As such, it would be appropriate to review all quantifiable and measurable categories of 
pharmacist interventions identified in the previous chapters in order to determine 
whether or not they are risk factors which may be identified prior to intervention. 
 
4.1.1.2. Data Available at University Hospitals NHS Foundation Trust 
 
At University Hospitals NHS Foundation Trust (UHBFT) pharmacists record their 
interventions on the Prescribing and Information Communication System (PICS) which is 
an electronic prescribing and clinical decision support system (CDS) which also includes 
many of the clinical features included in an electronic patient record (EPR) such as 
biochemistry, microbiology, observations, assessments, therapy records, admission and 
discharge details.  
Pharmacists at UHBFT are requested to record interventions in the PICS which enables 
data extraction to fulfil the requirements of the EQUIP study17, the Trust having been 
involved in gathering follow up data during 2011. Early in 2012 the UHBFT Clinical 
Pharmacy Standards were developed and launched which standardised the way in which 
pharmacists in the Trust recorded their interventions in the PICS. This electronic 
recording of interventions precluded the necessity for the clinical pharmacy team to 
record their interventions on paper. Figure 4.1 details the form which the team used prior 
to electronic recording. 
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Figure 4.1 Intervention Form used in the EQUIP Study and by UHBFT prior to Electronic 
Recording 
 
There is no pharmacy intervention form programmed into the PICS. Pharmacists use their 
pharmacist messaging system to record interventions as a free type entry (Figure 4.2).  
Interventions are recorded contemporaneously and as such, data extraction at the time 
of the intervention documents clinical details of the patient such as biochemical and 
haematological parameters and demographics such as ward, age, gender and hospital 
number. Details of the intervention included in Figure 4.1 which cannot be extracted 
without a standardised intervention entry into PICS are: 
1) Potential severity of DRP 
2) Name of the drug (since the entry in PICS appertains to the patient and not the 
respective drug) 
3) Brief description of the intervention 
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Thus, pharmacists document “Intervention 1, 2, 3 or 4” to indicate the severity of the 
DRP, followed by the name of the drug and a brief description of the intervention. 
Figure 4.2 Example of Documentation of Pharmacy Interventions at UHBFT 
 
1) Severity    2) Drug Name   3) Brief Description 
Figure 4.2 clearly demonstrates the simplicity of pharmacy intervention documentation 
at UHBFT and as such intervention recording in the Trust jumped in May 2012 to on 
average, 1,500 interventions per month compared to 20 per month when using paper 
based recording.  
At the same time of the launch of the standardised intervention recording in the PICS, the 
informatics department at UHBFT was asked to develop a monthly report which detailed 
interventions by ward and by pharmacist. The report is produced by searching for the 
word “Intervention” in the pharmacist messaging system. Figure 4.3 shows a screen shot 
of the report with outputs detailed by respective ward at UHBFT and Figure 4.4 when 
generated by clinical pharmacist undertaking the intervention. The report may be 
generated between any respective chosen dates as required for audit or review. 
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Figure 4.3 Monthly Intervention Report by Ward. 
Breakdown requested by Ward   Chosen start and end dates entered   
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Figure 4.4 Monthly Intervention Report by Pharmacist. 
Breakdown requested by Pharmacist Drill down to 138 interventions (see Figure 4.5). 
 
Respective 
Pharmacist’s 
name appears 
in each row 
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Analysis of the data contained in these reports has provided multiple benefits. Not only 
does the report allow intervention review for a particular ward which gives insight to the 
DRPs noted by pharmacists in a particular speciality but also they allow for an individual 
pharmacist’s performance to be reviewed. Pharmacists are reviewed on a bimonthly 
basis by senior colleagues, not only reviewing the number of interventions undertaken in 
comparison to their peers but also as to the complexity and quality of their interventions 
in terms of clinical pharmacy outcomes. Figure 4.5 shows how it is possible to closely 
examine the data from Figure 4.4, to identify the wards on which the respective 
pharmacist has made their monthly interventions.   
Similarly, it is possible to further examine the report shown in Figure 4.5, to view the 
detail documented in Figure 4.6.   The view in Figure 4.6 allows the reviewer to consider 
the specific detail of each intervention made by the respective pharmacist. 
Similar close examination of the report data is available when the report is generated by 
ward giving the opportunity to review the specifics of interventions in each clinical area. 
Each report may be exported into a database for manipulation for review, audit or 
presentation and as such provides a wealth of data for the purposes of research. Raising 
awareness, feedback to clinical pharmacy staff and ease of reporting has increased the 
numbers of interventions reported so that by June 2015 the total number of 
interventions being reported on a monthly basis reached almost an average 3,000 in total 
(Appendix 1 - Extract from Intervention Report July 2015). The interventions 
electronically recorded in this manner provide an opportunity for research into the 
factors which lead to pharmacists intervening in a patients care to avoid subsequent 
DRPs. 
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Figure 4.5 Examination of June data from One Pharmacist detailing Wards where Clinical Interventions Occur 
Examination of 44 interventions gives descriptive detail of interventions recorded in the pharmacist message (see Figure 4.6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacist’s Name 
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Figure 4.6 Examination of a single Ward’s Interventions by one Pharmacist 
 
“Free Type” description of intervention in Pharmacist Messaging in PICS 
 
Pharmacist’s Name 
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Analysis of the data from these reports may also help to determine at what point in the 
patient’s stay they are most likely to have issues which require pharmacy intervention.  
With up to 6% of hospital admissions attributed to a medicine related issue1, pharmacists 
are already targeted by NICE guidance to perform medicines reconciliation on patients 
within the first 24 hours post admission12. Medicines reconciliation on admission includes 
(as described in Chapter 1) confirming comprehensively, the patient’s medicines prior to 
admission and reconciling them with those prescribed as an inpatient. Acting in an 
advisory role, pharmacists will then communicate with prescribers and nursing staff 
regarding any inaccuracies and make recommendations for the administration and supply 
of drugs, future drug treatment and monitoring. This makes the first 24 hours of 
admission crucial in terms of pharmacist intervention. Figure 4.2 shows how a patient 
drug history is recorded in PICS as part of the reconciliation process. To identify if the 
time of medicines reconciliation is closely associated with the likelihood of intervention, 
comparison is required between the timing of drug histories and any pharmacist 
interventions.  
However, it is also likely that the point of discharge poses another risk to patients. Their 
medicines will be re-prescribed and re-defined as appropriate to take home which may 
put the patient at risk of DRPs and prompt a pharmacist intervention. 
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4.1.2. Aims 
To determine if there is an association between potential risk factors identified in 
Chapters 2 and 3 and the characteristics of inpatients on whom interventions are 
performed.  
To analyse the data to determine if these risk factors and categories can identify patients 
requiring intervention and therefore highlight their need for a pharmaceutical review. 
 
4.1.3. Objectives 
The objectives are to: 
a) Develop a request for data (dataset request) for the informatics department at UHBFT 
which obtains the retrospective data required from PICS. There are three clear objectives 
when developing the data set: 
1) Define the population from which the retrospective data is to be extracted 
2) Combine results from Chapters 2 and 3 to determine which potential risk factors 
are to be included in the dataset request and identify if these risk factors may be 
identified from PICS 
3) Produce a clear, concise and comprehensive written request for data which can 
be interpreted by informatics personnel who have little clinical knowledge or 
understanding of pharmacist interventions but who have a working knowledge of 
extracting data from PICS. The request must include clear explanation or 
definitions, for the following: 
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 How pharmacist interventions are recorded in PICS 
 The population to be included in the data extraction 
 The time of the data extraction in relation to a patient’s admission 
 The description of each risk factor (and therefore the data to be extracted) 
 
b) Statistically analyse the data to determine risk factors which may identify patients who 
are most likely to require a pharmacist intervention. Chapter 5 will detail the statistical 
analysis of the data. 
 
4.2. Methods 
 
4.2.1. Identification of Population to be Studied 
The objective is to provide data which can be statistically analysed to determine if there is 
an association between the potential risk factors (identified in Chapters 2 and 3) and the 
characteristics of those patients who are recipients of pharmacist interventions at UHBFT. 
Analysis will be of data derived from a retrospective comparative study of characteristics 
of patients who had an intervention with those who did not. Therefore, the simplest 
population to review would be: 
All inpatients admitted within a defined timeframe. 
A comparison could then be made between the incidence of potential risk factors for 
intervention in those patients in the population who did have an intervention during their 
admission with those who did not. However, a number of variables needed to be 
considered: 
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 Clinical Pharmacy Services are not provided in all clinical areas (wards) of UHBFT 
and as such an intervention may not occur owing to the fact that the medication 
chart has not been reviewed by a Pharmacist. 
 Patients may be admitted and discharged in less than 24 hours and therefore 
medicines reconciliation and full pharmacist review may not occur. 
 Patients may be admitted into complex settings such as ITU where the presence 
of experts in the speciality (sometimes providing one to one care), may reduce the 
likelihood of a DRP and the possibility of a pharmacist intervention. 
 Patients may not be the recipient of a pharmacist intervention if a pharmacist did 
not visit the ward during their ward stay (e.g. at the weekend where no clinical 
pharmacy service is provided) 
 
To ensure that an appropriate population was identified, agreement was sought from a 
Professor in Clinical Pharmacology at Birmingham University with a practical knowledge 
of prescribing using the PICS and a specialist interest in drug safety and clinical pharmacy 
services, a statistician from Birmingham University and a senior member of the UHBFT 
informatics team.  
Agreement was sought for: 
1. The study population admitted to the Trust in a specified time period 
2. A list of exclusion criteria for the population 
3. The time of data extraction in relation to a patient’s admission 
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4.2.2. Identification of Potential Risk Factors for Inclusion in Dataset Request 
 
Factors identified in the Systematic Review (Chapter 2) as risk factors for DRPs and the 
factors identified as common categories recorded when documenting interventions 
(Chapter 3) were reviewed. 
Criteria for inclusion of a potential risk factor in the dataset request were agreed with the 
Professor in Clinical Pharmacology as:  
 The factor prevalence must be in the 10 identified by the Systematic Review 
(Chapter 2) or a result of the Search for Common Categories of Interventions 
(Chapter 3) 
 The factor must be identifiable prior to the development of a DRP 
 The factor must be identifiable from data recorded within PICS 
 The factor must be unique and not a subset of another factor previously identified 
 
Figure 4.7 details the methodology used to develop the final dataset request. 
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YES/PARTIALLY 
Figure 4.7 Methodology for Development of Dataset Request 
Professor  
Professor Informatics of of 
 
Risk Factor included in 
top 10 of Chapter 2 or 
Chapter 3?  
Tabulated in tables 4.1 
and 4.2. 
Identifiable prior to 
development of a drug 
related problem? 
 
Identifiable from 
PICS? 
YES YES 
 
Unique and not a 
subset of another risk 
factor? 
EXCLUDE 
RISK FACTOR 
NO 
NO 
NO 
NO 
 
YES 
Subsets identified and  
resulting risks and 
subsets tabulated in 
table 4.3. 
 
PICS markers defined 
and agreed with 
Professor of 
Pharmacology and 
Clinical Ph’cist Focus 
Group. 
 
Table 4.4, final 
population and time 
of data extraction 
agreed with Professor 
of Pharmacology, 
Statistician and 
Informatics 
Representative 
 
 
 
FINAL 
DATASET 
REQUEST 
Clinical Pharmacist’s 
Focus Group identify 
markers in PICS for key 
stages of a patient 
stay. 
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4.3. Results 
4.3.1. Identification of Population. 
In order to ensure that the absence of pharmacy interventions was not due to the fact 
that a pharmacist had not visited the ward during their stay, it was decided that the 
population would include all patients present on a respective ward during the stay of 
individuals who were the recipient of a pharmacist intervention: 
 
1) All patients who had one or more pharmacist interventions between 01/04/2013  and  
31/03/2015 on wards visited by a pharmacist (CDU, Burns Unit, CCU, 302, 303, 304, 305, 
306, 407, 408, 409, 410, 411, 412, 513, 514, 515,516, 517, 518, 519, 620, 621, 622, 623, 
624, 625, 726, 727, 728, Edgbaston, Harborne, Bournville, West 1 and West 2 (excluding 
Critical Care Units) (“Lead Intervention” patients)  
And 
2) All patients who were present on the respective ward within the lead intervention 
patient’s ward stay (ward stay is termed “spell” in the PICS) (“spell” patients) 
Exclusions: 
 Patients whose pharmacist intervention occurred while on a Critical Care Unit 
 Patients with an admission duration <24 hours 
 “Spell” patients whose ward stay began prior to commencement of the lead 
intervention patient’s ward stay 
 “Spell” patients whose ward stay ended after the end of the master patient ward 
stay  
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4.3.2. Tabulation of Potential Risk Factors to Determine Inclusion in the Dataset 
Request 
 
Tables 4.1 – 4.3 detail the tabulation of potential risk factors in order to determine 
their appropriateness for inclusion in the final dataset request. 
 
Table 4.1 Potential Risk Factors Identified from the 10 most prevalent in Systematic 
Review 
Category 
 
Identifiable 
prior to DRP? 
 
 
Identifiable in 
PICS? 
 
Unique? 
 
Included 
Yes/No 
Drug Class    Yes 
Polypharmacy    Yes 
Older Age (?>65 years)    Yes 
Gender    Yes 
Number of co-
morbidities 
   Yes 
Length of pt stay    Yes 
History of Drug 
Allergy/Sensitivity 
   Yes 
Patient Compliance 
Issues 
   Yes 
Poor Renal Function    Yes 
Poor liver function    Yes 
 
Key (Table 4.1 and 4.2):  Yes    X    = No X  = Partially 
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Table 4.2 Potential Risk Factors Identified from Chapter 3 -Search for Common Categories 
of Interventions. 
Category 
 
Identifiable prior to 
DRP? 
 
 
Identifiable in PICS? 
 
Unique? 
 
Included 
Yes/No 
Intervention type/ Action X X  No 
DRP X X  No 
Severity/Risk of DRP X X  No 
Drug Name   X (Drug Class in table 4.1) No 
Acceptance/outcome X X  No 
Gender   X (included in table 4.1) No 
Age   X (included in table 4.1) No 
Location/Speciality    Yes 
Pharmacist ID X   No 
Consultant ID    Yes 
Disease state    Yes 
Time taken for Intervention X X  No 
No. of drugs   X (included in table 4.1 as 
polypharmacy) 
No 
Date X   No 
Patient ID X   No 
Allergies    X (included in table 4.1) No 
Drug Class   X (included in table 4.1) No 
Stage of Stay    (similar to length of stay) Yes 
Seniority of prescriber  X  No 
Interaction  X  No 
ADR X X  No 
Wrong Drug  X  No 
Wrong Dose  X  No 
No indication  X  No 
Untreated Indication  X  No 
Administration problem    (similar to compliance issue 
and omission) 
Yes 
Non-formulary/Guidelines   (non-formulary 
possible not 
guidelines) 
 Yes 
Monitoring   (relies on 
previous  
documentation in 
PICS) 
 Yes 
Dose too High  X  No 
Dose too Low  X  No 
omission    Yes 
Duration  X  No 
Frequency  X  No 
Compliance   X (included in table 4.1) No 
Pharmacokinetics  X  No 
Distribution  X  No 
Request for Information  X  No 
Supply issue    (similar to compliance issue 
and omission) 
Yes 
Incomplete order/legality  X  No 
Peri-operative  X  No 
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Table 4.3 Summary of Potential Risk Factors for Inclusion in Dataset Request 
 
Category 
 
 
Subsets if Applicable 
 
Drug class 
IV antimicrobials 
thrombolytics/anticoagulants 
cardiovascular agents 
Central Nervous System (CNS) agents 
corticosteroids 
diuretics 
chemotherapy 
insulin/hypoglycaemics 
opiates 
Anti-epileptics 
Polypharmacy Number of drugs 
Older Age (?>65 years) Age in years 
Female gender Male/Female 
Number of co-morbidities - 
Length of pt stay 
Stage at which intervention made 
Total length of stay 
History of Drug Allergy/Sensitivity Number of allergies 
Patient Compliance Issues - 
Poor Renal Function Mild/moderate/severe or continuum? 
Poor liver function - 
Location/Speciality 
Ward 
Speciality 
Consultant ID - 
Disease State - 
Administration Problems, Omissions and Supply Issues Reasons for omissions 
Non-Formulary Medication - 
Monitoring Issues - 
 
4.3.3. Identification of Potential Risk Factors in PICS 
To extract data at the time of the Lead Intervention patient’s intervention would produce 
data which would require highly complex data analysis and to do so add variables to the 
resulting data since spell patients would have variable lengths of stay at the time of data 
extraction.  
Data extraction would need to be at: 
 The same length of time post admission for all patients in the data set 
 Less than the average length of stay for the patient population 
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 At a point in time in the patient’s stay that it is practical for a pharmacist to visit 
(since the resulting model from the research may be used to direct pharmacist 
interventions) 
 
It was agreed with the Professor in Clinical Pharmacology and the statistician that 
the dataset request to informatics would request data from each patient at 24 
hours after admission (Time of data Extraction). Each potential risk factor was 
then discussed and agreement reached as to how the factor would be measured 
using the PICS (Table 4.4). In the case of disease states, a focus group of 5 senior 
clinical pharmacists at UHBFT identified the common disease states which in their 
experience, may increase incidence of interventions and the most common points 
during a patients stay at which patients are vulnerable to intervention. 
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Table 4.4 Detail of Data Representing each Potential Risk Factor in PICS 
Potential Risk 
Factor 
 
Data Representing Potential Risk Factor in PICS 
 
 
Comments 
Drug class 
Number regular drugs prescribed from each of the 
following PICS drug categories (report each category 
separately): 
 
Thrombolytics/anticoagulants: to include PICS drug 
classes ANTICOAG (except enoxaparin), NOAC, 
ANTIPLATE, THROMBO and ANTIFIB 
 
IV antimicrobials: to include PICS drug classes 
AMINOGLYC, ANTIMICC, ANTIMIC3, OTHER ANTI, 
ANTIBIO, ANTIMIC2, PENICIL, PENICILLIN, MACROLI, 
CARBAPEN, AMINOGLYC, TETRAC, ANTIFUN, 
IMIDAZOLES, POLYMYXINS, TB DRUG, ANTIMAL and 
QUINOL plus individual drugs Chloramphenicol IV, 
Vancomycin IV, Teicoplanin IV, CO-TRIMOX, 
Anidulafungin, Griseofulvin and Micafungin 
 
Cardiovascular agents: to include PICS drug classes ANTI-
ARRY, CARD GLYC, CARDIAC, INOTROPE, BETA BLOC, CA 
CHAN, VASODI, VASOCON, ANTIHYP-CA, AD NEUBLOC, 
APLHA BLOC, ACE INHIB, ANGIOII and ANTIHYPO plus 
individual drugs ILOPROST, nicorandil, adenosine, 
ranolazine and milrinone 
 
CNS agents: to include PICS drugs classes HYPNO, ANTI-
PSYCH, ANTIDEP, MAOIS, SSRIs, TRICYC, LEVODOPA, 
BENZO, C.N.S, PHENO, MAOIS plus individual drugs 
flupentixol, pericyazine, pimozide, valproic, lithium, 
Atomoxetine, Dexamfetamine sulphate, 
Lisdexamfetamine mesilate, Methylphenidate 
hydrochloride, Modafinil, tolcapone, ENTACAPONE, 
PRAMIPEXOL, ROPINIROLE, rotigotine, bromocriptine, 
cabergoline, pergolide, Apomorphine, amantadine, 
PIMOZIDE, ACAMPROSATE and Disulfiram 
 
Corticosteroids: to include PICS drug classes CORTICO, 
GLUCO, HYDROCOR and MINCORTICO 
 
Diuretics: to include PICS drug classes DIURET, LOOP 
DIUR, THIAZ and POT-SPAR 
 
Chemotherapy/immunosuppressants: to include PICS 
drug classes ANTINEO, CYTO, CYTO2, CYTOMOD, MABS, 
MALIG, INTERMIT, DIETHYLSTILBESTROL, PKINHIB, 
IMMUNO, TACRO, METHOTREX,SIROL and CICLOSPORIN 
plus individual drugs Fingolimod, Glatiramer, 
Lenalidomide and thalidomide 
 
Insulin/hypoglycaemics: to include PICS drug classes 
INSIMP12, INSIMP2, INSIMP23, INSIMP3, INSIMP4, 
INSUL, DIABET, SULPHONYL, BIGUAN, GLIPTINS and 
ORALHYPOG 
 
Opiates: to include PICS drug class OPIOID 
 
Anti-epileptics: to include PICS drug classes ANTICONVUL 
and ANTIEPIL 
 
NB. Include regular medications only prescribed at the 
time of data extraction (exclude when required (PRN), 
one off (OOF) and take home medication (REGT, PRNT). 
The British National Formulary BNF definition of 
drug category was used. 
 
PICS has its own unique drug categories and drug 
dictionary. The drug dictionary was reviewed and 
each drug code identified for the respective BNF 
class. Any additional individual drugs in the BNF 
class not identified by the PICS drug class code 
were included. 
Where drugs are in more than one section in the 
BNF, the main section of classification (bold type in 
BNF index) was used. 
 
PICS drug classes were requested from informatics 
and reviewed to ensure they corresponded to BNF 
classification. 
Polypharmacy 
Number of regular drugs prescribed at time of data 
extraction (exclude when required prescriptions, one offs 
and any prescriptions which do not require a pharmacist 
sign off e.g. TEDS, dietary supplements) 
PICS  includes some “prescriptions” for non-
medicinal products which act as prompts for 
nursing to administer and provide documentation 
of administration. 
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Potential Risk 
Factor 
 
Data Representing Potential Risk Factor in PICS 
 
Comments 
Age 
age (in years) of patient at the time of data extraction 
 
Definition of elderly varies in the literature and 
with an ageing population the definition may need 
revision. In addition, the systematic review 
excluded paediatric papers as “specialist” and 
therefore age reported as a continuum was felt to 
be more appropriate than defined age groups. 
 
Female gender 
gender 
 
Documented in the PICS 
Number of co-
morbidities 
number of ICD10 codes documented in PICS at the time 
of data extraction. 
PICS uses ICD10 codes to code for co-morbidities. 
When a co-morbidity is entered, PICS translates 
into the respective ICD10 code. 
Length of pt 
stay 
total spell length. 
 
“Stage” of intervention can be extracted from PICS 
but will require precise definition and study of 
time of the intervention in relation to other clinical 
pharmacy activities 
 
History of Drug 
Allergy/ 
Sensitivity 
number of allergies/sensitivities recorded 
 
 
Documented in the PICS 
 
Patient 
Compliance 
Issues 
number of missed doses  due to “pt refused” against all 
regular prescriptions within 24 hours prior to time 
specified for data extraction 
 
 
 
Identify patients who have a blister pack icon at the time 
specified for data extraction  (Yes/No) 
 
When recording a drug omission in PICS, staff 
administering must include a reason for non-
administration. A “drop down” selection includes 
“patient refused” as a reason for documentation 
of non-administration. 
 
PICS includes a Blister Pack Icon. Pharmacists may 
denote patients in need of a blister pack as a form 
of compliance aid. 
Poor Renal 
Function 
GFR or eGFR reported as the most recent prior to 24 
hours post admission. Where there is none reported 
prior to the data extraction, use GFR or eGFR up to 72 
hours post admission. 
 
NB. Use GFR wherever possible instead of eGFR. If there 
is a GFR then use this even if there is a later eGFR. Only 
use eGFR if no GFR has been reported prior to 24 hours 
post admission (in the same admission) or 72 hours post. 
Where there is NO GFR or eGFR on that admission prior 
to 72 hours post admission, record pt as “NA”. 
None of the studies identified in the systematic 
review defined renal function as mild/moderate or 
severe but reported renal function as a continuum. 
Poor liver 
function 
Identify patients (Yes/No)  who at the specified time of 
data extraction are either: 
 in Liver directorate (Medicine or 
Surgery) 
 have a liver “declared interest” 
recorded or 
 have ICD10 codes: 
o C22 Malignant neoplasm of liver and 
intrahepatic bile ducts. 
o D13.4 Liver. 
o D37.6 Neoplasm of uncertain or unknown 
behaviour of oral cavity and digestive organs 
// Liver, gallbladder and bile ducts. 
o K70-K77 Diseases of liver. 
o R94.5 Abnormal results of liver function 
studies. 
o B18.0 Chronic viral hepatitis B with delta-
agent. 
o B18.1 Chronic viral hepatitis B without 
delta-agent. 
o B18.2 Chronic viral hepatitis C. 
 
NB. Patients must only be counted once if they are in 
more than one of the categories (e.g. they may be in the 
Liver directorate AND have one or more of the respective 
ICD10 codes). 
There is no direct relationship between liver 
function tests and the degree of liver failure 
observed. Indicators of diagnosis of poor liver 
function in PICS were agreed to be more reliable. 
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Potential Risk 
Factor 
 
Data Representing Potential Risk Factor in PICS 
 
Comments 
Consultant ID 
consultant ID 
 
Documented in the PICS 
Ward / 
Speciality 
 
Ward and speciality of patient Documented in the PICS 
Disease state 
Identify patients (Yes/ No) with the following ICD10 
codes for Insulin dependent diabetes: E10 Type 1 
diabetes mellitus or O24.0 Pre-existing type 1 diabetes 
mellitus 
 
Identify patients (Yes/ No) with the following ICD10 
codes for epilepsy: G40 Epilepsy or G41 Status 
epilepticus 
 
Identify patients (Yes/ No) with the following ICD10 
codes for parkinsons’ disease: G20 
 
Identify patients (Yes/ No) with the following ICD10 code 
for tuberculosis: A15, A16, A17, A18 or A19 
 
Identify patients (Yes/ No) with the following ICD10 code 
for Acute MI: I21 
 
Identify patients (Yes/ No) with the following ICD10 
codes for stroke: I60 subarachnoid haemorrhage, I61 
Intracerebral haemorrhage, I62 other non-traumatic 
intracranial haemorrhage, I63 cerebral infarction, I64 
stroke, not specified as haemorrhage or infarction G46.3 
Brain stem stroke syndrome, G46.4 Cerebellar stroke 
syndrome, I69.4 Sequelae of stroke, not specified as 
haemorrhage or infarction 
 
Identify patients (Yes/ No) with the following ICD10 
codes for PE or VTE: I26 Pulmonary embolism, I74 
Arterial embolism and thrombosis, I82 other venous 
embolism and thrombosis 
 
Identify patients (Yes/ No) with the following ICD10 code 
for alcoholic liver disease: K70 
 
A focus group of 5 clinical pharmacists determined 
the main disease states which they felt would 
make patients vulnerable to pharmacist 
intervention. 
Administration 
problems/omis
sion and supply 
issues 
number of missed doses recorded on PICS. Include only 
regular prescriptions within first 24 hours of admission to 
Trust 
 
number of missed doses recorded on PICS due to “drug 
out of stock”. Include only regular prescriptions within 
first 24 hours of admission to Trust 
 
Comment as per “Patient Compliance Issues”. 
“Drop down” includes “drug out of stock” 
Monitoring 
issues 
Identify patients (Yes/No) who have the following 
recorded during the respective admission: 
 
1. INR recorded AND warfarin 
prescribed 
OR 
2. Any record on PICS Drug results tab 
 
PICS includes a separate section (“tab”) for drug 
level results. INR is not included in this tab as is not 
actually a drug level but a marker of drug activity. 
INR may be taken when pt is not prescribed 
warfarin so the combination would need to be 
evident to highlight patients at potential risk. 
Non-formulary 
medicine 
Identify (Yes/No) if patients have a “dot” prescription 
(either regular, prn or otherwise) at the specified time of 
data extraction 
 
 
The majority of medicines in the drug dictionary 
are UHBFT formulary drugs. Non-formulary drugs 
need to be prescribed on the system using a dot 
before free-typing the name of the drug. 
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4.3.2. Identification of Key Stages of Intervention 
The clinical pharmacist focus group identified 3 key points in time in which intervention 
from a pharmacist was most likely to occur: 
1) At the time of Medicines Reconciliation 
2) Long-term patients (staying more than 2 weeks) who require repeat review of 
medicines 
3) At the point of prescription of discharge medication (termed at UHBFT To Take 
Out medicines (TTOs) 
 
In response to the feedback from the focus group, it was agreed with the Professor in 
Clinical Pharmacology and the statistician that the dataset request to informatics would 
include the following information for both “lead intervention” and “spell” patients: 
 Date of admission to trust 
 Date of discharge from trust 
 Date and time “DH or DHx” appears in pharmacist message (upper or lower text) – 
i.e. time of medicines reconciliation 
 Respective ward name during the spell in which lead intervention patient and 
corresponding spell patients, were identified 
 Date and time of all interventions during their respective admission 
 
4.3.3. Compilation of Results to Provide Final Dataset Request 
The final dataset request is shown in Appendix 2. 
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4.4. Discussion 
Perhaps the most complex and controversial aspect of the dataset design was 
identification of the population for study. The most simple design would have been to 
review all patients admitted to the Trust in a given timeframe and compare the 
characteristics of those patients who had a pharmacist intervention with those 
patients who did not. However, there are a large and statistically relevant, number of 
patients who are admitted to UHBFT who are never reviewed by a pharmacist. As a 
consequence, these patients may never become the recipient of a pharmacist 
intervention, not due to their lack of potential risk factors, but owing to the fact, a 
pharmacist was not present to undertake such an activity. 
A crude reflection of the percentage of patients reviewed by pharmacists is the 
percentage of prescriptions validated and subsequently signed off on the PICS by 
pharmacists. Figure 4.8 details the number of prescriptions written in the PICS and 
shows in 2014 more than 2 million prescriptions were entered into the PICS. 
 
Figure 4.8 Number of Prescriptions entered into PICS between 2010 and 2014. 
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Figure 4.9 Number of Prescriptions Signed Off (validated) by a pharmacist in PICS 
 
 
In comparison, Figure 4.9 details the number of prescriptions signed off (validated) by 
pharmacists in the Trust. In 2014, of the 2.2 million prescription entered into PICS, 
approximately 850,000 prescriptions were signed off by pharmacists (less than 40%). This 
percentage precluded the study from including all patients admitted to the Trust as the 
population for the study. 
 
Although, it was accepted that there may be a large number of outpatient prescriptions 
in the data included in Figure 4.9, there are still numerous other reasons why pharmacists 
are not present to review prescription charts and therefore would not have the 
opportunity to intervene in a patient’s treatment. As such, it was felt that a more 
accurate method of identifying patients who would be present on a ward and subject to 
pharmacist review was required to ensure a statistically relevant outcome. The final 
method which was agreed upon was to identify all patients (“spell” patients) present on a 
ward in the same ward spell as a patient who was the recipient of a pharmacist 
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intervention (the “lead intervention patient”). By using this method, in most instances, it 
would be valid to assume a pharmacist was present and able to review all patients’ 
medication in the respective ward stay.  Exclusions included;   
1) “lead intervention” patients admitted to wards not covered by the clinical 
pharmacy service (since it is possible that the intervention occurred in the 
pharmacy dispensary, which would mean that “spell” patients  on the respective 
ward were not subject to pharmacist review) 
2) All patients with an admission length <24 hours (since it is possible that they could 
have been admitted and discharged without a pharmacist review) 
 
It was however, concluded that however complex the method of identifying the patient 
population there may still be inaccuracies. For example, patients admitted on a Friday 
evening and discharged on a Monday morning would be included in the population 
requested but are unlikely to be subject to a pharmacist review since the clinical 
pharmacy team currently only work from Monday to Friday. However, advice was sought 
from the statistician and the Professor in Clinical Pharmacology and it was agreed that 
the method of identifying the population was as near accurate as could be gleaned from 
the available data. 
The time of the data extraction was also difficult to determine. Ideally, a review of all the 
patients’ potential risk factors at the time of the master patient’s intervention would be 
thought to be most accurate. However, in this case, the characteristics of each patient 
“spell” and “lead intervention” would need to be compared in a comparative study for 
every intervention in the determined time scale. This would mean tens of thousands of 
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comparative studies within a 2 year dataset. In addition, “lead intervention” patients may 
appear more than once in the data, if they are the recipient of more than one 
intervention, likewise “spell” patients may appear as “lead intervention” patients if they 
are the recipient of an intervention.  If the time of data extraction (and resulting 
measurement of the potential risk factor) changed each time a patient was recorded in 
the dataset, statistical analysis of such data would be extremely difficult. It was agreed to 
extract data for all patients at 24 hours after their admission with the view that later 
work could be centred on analysing data later in patients’ stay. Twenty-four hours was 
chosen since;  
1) All patients included in the study would have data at this time. If a later time for 
data extraction was chosen, some patients may be excluded from data extraction 
due to shorter lengths of stay. 
2) Pharmacists aim to review all patients within 24 hours of admission to perform 
medicines reconciliation so it is likely that more interventions are performed 
around this time. 
 
Finally it is acknowledged that not all of the potential risk factors could be 
comprehensively and accurately determined from PICS.  
For example with respect to accuracy, when looking for non-formulary drugs on PICS the 
dataset request asks for the number of “dot” prescriptions.  A “dot” prescription denotes 
a free-typed prescription in PICS which is generally used for a non-formulary drug as this 
set of drugs are not usually programmed into the drug dictionary forcing a free-typed 
prescription by a senior medical practitioner. However, free-typed prescriptions (“dot” 
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prescriptions) may also be used for other prescribing issues where the drug dictionary 
templates do not fit the current licensing or approval of the drug in the Trust e.g. a 
prescriber may want to nebulise an antibiotic but the drug template for the respective 
drug on PICS does not allow nebulisation. In such instances, prescribers may use the free-
type facility.  
Another limitation with respect to the comprehensive nature of the dataset request 
includes as an example, the dataset request for patient compliance issues. Patients may 
have numerous other compliance issues other than those which lead to the use of a 
blister pack or cause the patient to refuse medications and any interpretation of the 
extracted data should take this into account.  
Since there was an awareness that the data extracted from the PICS as a result of the 
dataset request may have limitations, the resulting data required review and validation 
prior to statistical analysis.  
One of the main inaccuracies found in the resulting dataset was the use of ICD10 codes to 
identify disease states. The International Statistical Classification of Diseases and Related 
Health Problems (ICD) is a comprehensive classification of causes of morbidity and 
mortality. All inpatient episodes and attendances that contain diagnoses must be 
recorded to the mandated version of ICD. The ICD-10 refers to the tenth revision. The 
World Health Organisation (WHO) is responsible for publishing the ICD-10 classification.  
On reviewing the data generated from the dataset request, it became obvious that 
disease state recorded as an ICD10 code on the electronic prescribing system was 
unreliable. It was evident that when comparing the number of patients taking treatment 
for a given condition with the number of patients allocated the appropriate ICD10 code, 
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the number of patients with the ICD10 code was significantly lower. For example the 
demographics indicated that 9,755 patients were prescribed insulin or hypoglycaemics in 
the total population but only 673 were denoted by the respective ICD10 code for 
diabetes at 24 hours after admission. It is possible that this may be because admitting 
doctors tend to include only the presenting complaint on admission rather than a full 
scope of the patient’s co-morbidities. Therefore, at this stage it was decided not to 
include disease states in the analyses and exclude this data going forward. However, 
were the research to be repeated using different methodology for data collection, 
disease state should be considered alongside all other potential risk factors. 
In addition, it was decided not to include consultant ID in the data analysis since with 
over 350 different consultants within the data set it became apparent that any statistical 
analysis to determine any one of the individual consultants would not be significant. 
 
Further chapters will discuss the limitations of data analysis in greater detail. 
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CHAPTER 5 
ANALYSIS OF RISKS  
ASSOCIATED WITH 
CLINICAL PHARMACY INTERVENTIONS 
AT UHBFT 
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5. Analysis of Risks Associated with Clinical Pharmacy Interventions 
at UHBFT. 
 
 
 
5.1 Introduction 
 
 5.1.1 Background 
 
Data generated as a result of the dataset request detailed in Appendix 2 were presented 
by the informatics department in the form of an Excel spreadsheet. Initially, data was 
extracted from the PICS for a single ward only, and the records for 20 randomly selected 
patients were compared to that in the PICS, to assess the accuracy of the extraction. Any 
inconsistencies were reported to the informatics department, so that the data extraction 
could be refined. This process was repeated for several months, until validation indicated 
that the extracted data representing all sixteen risk factors was shown to be accurate 
(with the exception of the disease state variables, which were excluded as explained in 
Chapter 4). The informatics report was then generated for all wards as detailed in the 
dataset request.  
The resulting dataset reported 58,918 rows of data (i.e. 58,918 patient admissions). Rows 
detailed a “lead intervention patient” who had been the recipient of an intervention and 
all the patients who had been present on the respective ward during the period of their 
ward stay “spell patients”. Each row detailed whether or not the patient had had an 
intervention, as well as all of the data requested, as detailed in Chapter 4. 
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 5.1.2 Aims 
 
To statistically analyse the dataset (extracted from the dataset request in Appendix 2) 
detailing potential risk factors for pharmacist intervention to: 
 Identify any significant differences between the potential risk factors in patients 
who have been the recipient of a pharmacist intervention, and those who have 
not. 
 Identify if there is a point in time after the patient’s admission at which an 
intervention is more likely to occur. 
 Identify if any point in time in the patient’s stay determined above, is related to 
the time at which a drug history is taken by a member of the pharmacy team. 
 Develop a “risk score” for patients as the potential recipients of a pharmacist 
intervention. 
 
 5.1.3 Objectives 
 
 To “clean” and validate the dataset in an Excel spreadsheet to provide the 
necessary input data for analysis using IBM SPSS Statistics software. 
 To perform a survival analysis to determine the point in time of a patient’s stay at 
which an intervention is most likely to occur and whether the stage of a patient’s 
stay is related to the time at which a drug history is taken by a member of the 
pharmacy team. 
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 To perform univariable analyses to determine whether each potential risk factor is 
significantly associated with the likelihood of the respective patient receiving a 
pharmacist intervention. 
 To perform a multivariable analysis to identify independent predictors of the need 
for pharmacist intervention, and to convert the final model into a risk score.  
 To validate the above risk score against retrospective data. 
 
5.2 Methods 
 
 5.2.1 Data Cleansing and Validation 
 
5.2.1.1. Data Cleansing 
 
The original data set included “lead intervention patients” who had received an 
intervention and “spell patients” who were present on the ward during the stay of the 
lead intervention patient.  
Spell patients were duplicated; 
1. If they had received an intervention during their hospital stay, then they would 
also appear as a lead intervention patient. 
2. If they were present on wards where multiple patients received interventions (i.e. 
lead intervention patients), then they would appear as a spell patient for each of 
these interventions.  
3. If they were readmitted, duplication as in 1 and 2 above may apply. 
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In order to ensure that the cases in the data were independent, to meet the assumptions 
of the statistical analyses used, patients who had already appeared in the dataset in the 
same admission were removed from the data. For lead intervention patients, only the 
first interventions for an admission were included in the analysis, and any cases where 
the patient was a spell patient to another patient were excluded. For spell patients, only 
the first appearances in the data during each admission were included, with all 
subsequent duplications excluded. Repeated admissions to hospital were treated as 
being independent; hence if a patient was discharged and readmitted, they would be 
included in the data once for each admission. 
 
 
 
5.2.1.2. Validation of Final Dataset 
 
 
Once the exclusions had been made, the final dataset was compared back to the original, 
to ensure that no errors had been introduced, using the process below: 
 
1. Twenty five patients were randomly selected from the original dataset which 
included all duplicated entries  
 
2. For each patient, it was confirmed that: 
 The patient and their respective characteristics appeared in final dataset 
 Where there was  duplication of the patient number in the final dataset, 
the duplication was only in the case of readmission 
 All column entries detailing the patient’s characteristics were the same as 
the data in the original dataset for the respective admission   
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 Where the patient had intervention/s: 
o The number of interventions was the total for that admission in the 
final data set (original data set had given total for each ward stay) 
o The total number of pharmacist visits was correct according to original 
dataset time of intervention. 
 
 
5.2.2 Statistical Analysis 
 
 
5.2.2.1 Statistical Methodologies Compared 
 
The outcome being considered in the analysis was whether or not a patient received an 
intervention during their stay. This was a binary outcome, as patients either did or did not 
receive an intervention. However, there was also the added complexity introduced by the 
fact that the length of stay for patients varied. The longer that a patient stayed in 
hospital, the greater the opportunity for an intervention to occur, as it gave pharmacists 
more time to review their case and identify any interventions that would be necessary.  
 
If the duration of a patient’s stay was independent of other confounding factors, then the 
differing length of stay would introduce no bias to the analysis. However, this was 
unlikely to be the case, as patients with longer hospital stays are likely to be more 
complex than those with shorter stays, hence patients with longer stays may differ with 
respect to a range of the factors being considered (e.g. age and comorbidities). As a 
result, treating pharmacist interventions as a simple binary outcome could introduce bias 
into the analysis. 
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Treating pharmacist interventions as a simple binary outcome also does not account for 
the timing of these interventions. The data for the characteristics being considered in the 
analysis were recorded at 24 hours after admission, and some of these may vary over 
time, such as GFR. For this reason, for interventions that occurred several weeks after 
admission, the recorded characteristic data may not reflect a patient’s characteristics at 
the time of the intervention.  
 
The simplest way to mitigate these two issues was to introduce a time limit at which the 
intervention status of a patient would be assessed. The average length of stay at UHBFT is 
between 5 and 7 days, so seven days after admission was selected as a sensible point of 
assessment. For each patient, it would then be identified whether an intervention had 
occurred within seven days of the first admission.  Any patients for whom first 
interventions occurred after this point were classified as being in the non-intervention 
group. In addition, any patients with a length of stay that was less than seven days were 
excluded from this analysis, as their intervention status at seven days was unknown. 
 
This approach reduced the total period of follow up, preventing the issues relating to 
interventions occurring a considerable time after admission not being reflective of a 
patient’s baseline characteristics. Any bias from including patients with differing lengths 
of stay was also eliminated, as the length of stay considered in the analysis was now 
seven days for each patient. However, this approach also had limitations, the major one 
being that, since patients with shorter lengths of stay had been excluded, a biased subset 
of the original cohort of patients was now being considered. As a result, whilst analysis of 
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this data would be valid for patients with hospital stays of seven days or more, it was not 
necessarily generalizable to the population as a whole. Excluding such a large number of 
patients would also reduce the sample size, resulting in lower statistical power. 
 
The third potential approach would be to use a time to event methodology. This would 
consider, for each patient, the period of time that they were “at risk” of an intervention, 
and the timing of the intervention, where this occurred. Patients would then be included 
in the analysis for the period of their stay, before being “censored” (i.e. excluded) at the 
point that they were discharged. The total period of follow up could be truncated, for 
example to seven days, for the reasons detailed above. 
 
The benefit of this approach is that is accounts for both the timing of the intervention, 
and the differing lengths of stay for patients, without making any exclusions. The main 
limitation is the assumption of non-informative censoring. Time to event analyses assume 
that censoring of patients is a random process that is not related to factors associated 
with the study. In the case of the present investigation, this would involve making the 
assumption that a patient’s length of stay is independent of the characteristics being 
considered, which is unlikely to be the case. Where this assumption is not met, the 
strength of the associations between the characteristics being considered and pharmacist 
interventions may be under- or over-estimated, depending on the strength and direction 
of any associations between the characteristics and length of stay. 
A summary of the benefits and limitations of the three approaches is reported in Table 
5.1. 
 
136 
 
5.2.2.2   Univariable Analysis 
 
Owing to the limitations of method 1 detailed in Table 5.1, this approach was not used in 
the analysis. Methods 2 and 3 were deemed to be valid approaches to the analysis, and 
so univariable analyses were performed using both of these methodologies, and the 
results compared.  
Analysis 2 (Table 5.1) was termed the “binary outcome analysis” and analysis 3 (Table 5.1) 
was termed the “time to event analysis”: 
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Table 5.1 Statistical Methods Compared 
Analysis Tests Used Benefits Limitations 
1. Comparison of 
patients with 
interventions to 
patients without 
interventions for 
all patients 
Univariable: 
Kendall’s tau-b, Chi2 
 
Multivariable: 
Binary logistic 
regression 
Includes all patients in analysis 
Does not account for the timing of the 
interventions 
 
Does not account for the length of stay 
(LOS) (patients with a shorter LOS may be 
more “healthy”/younger etc. leading to 
bias) 
 
Includes interventions that occur weeks 
after admission which may be less likely to 
be related to the characteristics of patients 
at 24 hours. 
 
2. Comparison of 
patients with 
interventions at 7 
days to patients 
without 
interventions at 7 
days, excluding 
patients with <7 
days LOS 
 
Univariable: 
Kendall’s tau-b, Chi2 
 
Multivariable: 
Binary logistic 
regression 
Does not include interventions 
that occur weeks after admission 
 
Standardises the follow up for 
each patient 
Excludes short stay patients, so is looking at 
a biased sample of patients 
 
3. Time to event 
analysis, looking 
at the time to 
intervention over 
the first 7 days 
 
Univariable: 
Kaplan-Meier curves 
 
Multivariable: 
Cox regression 
Includes all patients in analysis 
 
Does not include interventions 
that occur weeks after admission 
 
Considers the timing of 
interventions, so may be more 
powerful 
 
Potential issues with informative censoring, 
which may overestimate the rate of 
interventions, and give unreliable 
comparisons 
  
1.  “Binary Outcome Analysis” – Patients with a length of stay less than seven days 
were excluded. The incidence (in percentage of population) of patients at seven 
days who had received an intervention displaying the respective characteristic 
was determined. P-values comparing patients with different characteristics were 
calculated using Chi-square and Kendall’s tau-b for binary and ordinal data 
respectively. 
 
2. “Time to Event Analysis” – All patients in the data were included. Kaplan-Meier 
curves were produced, and used to estimate the rate of intervention within seven 
days. Patient follow up started at the time of admission, with the event of interest 
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being pharmacist intervention. Patients were censored at the point that they were 
discharged, or after seven days of follow up without a pharmacist intervention. 
Comparisons between groups were then made using the log-rank test, which is a 
non-parametric test that addresses the null hypothesis that there are no 
differences in the survival times in the groups being studied, and compares events 
occurring at all time points on the survival curve. 
 
For both approaches, continuous variables were divided into ordinal categories prior to 
analysis. This was a requirement for the Kaplan-Meier analysis, as continuous variables 
cannot be analysed using this approach. The creation of categorical variables was also for 
consistency with the later multivariable analysis. For analyses involving a binary outcome, 
where continuous factors are considered, an assumption is made about the relationship 
between the factor and the outcome. If the assumed shape of this relationship is 
incorrect, the then results of the analysis will be misleading. Treating the factors as 
categorical prevents this issue from occurring. Categorical variables also mean that the 
resulting risk score can be calculated using an additive approach when used in practice, 
with no multiplication necessary, making manual calculation easier. 
For the continuous variables, if a national or international standard grouping was known, 
then this grouping was used, otherwise the data was tabulated and the population 
divided into approximately equal groupings, based on rounding the percentiles of the 
data to the nearest meaningful values. For the remaining ordinal variables, groups were 
combined where the numbers of patients were small, in order to maximise the within-
group sample sizes, to give a more precise estimate of outcome rates. The final groupings 
are detailed in Table 5.2.  
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Table 5.2 Subgrouping of Potential Risk Factors 
Potential Risk Factor 
 
Data 
 
Subgrouping 
1. Drug class 
 Number regular drugs prescribed from PICS drug categories 
 
No formal grouping. 
0,1, 2 and 2+ ( 3 approximately equal groups) 
2. Polypharmacy  number of regular drugs prescribed 
5 or more drugs cited80  but most likely to be linear relationship. 
<5, 5-9, 10 and 10+ (3 approximately equal groups) 
3. Age  age (in years) </=40, 41 -55, 56 – 70, 71 -80, 81+        (4 equal groups rounded to nearest 5 years) 
4. Female gender 
 gender 
 
Binary 
5. Number of co-morbidities  number of ICD10 codes documented 0, 1 or 2, 3 or 4, 5 and 5+
115 
6. Length of patient stay 
 Date of admission and discharge (to calculate length of stay in 
days) 
Linear. No subgroups as used as accounted for by survival analysis 
 
7. History of Drug Allergy 
 number of allergies/sensitivities recorded 
 
Multiple Drug Intolerance Syndrome defined as 3 or more unrelated drug class allergies 
0, 1, 2, 3 and 3+ 
8. Patient Compliance Issues 
 number of patient refusals 0, 1, 2 and 2+   (3 approximately equal groups) 
 identify patients who have a blister pack icon Binary 
9. Poor Renal Function  GFR 
NICE Guidance 2014: 
≥90  Normal and high 
60–89 Mild reduction related to normal range for a young adult 
45–59 Mild to moderate reduction 
15–29 Severe reduction 
30–44 Moderate to severe reduction 
<15 Kidney failure 
10. Poor liver function 
 Identify patients (Yes/No) 
 
No clear grouping classification using markers of disease. Binary. 
11. Consultant ID  consultant ID Over 350 consultants made any statistical analysis impossible –removed from analysis 
12. Disease state  Identify patients (Yes/ No) with the respective ICD10 codes. Binary 
13. Administration problems/omission and 
supply issues 
 number of missed doses 0, 1, 2 and 2+   (3 approximately equal groups) 
 number of “drug out of stock” 0, 1, 2 and 2+   (3 approximately equal groups) 
14. Monitoring issues 
 Identify patients (Yes/No): 
INR recorded AND warfarin prescribed OR 
Any record on PICS Drug results tab 
Binary 
 
15. Non-formulary medicine 
 
 Identify (Yes/No) if patients have a “dot” prescription Binary 
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5.2.2.3 Receiver Operating Characteristic (ROC) Curves 
 
In order to further quantify the ability of the characteristics being considered to predict 
the need for pharmacist intervention, receiver operating characteristic (ROC) curves were 
produced for each characteristic. Since ROC curves can only be applied to binary 
outcomes, this analysis was based on the data from the “Binary Outcome Analysis”. The 
areas under the ROC curves (AUROCs) were then calculated, as well as the standard 
errors (SEs), and associated p-values.   
 
 
5.2.2.4 Multivariable Analysis 
 
The two methodological approaches gave similar results in univariable analysis, so the 
multivariable analysis was performed using the “Time to Event” methodology, to 
maximise the sample size. Prior to performing the analysis, Spearman’s correlation 
coefficients were calculated between the factors, in order to determine any pairs that 
were strongly associated. Where strong correlations were detected, factors were 
excluded prior to the multivariable analysis, in order to reduce the risk of 
multicollinearity, as this can result in poor model fit. The data were then randomly 
divided into two subsets. The modelling set consisted of 75% of the patients, and was 
used in the multivariable analysis. The remaining 25% of cases made up the validation 
set, which were used to validate the findings of the analyses, to ensure that overfitting 
had not artificially inflated the accuracy of the analysis. 
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 A multivariable cox regression model was produced from the cases in the modelling set, 
with patients followed up from admission until the point of pharmacist intervention, and 
censored either at discharge or after seven days without an intervention. A backwards 
stepwise approach was used to select the variables for inclusion. This started with a 
model containing all of the factors, with an iterative process used to remove non-
significant factors (p>0.05), until the final model only included significant independent 
predictors of pharmacist interventions. The benefit of this stepwise approach is that 
those factors that do not add significantly to the prediction of pharmacist interventions 
are removed, simplifying the resulting risk score.  
 
A risk score was then produced based on the final model. The log-hazard ratios for each 
category were used as a basis for the score. This meant that the reference category for 
each factor would be given a score of 0, and the other categories would be given a 
positive or negative score, depending on whether interventions were more or less likely 
to occur for patients in this category. In order to simplify the score, each of these values 
was rounded to the nearest integer, after multiplying by 20 to minimise rounding errors. 
The total score for a patient could then be calculated by looking up the score for each of 
their characteristics, and adding together the resulting values.  
 
The resulting score was then validated, in order to assess how accurately it could identify 
those patients at risk of requiring pharmacist intervention. ROC curves were produced, as 
detailed previously, for both the modelling and validation sets of data. The latter was 
intended to give a reflection of the predictive accuracy of the score if used in practice, as 
it was based on data that were not used in the multivariable analysis. In order to visualise 
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the accuracy of the score, the rates of pharmacist interventions within seven days were 
calculated for the range of possible values, and plotted separately for the modelling and 
validation sets. 
 
ROC curves for both sets of sample data were also drawn up to determine the 
predictability of the score. 
 
5.3 Results 
5.3.1 Demographics 
 
Data were available for 58,918 patients, the demographics of whom are reported in Table 
5.3. Additional factors relating to comorbidities and medication usage are detailed in 
Appendix 3. 
Table 5.3 Demographics of Population 
Demographic N/Median (IQR*) 
Gender 
Male 31247 
Female 27671 
 
Age (years) 
 
62 (45 - 76) 
 
Number of Regular prescriptions 
 
7 (4 - 11) 
Length of Stay (days) 
 
5 (3 - 11) 
 
*Inter Quartile Range 
 
Pharmacist interventions occurred in a total of 34.9% (n=20582) of cases. However, this 
simplistic rate does not account for the differing lengths of follow up for patients. Since 
patients are only “at risk” of having an intervention for the period that they were in 
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hospital, a Kaplan-Meier curve was produced, in order to estimate the probability of an 
intervention occurring over the course of hospital stays of varying lengths (Figure 5.1). 
This plot illustrates that pharmacist interventions occur at a reasonably constant rate 
over the first seven days of a patient’s hospital stay. For patients still in hospital seven 
days after admission, the Kaplan-Meier analysis estimates that 36.4% will have received 
an intervention by a pharmacist. The median time to the first intervention, namely the 
point at which half of all admitted patients would be expected to have received an 
intervention, was found to be 15.7 days (95% CI: 15.2 – 16.2). 
 
Figure 5.1 Rate of Interventions over the first seven days of Admission 
 
 
 
 
A similar analysis was performed to assess the proportion of patients where drug 
histories were recorded. This occurred in a total of 48207 patients, giving a simplistic rate 
of 81.8%. A Kaplan-Meier analysis (Figure 5.2) found that, after seven days in hospital, 
91.5% of patients would have had a drug history taken, with the median time being 36.0 
hours (95% CI: 35.5 – 36.5) after admission. 
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Figure 5.2 Rate of Drug Histories (DHx) over the first seven days of Admission 
 
 
Figure 5.3 Plots the cumulative rate of interventions and drug histories on the same axis 
in order to make a comparison between the two curves and determine the likelihood of a 
relationship between the timing of drug histories an interventions. 
 
 
Figure 5.3 Cumulative Rate of Interventions and Drug Histories over the first seven days 
of Admission 
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For the 19258 patients who received both a drug history and a pharmacist intervention, 
the time between these two events was calculated and compared (Figure 5.4). In this 
subgroup of patients, the majority of interventions occurred within the first 12 hours 
after completion of the drug history (55%), with 43% of interventions within two hours, 
and 36% within one hour of the drug history.  
 
Figure 5.4 Time Period between Drug Histories and Pharmacist Interventions 
 
                                 Time of Intervention in Hours Post Drug History 
 
 
5.3.2 Univariable Analysis 
 
5.3.2.1 Summary of Univariable Analysis 
 
Univariable analyses were then performed, in order to identify potential predictors of 
pharmacy intervention. As outlined in the methods, two alternative approaches were 
used, which dealt with the issue of variable length of stay in different ways: 
1.  “Binary Outcome Analysis” – Patients with a length of stay less than 7 
days were excluded and rate of intervention calculated at 7 days. This was 
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then compared across factors using Chi2 tests for nominal variables, and 
Kendall’s tau for ordinal variables. 
2. “Time to Event Analysis” – All patients were included and the rate of 
intervention at 7 days was calculated using Kaplan-Meier curves, some of 
which are detailed in Figure 5.5. Comparison across factors were 
performed using log rank tests. 
 
Results for the two methods are detailed in Tables 5.4 – 5.11. The overall intervention 
rate at seven days was estimated to be 31.4% using the binary outcome approach, and 
36.4% for the time to event methodology. This variation is a reflection of the different 
populations being studied and the different assumptions being made in the two analytical 
approaches. The factors identified as significant were generally consistent for the two 
methods.  
147 
 
 
Table 5.4 Intervention Rate at 7 days according to Patient Demographics 
Demographics 
Binary Outcome Analysis Time to Event Analysis 
Total 
N 
Interventions  
at 7 Days 
P-value             
K = Kendall's tau 
Chi2 = Chi Square 
N 
Interventions  
at 7 Days 
P- value 
(Log Rank) 
Gender     <0.001
Chi2     <0.001 
Male 
12010 
3582 
(29.8%) 
 
31247 35% 
 
Female 
11149 
3687 
(33.1%) 
 
27671 38% 
 Age     <0.001
K     <0.001 
<= 40 
2875 
580 
(20.2%) 
 
11944 26% 
 
41 - 55 
3873 
1035 
(26.7%) 
 
11375 33% 
 
56 - 70 
6063 
1920 
(31.7%) 
 
15278 38% 
 
71 - 80 
4698 
1642 
(35.0%) 
 
10082 41% 
 
81 and 81+ 
5650 
2092 
(37.0%) 
 
10239 42% 
 Regular Prescriptions     <0.001
K     <0.001 
< 5 
4405 
1090 
(24.7%) 
 
15812 28% 
 
5 - 9 
9746 
2898 
(29.7%) 
 
24481 35% 
 
10 and 10+ 
9008 
3281 
(36.4%) 
 
18625 44% 
 
 
 
Table 5.5 Intervention Rate at 7 days according to Non-Formulary Prescription 
Non-formulary Drug 
Prescribed 
Binary Outcome Analysis Time to Event Analysis 
Total 
N 
Interventions  
at 7 Days 
p value             
K = Kendall's tau 
Chi2 = Chi Square 
N 
Interventions  
at 7 Days 
p value 
(Log Rank) 
Dot Drugs     0.129
Chi2     <0.001 
No 
22450 
7028 
(31.3%) 
 
57442 36% 
 
Yes 
709 
241 
(34.0%) 
 
1476 39% 
  
 
 
148 
 
Table 5.6 Intervention Rate at 7 days according to Allergies/Co-morbidities 
Number of Allergies/ 
Comorbidities 
Binary Outcome Analysis Time to Event Analysis 
Total 
N 
Interventions  
at 7 Days 
p value             
K = Kendall's tau 
Chi2 = Chi Square 
N 
Interventions  
at 7 Days 
p value 
(Log Rank) 
Allergies     <0.001
K     <0.001 
0 
15172 
4625 
(30.5%) 
 
39310 35% 
 
1 
4999 
1617 
(32.3%) 
 
12292 38% 
 
2 
1739 
591 
(34.0%) 
 
4291 40% 
 
3 and 3+ 
1249 
436 
(34.9%) 
 
3025 41% 
 Comorbidities     <0.001
K     <0.001 
0 
6772 
1888 
(27.9%) 
 
20534 31% 
 
1-2 
8905 
2657 
(29.8%) 
 
22203 35% 
 
3-4 
5121 
1805 
(35.2%) 
 
11182 42% 
 
5 and 5+ 
2361 
919 
(38.9%) 
 
4999 46% 
  
 
Table 5.7 Intervention Rate at 7 days according to Administration/Supply Issues 
Administration and 
supply issues 
Binary Outcome Analysis Time to Event Analysis 
Total 
N 
Interventions  
at 7 Days 
p value             
K = Kendall's tau 
Chi2 = Chi Square 
N 
Interventions  
at 7 Days 
p value 
(Log Rank) 
Total Missed Doses     0.507
K     <0.001 
0 
8652 
2693 
(31.1%) 
 
24071 35% 
 
1 
4933 
1552 
(31.5%) 
 
12778 37% 
 
2 and 2+ 
9574 
3024 
(31.6%) 
 
22069 37% 
 Missed Doses – Drug Out 
of Stock     <0.001
K     <0.001 
0 
18854 
5583 
(29.6%) 
 
49909 35% 
 
1 
2507 
945 
(37.7%) 
 
5321 44% 
 
2 and 2+ 
1798 
741 
(41.2%) 
 
3688 47% 
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Table 5.8 Intervention Rate at 7 days according to Liver/Renal Function 
Liver/Renal Function 
Binary Outcome Analysis Time to Event Analysis 
Total 
N 
Interventions  
at 7 Days 
p value             
K = Kendall's tau 
Chi2 = Chi Square 
N 
Interventions  
at 7 Days 
p value 
(Log Rank) 
Liver     <0.001
Chi2     <0.001 
No 
21789 
6920 
(31.8%) 
 
55692 37% 
 
Yes 
1370 
349 
(25.5%) 
 
3226 31% 
 GFR     <0.001
K     <0.001 
< 15 
728 
202 
(27.7%) 
 
1391 30% 
 
15 - 29 
1882 
667 
(35.4%) 
 
3200 40% 
 
30 - 44 
2744 
996 
(36.3%) 
 
4997 41% 
 
45 - 59 
3103 
1097 
(35.4%) 
 
6488 42% 
 
60 - 89 
5676 
1817 
(32.0%) 
 
14373 38% 
 
90 and 90+ 
8546 
2393 
(28.0%) 
 
25235 36% 
  
Table 5.9 Intervention Rate at 7 days according to Requirements for Drug Monitoring 
Requirements for 
Drug Monitoring 
Binary Outcome Analysis Time to Event Analysis 
Total 
N 
Interventions  
at 7 Days 
p value             
K = Kendall's tau 
Chi2 = Chi Square 
N 
Interventions  
at 7 Days 
p value 
(Log Rank) 
INR     <0.001
Chi2     <0.001 
No 
10834 
3734 
(34.5%) 
 
31679 39% 
 
Yes 
12325 
3535 
(28.7%) 
 
27239 34% 
 Warfarin     <0.001
Chi2     <0.001 
No 
22398 
6978 
(31.2%) 
 
57103 36% 
 
Yes 
761 
291 
(38.2%) 
 
1815 49% 
 Drug Monitoring     0.665
Chi2     0.001 
No 
22910 
7194 
(31.4%) 
 
58413 36% 
 Yes 249 75 (30.1%) 
 
505 42% 
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Table 5.10 Intervention Rate at 7 days according to Drug Class 
Number of Regular Drugs Prescribed from each Class 
Binary Outcome Analysis Time to Event Analysis 
Total N 
Interventions  
at 7 Days 
p value             
K = Kendall's 
tau Chi2 = Chi 
Square 
N 
Interventions  
at 7 Days 
p value 
(Log 
Rank) 
Anti-epileptics   <0.001K     <0.001 
0 19763 6110 (30.9%) 
 
51370 36% 
 
1 2875 974 (33.9%) 
 
6275 40% 
 
2 and 2+ 521 185 (35.5%) 
 
1273 42% 
 Thrombolytics/ anticoagulants     <0.001K     <0.001 
0 15010 4454 (29.7%) 
 
41672 34% 
 
1 6718 2358 (35.1%) 
 
13824 42% 
 
2 and 2+ 1431 457 (31.9%) 
 
3422 42% 
 CNS agents     <0.001K     <0.001 
0 17540 5254 (30.0%) 
 
46350 35% 
 
1 4181 1498 (35.8%) 
 
9428 41% 
 
2 and 2+ 1438 517 (36.0%) 
 
3140 45% 
 Cardiovascular agents     <0.001
K     <0.001 
0 10795 3212 (29.8%) 
 
32396 33% 
 
1 5043 1662 (33.0%) 
 
10860 39% 
 
2 and 2+ 7321 2395 (32.7%) 
 
15662 41% 
 Corticosteroids     <0.001
K     <0.001 
0 18476 5620 (30.4%) 
 
47827 35% 
 
1 4431 1563 (35.3%) 
 
10522 42% 
 
2 and 2+ 252 86 (34.1%) 
 
569 41% 
 Opiates     <0.001
K     <0.001 
0 15733 5302 (33.7%) 
 
42180 38% 
 
1 6116 1697 (27.7%) 
 
14150 33% 
 
2 and 2+ 1310 270 (20.6%) 
 
2588 28% 
 Diuretics     <0.001
K     <0.001 
0 17215 5189 (30.1%) 
 
47304 35% 
 
1 4934 1734 (35.1%) 
 
9833 42% 
 
2 and 2+ 1010 346 (34.3%) 
 
1781 40% 
 Chemotherapy/ immunosuppressants     <0.001
K     <0.001 
0 18121 5471 (30.2%) 
 
46987 35% 
 
1 3680 1345 (36.5%) 
 
9323 43% 
 
2 and 2+ 1358 453 (33.4%) 
 
2608 39% 
 0020/.;…Insulin/ hypoglycaemics     <0.001
K     <0.001 
0 18494 5635 (30.5%) 
 
49163 35% 
 
1 2533 853 (33.7%) 
 
5110 41% 
 
2 and 2+ 2132 781 (36.6%) 
 
4645 43% 
 IV antimicrobials     0.003
K     <0.001 
0 15051 4636 (30.8%) 
 
40725 36% 
 
1 5021 1592 (31.7%) 
 
12019 36% 
 2 and 2+ 3087 1041 (33.7%) 
 
6174 40% 
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Table 5.11 Intervention Rate at 7 days according to Patient Compliance Issues 
Patient Compliance Issues 
Binary Outcome Analysis Time to Event Analysis 
Total N 
Interventions  
at 7 Days 
p value             
K = Kendall's 
tau Chi2 = Chi 
Square 
N 
Interventions  
at 7 Days 
p 
value 
(Log 
Rank) 
Blister Packs     0.004
Chi2     <0.001 
No 22823 7139 (31.3%) 
 
58279 36% 
 Yes 336 130 (38.7%) 
 
639 50% 
 Missed Doses - Patient 
Refused     <0.001
K     <0.001 
0 18268 5597 (30.6%) 
 
45763 36% 
 1 2668 871 (32.6%) 
 
7365 38% 
 2 and 2+ 2223 801 (36.0%) 
 
5790 39% 
  
 
 
Figure 5.5 Time to Event Analysis – Kaplan Meier Curves  
(Cumulative Rate of Interventions) 
Age: 
 
 
 
 
Regular Prescriptions:  
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Allergies: 
 
 
Comorbidities:  
 
 
 
 
 
Opiates:  
 
 
Renal Function:  
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Gender:  
 
 
 
Drugs Out of Stock:  
 
 
 
 
5.3.2.1 Patient Demographics 
 
Of the demographic factors considered (Table 5.4), the intervention rate was found to be 
significantly higher in females, and increased significantly with patient age and the 
number of regular prescriptions. 
 
5.3.2.2 Non Formulary Prescribing 
 
Non formulary prescribing was found to significant increase the likelihood of pharmacy 
intervention in the time to event analysis (p<0.001), but not in the binary outcome 
analysis (p=0.129). Despite the difference in significances, the direction and magnitude of 
the difference in 7-day intervention rates was similar (39% vs. 36% in time to event 
analysis, 34% vs. 31% in binary outcome analysis), hence the non-significance of the latter 
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was likely to be as a result of lower statistical power, owing to the smaller sample size 
being considered. 
 
5.3.2.3 Allergies and Comorbidities 
 
Increasing number of allergies and comorbidities in patients were found to result in 
significantly increased intervention rates using both methodologies (Table 5.6).  
 
5.3.2.4 Missed Doses 
 
The number of missed doses in the first 24 hours (Table 5.7) was found to significantly 
increase the pharmacy intervention rate in the time to event analysis (p<0.001), but not 
the binary outcome analysis (p=0.507). This was due to a combination of the reduced 
statistical power of the latter, and the fact that the binary outcome analysis appeared to 
have selected a biased cohort for this analysis. Analysis of total missed dose rates by 
length of stay indicated that those patients who were admitted for less than seven days 
and, hence, were excluded from the binary outcome analysis, had a significantly higher 
rate of missed doses within the first 24 hours than those with longer lengths of stay 
(43.2% vs. 37.5%, p<0.001). It is possible that those patients with longer lengths of stay 
were more likely to be elective patients and patients with long term conditions who 
might be less likely to refuse their regular medication, while patients with shorter lengths 
of stay are more likely to result from acute, emergency admissions of younger patients 
who are less likely to be compliant with new medication prescribed and refuse when 
required analgesics. When considering the missed doses as a result of a drug being out of 
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stock, results from the binary and time to event analyses were consistent, with greater 
number of missed doses associated with an increased likelihood of pharmacy 
intervention (p<0.001). 
 
5.3.2.5 Renal and Liver Dysfunction 
 
Analysis of factors associated with liver function (Table 5.8) indicated that the presence 
of a liver comorbidity was associated in a significantly lower likelihood of pharmacy 
intervention (p<0.001). A significant association with GFR was also detected (p<0.001), 
with those patients with GFR<15 being the least likely to receive an intervention. 
 
5.3.2.6 Requirements for Drug Monitoring 
 
Of the drug monitoring requirements considered (Table 5.9), it was found that patients 
who had an International Normalised Ratio (INR) measurement were less likely to receive 
a pharmacist’s intervention than those that who did not (p<0.001). This was a surprising 
finding, since in the present study, the prescription of warfarin (the use of which is 
usually monitored through the measurement and assessment of INR), increased the 
likelihood of an intervention being performed (p<0.001). Analysis of whether drug 
monitoring had taken place gave inconsistent results for the two methods, with no 
significant association with pharmacist intervention in the binary outcome analysis 
(p=0.665), but a significant increase was observed in the time to event analysis. 
(p=0.001). As with the missed dose analysis, this was attributed to reduced statistical 
power in the former analysis, owing to the very small proportion of patients who had 
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drug monitoring performed, and a biased patient selection, with 1.1% of patients with a 
length of stay of 7 or more days having drug monitoring, compared to 0.7% of shorter 
stays (p<0.001). It is possible that this may be due to the fact that more monitoring takes 
place in those patients with long term prescriptions who tend to have longer stays, and 
that many drugs which require Therapeutic Drug Monitoring (TDM) take several days to 
reach steady state (the optimum time for drug monitoring). Therefore, patients who have 
shorter stays and are excluded from the binary outcome analysis may be less likely to be 
the recipients of TDM. 
 
5.3.2.7 Class of Drug Prescribed 
 
The frequency of prescribing of a range of drug classes over the first 24 hours of a 
patient’s stay were then considered (Table 5.10). All of those analysed were found to be 
significantly associated with pharmacy intervention rates, with rates increasing with the 
number of prescriptions for the majority of classes considered. The only exception was 
the prescription of opiates, where pharmacy intervention rates fell significantly from 38% 
for patients not prescribed opiates, to 28% where two or more opiates were prescribed 
(time to event analysis, p<0.001). 
 
5.3.2.8 Patient Compliance 
 
The final class of factors considered was those relating to patient compliance (Table 
5.11). Use of blister packs and increasing number of doses missed owing to patient 
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refusal were both found to be associated with significantly increased pharmacy 
intervention rates. 
 
5.3.3 Multivariable Analysis 
Since the two approaches to the univariable analysis had returned broadly similar results, 
the “time to event” methodology was used in the multivariable analysis. This was 
because it maximised the available sample size (since no patients needed to be 
excluded), and took into account the timing of interventions, both of which would result 
in greater statistical power. 
Prior to the analysis, correlations between the factors being considered were assessed 
using Spearman’s rank correlation coefficients (rho). A strong correlation was detected 
between the use of corticosteroids and chemotherapy / immunosuppressant drugs 
(rho=0.91). In addition, the total number of missed doses was correlated with the missed 
doses owing to patient refusal (rho=0.49) and drugs unavailable (rho=0.39). In order to 
minimise the risk of multicollinearity, the factors from these groups that had the weakest 
association with pharmacist interventions were excluded from the multivariable analysis, 
namely the number of corticosteroids and total number of missed doses.  
The patients were then randomly divided using computer software, into two sets. The 
first was made up of 75% of the cohort to retain a large population for statistical analysis 
and was used to perform Cox regression (main data). The remaining 25% of patients 
(validation data) were retained to use in the validation of the risk scores.  
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A total of 23 factors were considered for inclusion in the original model. The stepwise 
procedure then iteratively removed four factors that did not add significantly to the 
predictive accuracy of the model, namely drug monitoring (p=0.253), and the number of 
prescriptions of dot drugs (p=0.216), cardiovascular medications (p=0.143) and insulin 
(p=0.240). Appendix 4, Table 5.12 details the final model, after excluding these factors. 
For each of the categories considered, the hazard ratio is quoted and alongside the beta 
coefficient (the natural log of the hazard ratio).  
These beta coefficients were the basis of the risk score. Simply adding these values 
together for a patient would give the log-odds from the model, which could be used as an 
indicator of their risk of requiring pharmacy intervention. However, the beta coefficients 
were small, and so calculations would need to be performed using sub-unitary figures in 
order to produce an accurate risk score for a patient. In order to simplify the calculation 
and to make it more easily calculable should the results be used in practice, the beta-
coefficients were multiplied by 20, and rounded to the nearest integer. This gave each 
category a score ranging from -9 to +10. In order to ensure that a risk score for a patient 
was always positive, a constant value of 28 was also included, giving a theoretic range for 
the score of 1 to 80. The greater the value of a patient’s score, the greater the chance 
that they will require a pharmacist intervention. 
  
5.3.4 Validation of Risk Score 
In order to validate the risk score, it was applied to each patient in both the main and 
validation datasets. The resulting scores were then compared to the rates of pharmacy 
intervention at 7 days for those patients with at least 7 days of inpatient stay. Patients 
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were grouped by their risk score, with the intervention rates calculated within each 
category (Appendix 4, Table 5.14). This is shown graphically in Figure 5.6. 
 
 
Figure 5.6 Rate of Intervention at 7 days Versus Risk Score. 
  
 
 
A clear correlation between the risk score and intervention rate was observed in both the 
main and validation datasets. Intervention rates at 7 days increased from around 10% for 
the lowest risk patients, to almost 50% in those patients at the highest risk. However, risk 
scores in these extreme ranges were found in the minority of patients (<1%) shown by 
Figure 5.7. 
In order to quantify the degree of predictive accuracy, ROC curves were produced, and 
the areas under these curves are reported in Table 5.15 below. 
 
LOS = Length of stay 
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Figure 5.7 Number of Patients in Total Population (main and validation sets) Versus Risk 
Score 
 
Table 5.15 ROC Curves – Main Data and Validation Data 
  Areas Under ROC Curves* 
Main Data 0.607 (SE=0.005, p<0.001) 
Validation Data 0.616 (SE=0.008, p<0.001) 
*For the prediction of intervention at 7 days 
(for Length of stay ≥ 7 days) 
 
 
The areas under the ROC curves (AUROCs) were consistent for both the main and 
validation sets, indicating that overfitting to the data used to generate the score was not 
a major issue, and that the performance of the model when used in practice should be 
similar to that observed in this analysis. The AUROCs for both datasets were significantly 
greater than 0.5, hence the performance of the risk score was significantly better than 
would be expected by chance. Despite this, the AUROC of around 0.6 indicated that, 
whilst the score was significantly predictive of pharmacist interventions, the degree of 
predictive accuracy was low. 
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The performance of the risk score was also compared to that of the individual factors 
included in the univariable analysis. ROC curves were produced for all of factors 
considered for inclusion in the score, with the AUROCs reported in Appendix 5. Table 
5.16. The strongest predictor of pharmacy intervention was patient age, with an AUROC 
of 0.57. This was of a similar magnitude to that observed for the risk score as a whole, 
indicating that the use of patient age in isolation would allow the prediction of pharmacy 
intervention with a similar degree of accuracy to that of the risk score.   
 
 
5.4 Discussion 
 
 
The original data set consisted of 58,918 patient admissions, which comprised only 63% 
of the total 93,239 admissions to the relevant wards during the study period. However, 
32,850 of the total admissions were to the clinical decision unit (CDU) where more than 
70% of stays are less than 24 hours which would result in these admissions being 
excluded from the study. The remaining exclusions were likely to be patients who were 
not present on the wards included in the study at the time of a pharmacist intervention. 
 
A Kaplan-Meier survival curve was plotted for cumulative intervention rate against time 
to intervention. The graphic showed a smooth rise in cumulative intervention rate to 7 
days post admission, at which point, just under 40% of patients would have received an 
intervention. The gradient of the curve was marginally steeper over the first day of 
hospital stay, but was near linear subsequently, indicating that the risk of intervention 
increased proportionally with the duration of stay.  
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The results from Chapter 4 identified three key stages of a patient’s stay at which they 
may be at risk of intervention, namely, admission, discharge and during the two weeks 
post admission for long stay patients. When a Kaplan-Meier survival curve was produced 
for the rate of drug histories taken against time, the curve was steeper in the first 2 days, 
with 60.7% of patients receiving drug histories within this period.  This initial rise is 
unsurprising as pharmacists aim to undertake medicines reconciliation in the first 24 
hours post admission. 
 
Using this methodology it was not possible to identify a particular stage of a patient’s 
admission at which they would be more likely to experience an intervention. However, it 
is important to note that 43% of patients who receive at least one intervention will do so 
within 2 hours of having their drug history. This is an unsurprising finding, since once a 
drug history is taken by a member of the pharmacy team, it is at this point that 
reconciliation of the drug history against the patients current medication chart/order 
would occur and any discrepancies would be identified by the pharmacist. It is very likely 
that a large proportion of the 43% of interventions which occur within 2 hours of 
establishing the drug history, are directly attributable to errors in the prescription of 
medication which the patient usually takes at home, although further analysis of this 
subset of interventions would be required before this can be proven. Figure 5.3 plotted 
the cumulative rate of drug histories and cumulative rate of interventions on the same 
axis and shows how in the first 2 days of patient’s admissions , there does appear to be a 
steep rise in both parameters which tends to tail off over time. 
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When performing univariable analysis, the rate of interventions was consistently lower 
using the binary outcome analysis. It is possible that this may be because the excluded 
patients experienced less complex conditions than those staying 7 days or longer. In 
which case, interventions to these individuals would be likely to be less complex and 
occur at an earlier stage in their stay, perhaps around the time of medicines 
reconciliation. Patients with more complex conditions are more likely to have 
interventions later in their stay. In particular, the number of patients in the respective age 
groups shows that the binary outcome analysis excluded a larger percentage of younger 
patients from the population than older patients: the under 40s were by far the smallest 
age group while in the time to event analysis, (where the whole population was included) 
the under 40s were the largest group. Younger patients might be healthier, take fewer 
medications and may have less comorbidity which could cause some bias in the binary 
outcome methodology. In addition, if the present research produced acceptable 
computable risk scores for patients admitted to a Trust, it is extremely unlikely that on 
calculation of risk scores at 24 hours, there would be an awareness of whether a patient 
would be likely to stay for 7 days. As such, the risk model would need to include all 
patients on admission irrespective of their length of stay supporting the time to event 
analysis as a method for determining significance of potential risk factors.  However, both 
methods showed similar results, some of which were surprising and revealed some 
limitations to the data collected. 
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5.4.1 Risk Factors for Intervention 
 
A random sample of 75% of the total population was used to perform multivariable 
analysis using Cox regression to determine independent risk factors for pharmacist 
interventions and their associated hazard ratios. The use of the beta coefficients from 
these models enabled calculation of a risk score.  
The following risk factors were all shown to be independently and significantly associated 
with the outcome: age, female gender, number of allergies, number of comorbidities, 
presence of liver dysfunction, presence of renal impairment, record of an INR, 
requirement for a blister pack, number of regular prescriptions, refusal of medicines by 
a patient, drug out of stock, prescription of warfarin, and number of anti-epileptics, 
thrombolytics/anticoagulants, CNS agents, opiates, diuretics, chemotherapy / 
immunosuppressants or  intravenous antimicrobials prescribed. This was generally 
consistent with the results of the univariable analysis. 
Age was the dominant risk factor in the multivariable analysis with the highest risk score 
of 10 (hazard ratio of 1.63 for 81+years vs. <=40 years). This was in line with the 
univariable analysis, and many studies detailing age as a risk factor for issues related to 
medicines 46,50,53–56,60,61,63,65–67,69,81. However, although the present study indicates that 
age is an independent risk factor, it is only independent of the other factors which were 
included in the analysis. There are likely to be many factors which may predispose an 
elderly patient to a pharmacist intervention which are not routinely recorded, and may 
be difficult to quantify such as hearing loss, dementia and general confusion. It remains 
highly likely that age is acting, in part, as a surrogate marker of these confounding factors, 
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which lead pharmacists to intervene more frequently into the care of older patients. The 
number of regular prescriptions (ten or more drugs) gave a risk score of 7 (hazard 
increases by 44% compared to patients on less than 5 drugs), which again was consistent 
with both the univariable analysis, and what is reported elsewhere in the literature46–
48,51,52,55–57,61,63,67,69,70,74,75,78,80,81.  
Also with a risk score of seven in the multivariable analysis was the requirement of a 
patient to have a blister pack. As a measure of patient compliance, this score is supported 
by the positive associations reported in the literature47,52,81 and by the univariable time to 
event analysis, which found that 50% of these patients were in receipt of intervention at 
7 days.  
Female gender was shown to be an independent risk factor in the multivariable analysis 
in line with risks associated with problems with medicines in the literature48,49,54–57,61,67,81 
but only with an approximate 6% increase in the hazard ratio compared with males. This 
small increase is not unsurprising, in that at least one study has indicated previously that 
female gender is not an independent risk factor for medicines related problems51, while 
another reported that being male was a risk factor63. However, since the present study is 
determining risk factors for pharmacist intervention rather than the numerous potential 
issues associated with medicines, the increase in risk observed with female patients does 
give an example of the likelihood that risks for intervention may not be identical to those 
for drug related problems. It is possible for example, that females are (controversially and 
arguably) more likely to engage in conversation with pharmacists and discuss their 
medicines in more detail, which may lead to more interventions into their treatment than 
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males. Further research into the type of interventions carried out in both groups would 
be required to make any conclusions. 
The increase in hazard seen in patients with allergies was in line with the 
literature47,61,70,71. However, the magnitude of the increased risk of intervention was 
similar for the patients with 1, 2 or 3+ allergies, implying that it is the presence of any 
allergies, rather than the number of allergies, that is important. Additionally, in line with 
the univariable analysis, the following showed statistically significant positive associations 
with intervention rates: 
number of comorbidities47,50,52,54,56,70,81, refusal of medicines by a patient, drug out of 
stock, prescription of warfarin, and number of anti-epileptics, thrombolytics / 
anticoagulants, CNS agents or chemotherapy / immunosuppressants prescribed. 
However, as in the univariable analysis there was surprisingly, an inverse relationship 
between a number of factors and the likelihood of intervention. These factors included: 
renal and liver dysfunction, prescription of opiates and diuretics, record of an INR and 
prescription of a single intravenous antibiotic. 
In the univariable analysis, reduced GFR appeared to increase the likelihood of 
intervention in cases of minor and moderate renal impairment but, as renal dysfunction 
became severe, pharmacists were less likely to intervene. This is not in line with literature 
detailing risks associated with medicines related problems, which indicate an increase in 
problems as renal function declines46–48,58,67,69–71,75. It is possible that minor impairment is 
less well noted by prescribers and, therefore, in cases of minor renal impairment, 
pharmacists are likely to intervene when doses or frequencies have been unaltered in 
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reduced renal elimination. Patients who have severe impairment (GFR <15) are more 
likely to be treated by clinicians who have an awareness of their renal impairment or may 
be admitted to a renal speciality where expertise mitigates the risk of error, hence fewer 
interventions are required.  
Notably, in the multivariable analysis, even mild and moderate renal dysfunction 
demonstrated an inverse relationship with the likelihood of pharmacist intervention. This 
may be due, in part, to the fact that renal function deteriorates with age, hence 
accounting for age in the model highlights the independent effect of renal function.   
With this in mind, the multivariable analysis demonstrates that pharmacists are not 
currently targeting patients with poor renal function at UHBFT. It is likely that this is 
because of other mitigating factors which are occurring which reduce the risk of 
medicines related problems at UHBFT in this group of patients. At UHBFT, patients whose 
presenting complaint is poor renal function are admitted to specialist renal wards where 
they are treated by specialist renal nurses and nephrologists who are familiar with drug 
treatment of the renally impaired patient. It is possible that as a result, drug errors are 
significantly less common in these patients at UHBFT. A similar argument could be made 
for the inverse relationship seen with poor liver function, as UHBFT has specialist liver 
wards. Liver patients are treated on a specialist ward and receive treatment from 
clinicians, many of whom are members of the Trust transplant team and as such, it is 
possible that there is little cause for pharmacists to intervene.  
The other factors with inverse relationships are more difficult to explain. These were the 
prescription of opiates, an IV antibiotic or diuretic and the presence of an INR result. In all 
of these cases, it is unlikely from the previous research identified in the systematic review 
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(Chapter 2) that these risk factors for drug related issues should be inversely related to 
pharmacist interventions. However, these negative relationships were present in both of 
the univariable methodologies considered, as well as the multivariable analysis.  
It remains possible that pharmacists are not intervening as frequently as perhaps they 
should in this group of patients and that the present research needs to be repeated on a 
set of data which has been verified for appropriate and comprehensive interventions by 
pharmacists. Currently with a hazard ratio of 0.657 and a risk score of -8, patients with 
GFR <15 have a reduction in their hazard ratio of approximately 34% compared to 
patients without renal impairment. 
 
5.4.2 Risk Score as a Predictor of Intervention 
 
In terms of predicting where pharmacists will direct their interventions, the risk score was 
calculated for a random subset of 25 percent of the population (validation data). When 
plotted against the rate of intervention at 7 days, the main data and validation data 
showed very similar, almost linear, results (Figure 5.6) indicating a clear relationship 
between the risk score and  the intervention rate for the population at 7 days. However, 
a true linear relationship would result in the rate reaching 100% at some point in time 
which is unlikely. It is possible that not all patients will require intervention and even the 
highest risk score indicated a rate of 50% which suggests that there may be a rate at 
which an increasing score no longer increases the rate of intervention. Further research 
would be required to prove or disprove this theory.  
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On validation of the risk score, a four-fold increase (12% to 48%) in risk was observed 
between the groups with the highest and lowest risk scores. However, these rates were 
at the extremes and constituted less than 1% of the total population (Figure 5.7). 
In the univariable analysis, age followed by number of regular prescriptions had the 
largest impact on the likelihood a patient would receive an intervention. However, 
AUROCs were disappointing at only 0.570 and 0.565 respectively showing the factors 
were poor predictors of intervention when used alone.  The prescription of multiple 
central nervous system agents prompted pharmacists to intervene more than any other 
drug class. However, again the AUROC for prescription of CNS agents was only 0.525 
indicating that the drug class was a poor predictor of intervention. 
In the multivariable analysis, ROC curves were produced for both sets of data (main data 
and validation data) to indicate whether patients with a particular risk score are likely to 
experience an intervention at any point in time. The resulting AUROC was 0.607 for main 
data and 0.616 for the validation data, which is only a marginal improvement over using 
the individual factors alone as predictors of intervention. To use the score alone as a 
method of prediction of interventions, refining of the score to improve the AUROC would 
be required. 
 
 
5.4.3 Limitations 
 
Very early on in the collection and manipulation of the data, it became apparent that 
there were several different methodologies which could have been chosen for handling 
the data. The major difficulty was that there were several factors that could vary with 
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time. For some of the potential predictors being considered (e.g. GFR), measurements 
could be made at any point of a patient’s stay, and there could potentially have been 
multiple measurements made, allowing for these factors to vary over time. In addition, 
the length of stay of patients varied widely, and any interventions could occur at any 
point during this period. Attempting to account for all of this variability would require a 
considerably more complex statistical approach, which would also require many more 
assumptions. In addition, the resulting risk score would have the potential to 
continuously vary over time, and give different intervention probabilities depending on a 
patient’s projected length of stay, which would be more difficult to understand and 
implement in practice. 
As a result, a more pragmatic approach was taken in the present study, where the effect 
of time based variability was minimised where possible. All of the potential 
methodologies would have limitations, which is why multiple approaches were utilised in 
specified cases, with acceptance of their potential benefits and limitations. The decision 
to collect data for the potential predictors being considered at 24 hours after admission 
was an attempt to reduce the aforementioned variability over time in these factors, and 
has been discussed further in Chapter 4. This had the effect of simplifying the analysis, 
and is also more in line with how the risk score might be used clinically, as identification 
of patients at risk of requiring an intervention would be most useful as early as possible in 
a patient’s stay, in order to prevent possible harms of prescribing errors. However, the 
limitation of this approach was that some long stay patients and those patients whose 
stay is less than 24 hours have been excluded from the study, resulting in a biased 
sample, which may not be generalizable to the whole hospital population in practice.  
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It was not possible to analyse data associated with disease states as the recording of 
ICD10 codes on the PICS is poor, particularly where these were secondary to the main 
reasons for admission (e.g. diabetes). Prior to any future study, clinicians should be 
encouraged to improve ICD10 code recording rates.  
 
It is extremely significant to this research to note that all of the data analysed consisted 
of data generated on the assumption that pharmacists were carrying out interventions 
where patients were at most at risk, and that the model developed would be ideal in 
determining where future services should be directed. However, when considering the 
factors which had an inverse relationship with the likelihood of a patient receiving an 
intervention, it is possible that pharmacists may not be carrying out interventions on all 
patients who are most at risk of a drug related problem. There may be numerous 
explanations for this. It may be that pharmacists are avoiding complex or palliative 
patients on significant numbers of opiates through a need for training or because of 
anxieties associated with treating this group of patients. Pharmacists who visit liver or 
renal patients may be less likely to make interventions than their peers or patients with 
INR results on admission are referred to the anticoagulant team and are not thoroughly 
reviewed by pharmacists.  
It should also be considered that the markers chosen in the PICS to represent the 
predictors of intervention were either not sensitive or specific enough and therefore 
were not sufficiently accurate to measure the respective predictor. For example, in the 
case of renal function, it may be that a change in renal function is a more accurate 
marker of a drug related risk than GFR. 
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However, it is also possible that for other reasons, these groups of patients at UHBFT do 
not require intervention by pharmacists and that there are other factors mitigating the 
risk in these patients. For example, patients who are prescribed opiates are likely to be 
mainly in one of two categories, patients who have non-complex needs who are in pain 
post-surgery or patients with complex needs who have some sort of malignancy or are 
palliative. The non-complex prescriptions are simple and often short term prescriptions 
which may be less likely to be prone to intervention by a pharmacist whilst the pain 
control of a palliative patient is likely to have been prescribed by the chronic pain team 
who are experts in their field. Similarly, at UHBFT, patients with liver and renal 
dysfunction are mainly located on wards dedicated to the treatment of patients with 
hepatic and renal problems rather than on general medical wards. Therefore, unlike 
many other hospitals in the UK, liver and renal patients are treated by specialist 
professionals who may mitigate the risk of pharmacist intervention through a reduction 
of error in the treatment of patients with liver and renal dysfunction. Indeed, UHBFT is a 
tertiary centre offering solid organ transplant services and therefore patients are treated 
by the experts delivering these services.  
It is also possible that risks associated with drug related problems are not identical to 
those risks leading to pharmacist intervention and further research would be required to 
identify the root cause of these inverse relationships. However, it remains possible that 
there is an error in the assumption that pharmacists are currently carrying out 
interventions comprehensively and adequately in all settings. In the present analysis, it is 
assumed that the outcome data collected, identified all of those patients who needed a 
pharmacist intervention. However, owing to the retrospective nature of the study, the 
only outcome available was whether an intervention occurred, which is a subtle, but 
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important difference. It is likely that some patients requiring interventions will have been 
missed, for example, because they were discharged before a drug history was recorded. 
As such, it would be advisable to repeat this research in a prospective study, where senior 
clinical pharmacists are asked to review respective patients without time constraints or 
interruption and their interventions validated by a senior clinician to seek to determine a 
“best case” scenario for targeting interventions. This would be time consuming, and be 
limited to a smaller quantity of data, but the quality of the data may be superior to that 
used in this analysis. A prospective study of this nature may also seek to verify the 
counterintuitive finding that patients who are prescribed no medications at all are more 
likely to receive a pharmacist intervention than a patient who is prescribed one or more 
opiates.  
 
 
5.5 Conclusion 
 
The primary aim was to develop a risk score for patients as potential recipients of 
pharmacist interventions. The intention was to then use these risk scores to identify 
patients who were at high risk of intervention and direct pharmacists as part of a clinical 
pharmacy service to those patients who had highest risk scores, whilst other patients 
could potentially be reviewed by another member of the pharmacy team (potentially 
pharmacy technicians). A risk score was successfully produced from the data, which was 
found to be significantly predictive of the requirement for pharmacy intervention, and 
remained significant when applied to a validation cohort. However, the score had two 
main limitations. 
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The first was that, although it was found to be significantly predictive of the need for 
pharmacy intervention, the degree of predictive accuracy was low. Although a small 
number of patients in the extreme ends of the score were found to have very low or high 
probabilities of requiring an intervention, the discrimination between high and low risk 
patients for the majority of the cohort was poor. In addition, the predictive accuracy of 
the score was only a small improvement over what could be achieved by some of its 
individual components (e.g. patient age). If the score is to be used in practice then it 
should be used as a guidance tool rather than directive policy. 
The second limitation related to the fact that some potential risk factors were found to 
demonstrate inverse relationships with pharmacist interventions. This was unexpected 
since, as discussed in Chapter 2, all of the potential risk factors considered were identified 
as risk factors for problems related with the use of drugs. Although the link between 
pharmacist interventions and drug related problems has never been proven, there is an 
expectation that the role of the clinical pharmacist is to target medicines related issues in 
an attempt to avoid or minimise the impact of adverse incidents from the use of drugs. 
This concept is a fundamental part of clinical pharmacy training both at undergraduate 
and post graduate level. As such, it was a significant finding to identify that currently at 
UHBFT, there is an inverse relationship between pharmacist interventions and the 
following independent risk factors: renal and liver dysfunction, prescription of opiates 
and diuretics, record of an INR and prescription of a single intravenous antibiotic. This is 
potentially indicative of the fact that the outcome being analysed was not the need for 
pharmacist intervention, but whether a pharmacist intervention actually occurred. If 
pharmacists are intentionally avoiding interventions for subgroups of patients, then this 
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will introduce bias into the data, which could potentially result in the observed inverse 
relationships between use of specific drugs and intervention rates.  
 
A question arises as to whether the analysis needs to be repeated using a dataset derived 
from an “ideal” population, who have been identified as recipients (or not) of pharmacy 
interventions by experts in the field, without the usual constraints imposed on a 
pharmacists time, and validated by at least one other expert. However, it is also possible 
to argue that the dataset used in this study was extremely large (58,918 admissions) and 
taken over a 2-year period and, as such, the current data analysis should give an 
excellent, albeit unexpected, picture of where pharmacists currently practice at UHBFT. It 
could be argued that they currently act safely and competently and they do so alongside 
other healthcare professionals who may, indeed, be mitigating the potential risks for the 
use of drugs by practicing as experts in their own field such as renal and liver transplant. 
In the unlikely event, the model developed as part of this present research were to be 
used in practice, then it may not be applicable to other hospitals as the risk mitigation in 
place at UHBFT would not be evident in other settings. 
The combination of the poor predictive accuracy of the score, and the potentially 
misleading inverse relationships between interventions and prescriptions of specific 
drugs indicates that the score requires further refinement before use in practice. Use of 
the score as the sole method to identify patients likely to need review by pharmacists 
may mean that resources are used incorrectly, or may mean that patients requiring 
intervention are missed.  However, using the score to identify those at the highest risk of 
intervention to be seen by promptly by a senior pharmacist, those with “average” scores 
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to be reviewed by a junior pharmacist and that those with a very low score to be seen by 
a pharmacy technician may have merit in practice.  
Another aim of this chapter was to identify if there was a point in the patients stay at 
which they were more likely to experience a pharmacist intervention. When plotting a 
Kaplan- Meier curve detailing one-minus survival for the rate of interventions during the 
first seven days of a patient’s admission, it was clear that there was a higher rate of 
interventions over the first 1-2 days after admission, which then stabilised to a gradual 
increase in rate of intervention, as shown by Figure 5.1. Although 36% of patients who 
had both a documented drug history and an intervention were recipients of the 
intervention within an hour of documentation of the drug history, the specific time of the 
intervention could not be pre-determined prior to taking a drug history. The Kaplan- 
Meier curve for drug histories did not indicate a sudden increase in the rate of drug 
history documentation making it difficult to determine the likely time of drug histories 
and most interventions. 
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6. General Discussion 
6.1 Discussion 
 
6.1.1 Review of Aim 
 
The present research was undertaken with the primary aim to: 
Develop a risk assessment tool as a safe and effective method of delivering a clinical 
pharmacy inpatient service in which the need for a clinical review by a member of the 
pharmacy team, is clearly defined, based on pharmaceutical and clinical risk as 
determined through an electronic prescribing system. 
 
This present research explored the possibility that risks for experiencing a problem with 
medicines may be identified from a patient’s electronic record on admission to hospital 
and the possibility that pharmacists might be directed to those most at risk by an 
electronic computable risk score. This potentially, would be a more efficient way of 
directing services, since the current service model requires pharmacists to visit every 
inpatient at UHBFT on a daily basis, irrespective of their requirement for a review. Some 
patients have more complex drug regimens than others, while other patients have a good 
understanding of their drug regimen allowing them to manage without intervention from 
a pharmacist. Patients are very complex in their needs, and there are multiple factors 
which affect their requirement for intervention by a pharmacist and the possibility of 
them experiencing an adverse incident related to the use of their medicines. As such, the 
present research partially met its primary aim. 
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6.1.2 Identification of Risk Factors for Drug Related Problems 
 
The systematic review of the literature in Chapter 2 sought to identify what factors were 
likely to lead to a patient becoming a recipient of a pharmacist intervention or a problem 
with their medicines. Review of the literature found 38 papers, which detailed 10 
measurable risk factors linked with drug related problems in hospital inpatients. All of the 
risk factors were potentially identifiable from an individual patient’s records on admission 
to hospital. However, the search did not identify any papers which detailed the risk 
factors which were directly linked to pharmacist interventions.  It was therefore 
identified that there was a need for further research to determine if there was a direct 
association with the risks documented in the literature for problems associated with the 
use of medicines such as adverse drug events, drug related problems, medicines related 
problems etcetera and pharmaceutical intervention. Certainly it is likely that there are a 
number of factors which are more “holistic” in nature which cause pharmacists to 
intervene that are unlikely to be included as risk factors for adverse outcomes from 
medicines. For example, patients with communication problems or learning difficulties 
are more likely to be targeted by pharmacists in order to determine if they have any 
compliance issues. However, patients with communication problems are also less likely to 
engage in conversation with a pharmacist, which may make them less likely to be the 
recipient of an intervention, while patients who enjoy engaging in conversation with the 
pharmacist are may be more likely to hold their attention. It is clear that causes of 
pharmacist intervention may not necessarily be bound purely by a patient’s prescription 
and previous medical history. In particular, age was found to be an independent risk 
factor for pharmacist intervention in this study and although it is very unlikely that age is 
an independent factor per se, there are so many confounding factors which vary as 
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patients age and also may increase the likelihood of patients experiencing problems with 
their medicines such as hearing loss, deteriorating dexterity, sight impairment and 
memory loss, that it becomes irrelevant in practice, to prove that age is not an 
independent risk factor. In the main, older patients are more likely to be the recipient of 
a pharmacist intervention with patients over 81 years having a risk score of 10 in our risk 
model. 
In order to identify factors, which lead to pharmacist interventions which may not be 
directly associated with drug related problems, Chapter 3 reviewed the literature. The 
aim was to identify if there was any consensus with regards to the recording of 
pharmacists’ interventions with a view to determine whether or not factors recorded for 
the purpose of retrospective analysis of interventions were also risk factors for the 
interventions themselves. Compliance issues were the most notable addition to the 
potential risks for pharmacist interventions included at this stage.  
 
6.1.3 Measurable Risk Factors In the Electronic Prescribing System 
 
By combining potential risk factors identified by the reviews in Chapters 2 and 3, some 
work went into defining how these factors could be identified from the electronic 
prescribing system (PICS) at UHBFT. However, there was no assurance that the potential 
risks identified in Chapter 2 or 3 would have a direct association with clinical pharmacy 
intervention.  Identifying some of the potential risk factors using an electronic prescribing 
system was in some cases, difficult. For example “compliance issues” were identified by 
only the requirement for a blister pack or refusal of medication recorded on the 
prescribing system. Patients may have numerous other compliance issues, such as 
problems opening medication containers or shift working on return home which would 
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not be identified by the PICS but may cause a pharmacist to intervene into a patient’s 
treatment regimen as an inpatient.  
Further work to improve the predictive accuracy of the risk score may include improving 
the sensitivity and specificity of the predictors of risk in the electronic prescribing system. 
 
6.1.4 Statistical Analysis and Risk Score 
 
Statistical analysis of the data produced some surprising results. Both univariable and 
multivariable analysis indicated that there were risk factors for problems with medication 
which had an inverse relationship with the likelihood of experiencing a clinical pharmacy 
intervention. At UHBFT patients who have a deteriorating GFR, have liver impairment or 
are taking opiates, diuretics or a single intravenous antibiotic are all less likely to have an 
intervention than those who do not. On analysis the risk score was shown to be a 
significantly associated with the need for intervention, but the degree of predictive 
accuracy was found to be poor. It is possible that the markers chosen in the PICS may 
require refinement to improve their accuracy as predictors of intervention. 
Another limitation of the methodology was that the data representing each risk for 
intervention was measured at 24 hours after the patient’s admission. It could be argued 
that the characteristics of all patients who were recipients of an intervention should have 
measured at the time of the respective intervention and compared with those who did 
not receive an intervention. However, this posed the question as to what time in the 
patient’s stay should the patients who did not receive an intervention, have their 
characteristics compared. Twenty-four hours was chosen as this was thought to be the 
time at which most patients were reviewed by the pharmacy team for medicines 
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reconciliation and therefore likely to be associated with a high rate of interventions at 
this point in the patient’s stay. 
 
6.1.5 Use of the Risk Score in Practice 
 
Although statistically the AUROC was poor, the score may be of use in practice as a 
guidance tool for clinical pharmacists, directing the team to those patients at high risk of 
intervention who have not been reviewed within the first 24 hours of their stay. 
Thereafter, a manual re-assessment of risk could be undertaken by the pharmacist in 
accordance with a guidance document detailing the high risk factors for intervention 
detailed in this present research. 
In practice, the score would be best utilised in the early stages of a patient’s stay and for 
those patients with stays of more than 24 hours for a number of reasons. Firstly, if 
programmed into the PICS, the score would not be visible until the patient had been 
admitted for at least 24 hours. Pharmacists will endeavour to see patients as soon as 
possible after their admission and start their daily round at 9am in the morning, at which 
time, only the scores for those patients admitted prior to 9am the previous day would be 
visible. In addition, for patients who stay much longer than 7 days, the score on 
admission would become less relevant over time as their treatment and clinical condition 
changes. As such it would seem sensible that scores should be recalculated for patients 
with longer lengths of stay. However, this would require additional data analysis not 
covered by this research and in which case, a manual risk assessment from a pharmacist 
could be employed for patients with longer lengths of stay until further research is 
completed. 
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In Chapter 4 some potential risk factors were excluded from the analysis as they could 
not be identified in the PICS e.g. interactions, untreated indication, dose too high or low, 
duration of prescription or request for information. These potential risks should be borne 
in mind for future development of the system. In the main, these excluded factors were 
factors which were directly attributable to pharmacist intervention, i.e. those factors 
which are recorded as part of the documentation of pharmacist intervention. They were 
not factors which may (or may not) lead to a problem with medicines such as poor renal 
function or polypharmacy. As such, it may be pertinent to also consider programming the 
electronic prescribing system to alert pharmacists to when there is an actual problem 
with a medicine in addition to highlighting patients at risk. Currently, prescribers receive 
alerts regarding interactions or they may need to confirm a high dose but where 
prescribers confirm that they wish to override an alert and continue with a prescription, 
pharmacists are not alerted. An alert to a pharmacist would serve as a potential referral 
system and with appropriate programming could allow referral requests from healthcare 
professionals and patients alike. However, such a system would require extensive 
programming and could potentially generate significant numbers of inappropriate alerts 
if it were to be a comprehensive enough to ensure patient safety. To avoid alert fatigue 
(i.e. ignoring potentially critical alerts due to the number of insignificant alerts 
generated), it would be appropriate that alerts were only generated when certain criteria 
are met prompting pharmacist review. Certainly, since commencing this research, there 
have been publications of such rule based clinical decision support systems improving the 
number/effectiveness of pharmacist interventions116,117. 
Ideally, an approach using both a rule based alert system to identify any patients who 
have already been prescribed a regimen identified as inappropriate used alongside a 
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potential risk score for those for the potential to experience a drug related problem 
should be developed. 
 
 
6.2 Conclusions and Future Research 
 
The poor statistical predictability of the score in an individual and the finding that there 
were inverse relationships with some of the factors examined, suggests that there may 
be scope for refinement of the score to improve its accuracy.  
Prior to using the risk score, it would be important to ascertain whether or not the 
inverse relationship which consequently would be used to direct the pharmacy team 
away from this subset of patients was appropriate or not. It is possible that in the case of 
renal and liver dysfunction the treatment of patients on specialist wards mitigates the 
risk of pharmacist intervention. These wards receive input from senior specialist 
pharmacists so there is little reason to assume that there are a large number of drug 
related problems which go undetected by a pharmacist. It would be beneficial to 
generate the data again but exclude patients from Liver and Renal specialist wards. It may 
be the case that patients with renal or liver impairment who have been admitted to other 
wards at UHBFT (perhaps when their renal or liver impairment is not the presenting 
complaint) do in fact, have an increased risk of pharmacist intervention.  
In the case of patients who have been prescribed opiates, diuretics or a single 
intravenous antibiotic, it is possible that at UHBFT there is a lack of expertise by the 
pharmacy team in the treatment of these patients. Further analysis would be required to 
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identify the true cause. If this was found to be the case, then a package of education and 
training should be instigated and the research repeated. 
Future development of the score will focus on improving the sensitivity and specificity of 
individual predictors of intervention in an attempt to improve the AUROC of the score. 
For example, problems with renal function may be more accurately measured by a 
change in renal function rather than GFR and compliance may be better measured by a 
combination of the requirement of a blister pack with the refusal of medicines. With the 
refinement of the predictors of intervention, the score would then be recalculated with 
the expectation of an improved AUROC and therefore predictive accuracy. 
Once a new risk score is developed, research should focus on how to use the score in 
practice. Scores of varying magnitudes need to give an indication to the pharmacy team 
as to the level of pharmaceutical input required in respective patients and currently this 
research has not addressed this issue. 
As such, the PICS has been developed to allow manual risk assessment of patients by 
pharmacists who assign them to “HIGH”, “MEDIUM” and “LOW” risk categories. Future 
research will focus on using the data from manual risk assessment to undertake a 
comparative analysis of the manual risk categories assigned and the computable risk 
score to determine the range of scores in each category. Statistical analysis will then be 
used to indicate the risk score range for each category which can then be used to 
determine the level of pharmaceutical input required by the pharmacy team. It is likely 
that HIGH risk patients will be reviewed daily by a pharmacist, MEDIUM risk patients 
every 48 hours and LOW risk patients by a pharmacy technician. 
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It is also possible there are many other factors which are associated with pharmacist 
intervention which have not been highlighted by this research. These factors are also 
likely to be variables that are either not measurable, or are not currently recorded in 
patient notes. For example, patients when in conversation with pharmacists will often 
highlight issues with their medication which is not documented on the inpatient chart. It 
is possible that if an electronic prescribing system was used to direct the pharmacy team 
away from patients who were deemed to be low risk, that the opportunity for pharmacist 
intervention (unidentified by an electronic risk model) would be removed from these 
patients entirely. As such it is crucial that all patients are reviewed by a member of the 
pharmacy team (which could include a pharmacy technician for “low” risk patients) to 
allow the opportunity for conversation and identification of risks not apparent from this 
research therefore increasing the possibility of intervention.  
In some cases, it is possible that carrying out one intervention may also increase a 
patient’s chances of receiving multiple interventions as a pharmacist may return to 
confirm the outcome of intervention. Further investigation should seek to confirm if 
those patients who have received an intervention are more likely to be visited again by a 
pharmacist and consequently more likely to be the recipients of multiple interventions. It 
is also possible that patients with low risk scores may not only be less likely to be the 
recipient of an initial intervention but also subsequent interventions.   As such, analysis of 
the current data may be warranted to determine if the risk score is a predictor of the 
total number of interventions in a patient’s stay.  
This research used the data generated from PICS to determine a risk score for patients as 
recipients of an intervention within the first 7 days of their stay. The records of 
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intervention at UHBFT also record a severity score based on the severity of the potential 
outcome in the absence of intervention. It may be advantageous to determine whether 
or not the risk score developed as part of this research could also be used to determine 
which patients are more likely to be the recipient of a potentially lifesaving intervention.  
 
6.3 Summary 
 
In summary, this evidence based risk score may be used as a useful guide to determine 
which patients are at highest risk of pharmacist intervention within their first 7 days of 
stay. Further refinement of the score and a comparative study with manual risk 
assessment by pharmacists may determine if it is possible for the score to indicate the 
level of service delivery. 
This research may be of interest nationally and as such, publication of the development 
of the score will disseminate the findings in order that the conclusions and research and 
development opportunities may be shared amongst organisations. 
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